


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:38Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406257" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406257</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="b265308802" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406257</article-id><article-id pub-id-type="pmcid-ver">PMC12406257.1</article-id><article-id pub-id-type="pmcaid">12406257</article-id><article-id pub-id-type="pmcaiid">12406257</article-id><article-id pub-id-type="pmid">40765414</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c00974</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Tetrahydropyrazolopyridinones
as a Novel Class of
Potent and Highly Selective LIMK Inhibitors</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6197880</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7126-5220</contrib-id><name name-style="western"><surname>Baldwin</surname><given-names initials="AG">Alex G.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7350799</contrib-id><name name-style="western"><surname>Foley</surname><given-names initials="DW">David W.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6193675</contrib-id><name name-style="western"><surname>Jones</surname><given-names initials="DH">D. Heulyn</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7350811</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="H">Hyunah</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7350806</contrib-id><name name-style="western"><surname>Collins</surname><given-names initials="R">Ross</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7350815</contrib-id><name name-style="western"><surname>Wahab</surname><given-names initials="B">Ben</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7350823</contrib-id><name name-style="western"><surname>Pedder</surname><given-names initials="JH">Josephine H.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6193689</contrib-id><name name-style="western"><surname>Waters</surname><given-names initials="L">Loren</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6193691</contrib-id><name name-style="western"><surname>Paine</surname><given-names initials="M">Marie</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7350847</contrib-id><name name-style="western"><surname>Schino</surname><given-names initials="L">Lauramari&#250;</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7350831</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6145-8504</contrib-id><name name-style="western"><surname>Feng</surname><given-names initials="GJ">Gui Jie</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath12" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">894563</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8658-3897</contrib-id><name name-style="western"><surname>Kariuki</surname><given-names initials="BM">Benson M.</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath13" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1352014</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2858-8929</contrib-id><name name-style="western"><surname>Elkins</surname><given-names initials="JM">Jonathan M.</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath14" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5362676</contrib-id><name name-style="western"><surname>Atack</surname><given-names initials="JR">John R.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath15" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">371171</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8745-8377</contrib-id><name name-style="western"><surname>Ward</surname><given-names initials="SE">Simon E.</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Medicines
Discovery Institute, School of Biosciences</institution>, <institution>Cardiff University</institution>, <addr-line>Main Building, Park Place</addr-line>, <city>Cardiff</city>
<postal-code>CF10 3AT</postal-code>, <country country="GB">United Kingdom</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Centre
for Medicines Discovery</institution>, <institution>University of Oxford</institution>, <addr-line>Roosevelt Drive</addr-line>, <city>Oxford</city>
<postal-code>OX3 7FZ</postal-code>, <country country="GB">United Kingdom</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">School
of Chemistry</institution>, <institution>Cardiff University</institution>, <addr-line>Main Building, Park Place</addr-line>, <city>Cardiff</city>
<postal-code>CF10 3AT</postal-code>, <country country="GB">United Kingdom</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>WardS10@cardiff.ac.uk</email>. Phone: <phone>(+44)2920 876984</phone>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17427</fpage><lpage>17456</lpage><history><date date-type="received"><day>07</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>21</day><month>7</month><year>2025</year></date><date date-type="online"><day>06</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-06"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-06">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c00974.pdf"/><abstract><p>LIMKs are serine/threonine and tyrosine kinases that
play critical
roles in regulating actin filament turnover, affecting key cellular
processes such as cytoskeletal remodeling, proliferation and migration.
Aberrant LIMK overactivation has been implicated in several diseases,
including cancers and neurodegenerative disorders. Understanding the
precise molecular mechanisms by which LIMKs modulate actin cytoskeletal
dynamics necessitates highly potent and selective LIMK pharmacological
inhibitors. We report the discovery of a novel class of allosteric
dual-LIMK1/2 inhibitors based on the tetrahydropyrazolopyridinone
scaffold. Using structure-based drug design, we identified MDI-117740
(<bold>69</bold>) as a highly potent dual-LIMK1/2 inhibitor with significantly
improved DMPK properties compared to prior inhibitors, suitable for <italic toggle="yes">in vivo</italic> evaluation. Importantly, <bold>69</bold> has very
low kinome promiscuity, including former off-target RIPK1, representing
the most selective LIMK inhibitor reported to date. Such a chemical
probe will enable researchers to selectively dissect LIMK activation
under physiological or disease conditions and spur translation of
new therapeutics targeting LIMK pathologies.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c00974_0021.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c00974_0019.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Medical Research Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MR/S005331/1</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c00974</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c00974</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>eba154b39c90f86f5f753da520df1f75c20db79a863775879505c420b459c680</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>The LIM domain kinases (LIMKs) are dual
specificity, serine/threonine
and tyrosine kinases that belong to the tyrosine-kinase family (TKL).
They are a family of proteins comprised of two highly conserved members,
LIMK1 and LIMK2, sharing 50% overall sequence similarity with 70%
identity in the kinase domain. LIMKs have a unique structure of signaling
domains composed of two N-terminal LIM domains and a PDZ domain, which
are important in regulating kinase activity, a proline/serine-rich
region and a C-terminal kinase domain.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>&#8722;<xref rid="ref2" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref3" ref-type="bibr"/>
</named-content> LIMK1/2 are a convergence
point for at least four different signaling pathways: (i) the Rac-PAK
(p21-activated kinase), (ii) Rho-ROCK (Rho kinase), (iii) Cdc42-MRCK&#945;
(myotonic dystrophy kinase-related Cdc42-binding kinase), and (iv)
CaMKIV (Ca<sup>2+</sup>/calmodulin-dependent protein kinase) cascades.
These upstream pathways all activate LIMKs by phosphorylating a conserved
threonine residue, Thr508 in LIMK1 and Thr505 on LIMK2, on the activation
loop.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>&#8722;<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref7" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref8" ref-type="bibr"/>
</named-content> LIMK activation leads to phosphorylation at Ser3 of its substrates
cofilin 1, cofilin 2, and destrin (actin depolymerizing factor) family
of proteins, commonly referred to as &#8220;cofilin&#8221;.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>
</named-content> This phosphorylation event inactivates cofilin, causing actin polymerization
and stabilization. Therefore, LIMKs are key regulators of actin stability
and control cytoskeletal dynamics responsible for cell motility, proliferation
and migration, in addition to synapse stability. There is also evidence
that LIMKs regulate microtubule stability independently of their central
role in modulating actin filament dynamics through interaction of
its PDZ domain with tubulin.<xref rid="ref10" ref-type="bibr"/>
</p><p>Inappropriate
activation or overexpression of LIMK1 and LIMK2 has
been associated with increased cellular invasion and tumor growth
in several cancers, including breast,<named-content content-type="bibref-group">
<xref rid="ref11" ref-type="bibr"/>&#8722;<xref rid="ref12" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref13" ref-type="bibr"/>
</named-content> gastric,<xref rid="ref14" ref-type="bibr"/> prostrate<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> and colorectal cancers.<xref rid="ref17" ref-type="bibr"/> Fragile X Syndrome (FXS), the most common hereditary
cause of intellectual disability and autism spectrum disorder (ASD),
is caused by gene silencing of the fragile X mental retardation 1
protein (FMRP).<xref rid="ref18" ref-type="bibr"/> This leads to LIMK1 activation
due to increased levels of full length bone morphogenetic protein
type II receptor (BMPR2) that directly binds LIMK1<xref rid="ref19" ref-type="bibr"/> as well as increased activation through the Rac1-PAK1 pathway.<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>,<xref rid="ref21" ref-type="bibr"/>
</named-content> Such inappropriate LIMK1 activity drives abnormal synaptic and dendritic
spine morphology in the well-established <italic toggle="yes">Fmr1</italic> KO
mouse model<xref rid="ref20" ref-type="bibr"/> and Drosophila model of FXS,<xref rid="ref22" ref-type="bibr"/> which can also be observed in FXS individuals.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref23" ref-type="bibr"/>,<xref rid="ref24" ref-type="bibr"/>
</named-content> LIMK dysregulation has also been
implicated in other CNS disorders, particularly Alzheimer&#8217;s
disease,<xref rid="ref25" ref-type="bibr"/> amyotrophic lateral sclerosis<xref rid="ref26" ref-type="bibr"/> and schizophrenia.<named-content content-type="bibref-group">
<xref rid="ref27" ref-type="bibr"/>,<xref rid="ref28" ref-type="bibr"/>
</named-content>
</p><p>Given the pivotal role of LIMKs in disease and their therapeutic
potential, there has been a growing number of reported LIMK inhibitors.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref29" ref-type="bibr"/>
</named-content> The most characterized inhibitor is LIMKi3 (<bold>1</bold>, BMS-5, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>), a highly potent,
type I dual LIMK1/2 inhibitor originally developed by Bristol-Myers
Squibb.<xref rid="ref30" ref-type="bibr"/>
<bold>1</bold> inhibits cell
proliferation and motility in several cancer cell lines,<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref31" ref-type="bibr"/>,<xref rid="ref32" ref-type="bibr"/>
</named-content> reverses abnormal dendritic spine
morphology and normalizes anxiety-related behavior in the <italic toggle="yes">Fmr1</italic> KO mouse model.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref22" ref-type="bibr"/>
</named-content> Nevertheless, it has
promiscuous kinome selectivity<xref rid="ref33" ref-type="bibr"/> and has
not been progressed further. FRAX486 (<bold>2</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) is a highly potent, CNS-penetrant
group I PAK inhibitor that restores abnormal synaptic morphology and
rescues seizures and behavioral abnormalities in <italic toggle="yes">Fmr1</italic> KO mice<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>,<xref rid="ref34" ref-type="bibr"/>
</named-content> that was progressed as a clinical candidate
for FXS. However, we have shown that <bold>2</bold>is unselective
and strongly inhibits LIMK1/2,<xref rid="ref29" ref-type="bibr"/> therefore
its efficacy in FXS models is likely to be attributed to dual PAK1/LIMK
inhibition. The pyrrolopyrimidines LX7101 (<bold>3</bold>), developed
by Lexicon Pharmaceuticals, and SR7826 (<bold>4</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) have also been disclosed
as potent type I LIMK inhibitors.<named-content content-type="bibref-group">
<xref rid="ref35" ref-type="bibr"/>&#8722;<xref rid="ref36" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref37" ref-type="bibr"/>
</named-content>
<bold>3</bold>is a dual
LIMK/ROCK inhibitor that advanced to phase 1/2a clinical trials for
primary open-angle glaucoma or ocular hypertension.<xref rid="ref38" ref-type="bibr"/>
<bold>4</bold>, an analogue devoid of ROCK inhibition,
protects against A&#946;-induced hippocampal thin spine loss, dendritic
spine degeneration<xref rid="ref25" ref-type="bibr"/> and rescues impaired
hippocampal long-term potentiation in neonatal <italic toggle="yes">Fmr1</italic> KO mice.<xref rid="ref39" ref-type="bibr"/> However, both <bold>3</bold> and <bold>4</bold> remain as unselective, type I LIMK1/2 inhibitors.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Chemical
structures of reported LIMK1/2 inhibitors and structurally
related RIPK1 inhibitors.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="jm5c00974_0001.jpg"/></fig><p>Consequently, there has been greater interest in
developing allosteric
type III LIMK1/2 inhibitors that are more selective and whose potencies
are not appreciably different in PAK-phosphorylated LIMK variants.<xref rid="ref29" ref-type="bibr"/> TH-257 (<bold>5</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) reported by Knapp et al.<xref rid="ref33" ref-type="bibr"/> and closely related to a series first discovered by Lexicon
Pharmaceuticals,<xref rid="ref41" ref-type="bibr"/> is a highly selective,
type III dual LIMK1/2 inhibitor that dose-dependently inhibits neurite
outgrowth and reduces phospho-cofilin levels in human iPSC-derived
cortical neurons from FXS patients.<xref rid="ref39" ref-type="bibr"/> We
recently disclosed the very potent dual LIMK1/2 inhibitor MDI-114215
(<bold>6</bold>), which significantly reduces phospho-cofilin in hippocampal
brain slices and rescues impaired long-term potentiation in the <italic toggle="yes">Fmr1</italic> KO mouse model. Unfortunately, compounds <bold>5</bold> and <bold>6</bold> could not be progressed further due to their
suboptimal DMPK properties and poor CNS penetration, respectively.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/> ,<xref rid="ref33" ref-type="bibr"/> ,<xref rid="ref39" ref-type="bibr"/>
</named-content> Therefore, alternative starting
points to develop allosteric type III LIMK1/2 inhibitors with improved <italic toggle="yes">in vitro</italic> DMPK properties suitable for <italic toggle="yes">in vivo</italic> evaluation are highly desirable.</p><p>The X-ray crystal structure
of the LIMK1 kinase domain bound to
LIJTF500025 (<bold>7</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) was recently published (PDB: <ext-link xlink:href="7ATU" ext-link-type="PDB">7ATU</ext-link>).<xref rid="ref42" ref-type="bibr"/>
<bold>7</bold> was originally developed as a potent receptor
interacting protein 1 (RIP1) kinase inhibitor by Takeda Pharmaceuticals
as part of a CNS-penetrant, orally available RIPK1 inhibitor program
leading to compound 22 (<bold>8</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>).<xref rid="ref43" ref-type="bibr"/> This series
features a tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-7-one core designed from a merging strategy between an identified
HTS hit and the previously reported RIPK1 inhibitor GSK2982772 (<bold>9</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>).<xref rid="ref44" ref-type="bibr"/>
<bold>9</bold> is a clinical candidate
that has recently completed phase II clinical trials for psoriasis,
ulcerative colitis and rheumatoid arthritis<named-content content-type="bibref-group">
<xref rid="ref45" ref-type="bibr"/>&#8722;<xref rid="ref46" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref47" ref-type="bibr"/>
</named-content> that constitutes
an advanced RIPK1 inhibitor series developed by GlaxoSmithKline, exemplified
by GSK&#8242;481 (<bold>10</bold>)<xref rid="ref48" ref-type="bibr"/> and
GSK3145095 (<bold>11</bold>, <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>).<xref rid="ref49" ref-type="bibr"/>
</p><p>
<bold>7</bold> is a type III, allosteric dual LIMK1/2 and RIPK1
inhibitor whose binding to LIMK1 causes distortion of the P-loop and
outward displacement of the &#945;C helix, whereby the DFG motif
adopts the DFG-out conformation.<xref rid="ref42" ref-type="bibr"/> The
central tetrahydropyrazolopyridinone core is supported in place with
interactions of the carbonyl (and potentially pyrazolo N) with the
catalytic D478 of the DFG loop. The ligand also makes an important
diatomic interaction of the primary amide with M388/L397 and an edge
&#960;-cation interaction of the benzyl ring with H458 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A). The narrow lipophilic
back pocket is filled by the benzoxazepin-4-one motif which positions
the haloaromatic into this hydrophobic region, encompassed by F350,
A353, V366, and F479 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>B). Interestingly, comparable interactions were observed in
the X-ray structure of TH-300 (<bold>30</bold>, <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C), a close analogue of <bold>5</bold>, in
complex with LIMK2 (PDB: <ext-link xlink:href="5NXD" ext-link-type="PDB">5NXD</ext-link>) and the LIMK1 homology model of <bold>6</bold>.<xref rid="ref39" ref-type="bibr"/> Given these similarities, we wished to develop
a hybrid series between the RIPK1 inhibitor <bold>7</bold> and our
potent dual LIMK1/2 inhibitor <bold>6</bold> that aimed to further
improve the suboptimal <italic toggle="yes">in vitro</italic> DMPK properties of
6 while avoiding any related RIPK1 activity.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>(A) Co-crystal structure
of allosteric inhibitor <bold>7</bold> (LIJTF500025) bound to LIMK1
(PDB: <ext-link xlink:href="7ATU" ext-link-type="PDB">7ATU</ext-link>).
(B) Ligand interaction diagram of <bold>7</bold>. Shading represents
the following: hydrophobic region (green),
charged interaction (positive, blue; negative, red), polar (teal).</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="jm5c00974_0002.jpg"/></fig><p>Here we report this merging strategy and successive
SAR campaigns
that led to the discovery of a novel class of highly potent, selective
LIMK1/2 inhibitors devoid of RIPK1 binding. The most advanced molecule
from this series, MDI-117740 (<bold>69</bold>), has similar LIMK1/2
binding and cellular potency and target engagement but significantly
improved <italic toggle="yes">in vitro</italic> DMPK compared to our previously
reported lead compound <bold>6</bold>. Notably, <bold>69</bold> is
the most selective LIMK inhibitor known to date. We also characterized
structure-permeability relationships within this new series of allosteric
inhibitors.</p></sec><sec id="sec2"><title>Results and Discussion</title><p>To identify the chemical features
necessary for potent dual LIMK1/2
activity, structurally related RIPK1 inhibitors <bold>8</bold>-<bold>11</bold> and an initial set of analogues of <bold>7</bold> were
screened using our previously reported LIMK1/2 RapidFire mass spectrometry
assay.<xref rid="ref29" ref-type="bibr"/> First, we attempted to access
key intermediate 5-cyano-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate <bold>12</bold> (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Scheme S1</ext-link>) to enable a
regioselective synthesis of amide analogues of <bold>7</bold> (Series
A, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>) via nitrile
hydrolysis and amide coupling. 5-Bromo-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate <bold>14</bold> was synthesized from ethyl 1-benzyl-5-hydroxy-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate <bold>13</bold> using POBr<sub>3</sub> and DMF prior to Wittig reaction with (methoxymethyl)&#173;triphenylphosphonium
chloride, HCl-mediated deprotection, reductive amination and ester
hydrolysis/amide coupling (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Scheme S1</ext-link>).
Despite our more convergent synthetic route, late-stage Pd-catalyzed
cyanation of <bold>19</bold> using Zn&#173;(CN)<sub>2</sub>
<xref rid="ref50" ref-type="bibr"/> failed to afford the nitrile derivative <bold>12</bold>. As an alternative, derivatives <bold>20</bold>&#8211;<bold>26</bold> were synthesized similar to previously described by Yoshikawa et
al.<xref rid="ref43" ref-type="bibr"/> using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate <bold>27</bold> and substituted
benzoxazepine-4-one starting materials (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Scheme S2</ext-link>). Typically, the reductive aminated intermediates <bold>28a</bold>&#8211;<bold>b</bold> spontaneously cyclized overnight
to afford a mixture of regioisomers. After separation by flash column
chromatography and amide coupling, this led to two distinct series:
1-benzylpyrazolo-5-carboxamides (Series A) and 1-benzylpyrazolo-3-carboxamides
(Series B, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).
Ring-opened analogue <bold>29</bold> was synthesized from <bold>50</bold> (see <xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>).</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Evaluation of Structurally Related
RIPK1 Inhibitors 8&#8211;11 and Analogues 19&#8211;26 and 29 against
LIMK1 and LIMK2 to Explore Early Structure-Activity Relationship (SAR)
of LIJTF500025 (7)</title></caption><graphic id="fx1" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00974_0015.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" rowspan="1">enzymatic
pIC<sub>50</sub>
<xref rid="t1fn1" ref-type="table-fn"/>
<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">R<sup>1</sup>
</th><th align="center" colspan="1" rowspan="1">R<sup>2</sup>
</th><th align="center" colspan="1" rowspan="1">series</th><th align="center" colspan="1" rowspan="1">LIMK1</th><th align="center" colspan="1" rowspan="1">LIMK2</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>7</bold>
</td><td align="left" colspan="1" rowspan="1">CONH<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">Cl</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">7.17<xref rid="t1fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.82<xref rid="t1fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>8</bold>
</td><td align="left" colspan="1" rowspan="1">Cl</td><td align="left" colspan="1" rowspan="1">CN</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">5.22<xref rid="t1fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>9</bold>
</td><td colspan="3" align="left" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">5.04<xref rid="t1fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">5.03<xref rid="t1fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>10</bold>
</td><td colspan="3" align="left" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">5.39<xref rid="t1fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>11</bold>
</td><td colspan="3" align="left" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">5.13<xref rid="t1fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">5.12<xref rid="t1fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>19</bold>
</td><td align="left" colspan="1" rowspan="1">Br</td><td align="left" colspan="1" rowspan="1">Cl</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">5.29&#160;&#177;&#160;0.57<xref rid="t1fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">5.91&#160;&#177;&#160;0.35<xref rid="t1fn3" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>20</bold>
</td><td align="left" colspan="1" rowspan="1">CONH<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">Cl</td><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">5.24<xref rid="t1fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">5.53<xref rid="t1fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>21</bold>
</td><td align="left" colspan="1" rowspan="1">CONH<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">6.98&#160;&#177;&#160;0.03<xref rid="t1fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.95&#160;&#177;&#160;0.09<xref rid="t1fn3" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>22</bold>
</td><td align="left" colspan="1" rowspan="1">CONH<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>23</bold>
</td><td align="left" colspan="1" rowspan="1">CONHMe</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">5.76<xref rid="t1fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">5.82<xref rid="t1fn2" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>24</bold>
</td><td align="left" colspan="1" rowspan="1">CONHMe</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>25</bold>
</td><td align="left" colspan="1" rowspan="1">CONMe<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">A</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>26</bold>
</td><td align="left" colspan="1" rowspan="1">CONMe<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>29</bold>
</td><td colspan="3" align="left" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">5.16<xref rid="t1fn2" ref-type="table-fn"/>
</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>The phosphorylation of cofilin was
assessed by RapidFire mass spectrometry following an enzymatic assay.</p></fn><fn id="t1fn2"><label>b</label><p>
<italic toggle="yes">n</italic> = 1.</p></fn><fn id="t1fn3"><label>c</label><p>Mean of two independent experiments.</p></fn></table-wrap-foot></table-wrap><p>RIPK1 inhibitors <bold>8&#8211;11</bold> were not
potent LIMK1
or LIMK2 inhibitors (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Given bromo analogue <bold>19</bold> also demonstrated
poor potency, these data strongly suggest the C5-substituted amide
moiety is indispensable for dual LIMK1/2 inhibitory activity. Indeed,
mono- or dimethylation of the primary amide (<bold>23</bold> and <bold>25</bold>, respectively) led to significant weaker inhibitors (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), consistent with
its known HBD interactions with LIMK1 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). Interestingly, comparison between the
1-benzylpyrazolo-5-carboxamide and 1-benzylpyrazolo-3-carboxamide
regioisomers showed a clear preference for the 5-regioisomer, with
the 3-regioisomer of <bold>7</bold> (<bold>20</bold>) displaying at
least 100-fold potency drop against LIMK1 and LIMK2. Breaking the
annulated 5,6-fused ring similarly led to weak inhibitory activity
(<bold>29</bold>, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), as did sulfonamide and secondary amine replacements of the amide
in compound <bold>29</bold> (data not shown). Therefore, these initial
SAR data indicate the tetrahydropyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-5-carboxamide
moiety is a privileged scaffold to develop potent LIMK1/2 inhibitors.
As the des-Cl analogue of <bold>7</bold> is also a highly potent RIPK1
inhibitor (compound 20, p<italic toggle="yes">K<sub>i</sub>
</italic> = 8.60<xref rid="ref43" ref-type="bibr"/>) and expectedly shows high RIPK1 binding in
a kinome selectivity panel (27% of control @1 &#956;M, data not shown),
we sought to eliminate off-target RIPK1 activity through a hybridization
approach with highly selective, allosteric LIMK inhibitors.</p><p>Using the X-ray crystal structures of LIMK2 bound to the allosteric
inhibitor TH-300 (<bold>30</bold>, PDB: <ext-link xlink:href="5NXD" ext-link-type="PDB">5NXD</ext-link>), <bold>7</bold> was overlaid in order
to identify possible sites for hybrid generation. Although there is
variance between the benzoxazepin-4-one and <italic toggle="yes">N</italic>-benzylpropyl
motifs, the spatial and electrostatic fields between the 2-benzyl
tetrahydropyrazolopyridine-3-carboxamide of <bold>7</bold> and <italic toggle="yes">N</italic>-phenylsulfamoylbenzamide of <bold>30</bold> share high
similarity (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A). In particular, the electrostatic potentials are shared in two
loci which demonstrate the common positioning of (i) the cyclic amide
carbonyl of <bold>7</bold> and branched amide carbonyl in <bold>30</bold>, and (ii) the primary amide carbonyl of <bold>7</bold> and sulfonamide
O in <bold>30</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B). Two instances where atoms from both series overlaid well
were identified:<list list-type="simple"><list-item><label>(1)</label><p>Carbonyl carbon of <bold>7</bold> with
the quaternary carbon of <bold>30</bold> (highlighted in yellow).</p></list-item><list-item><label>(2)</label><p>sp<sup>3</sup> Hybridized
carbon of <bold>7</bold> with the benzyl carbon of <bold>30</bold> (highlighted in
red, <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C).</p></list-item></list>
</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Overlay of RIPK1 inhibitor <bold>7</bold> (LIJTF500025)
and <bold>30</bold> (TH-300) and design of novel hybrids <bold>31</bold>-<bold>34</bold>. (A) Binding mode images of <bold>7</bold> (from
LIMK1,
PDB: <ext-link xlink:href="7ATU" ext-link-type="PDB">7ATU</ext-link>, magenta)
and <bold>30</bold> (from LIMK2, PDB: <ext-link xlink:href="5NXD" ext-link-type="PDB">5NXD</ext-link>, white). (B) The shape and electrostatic
field of <bold>30</bold> (LIMK2, <italic toggle="yes">loc cit</italic>.) with <bold>7</bold> (LIMK1, <italic toggle="yes">loc cit</italic>., magenta) overlaid. (C)
Chemical structures of <bold>7</bold> and <bold>30</bold> highlighting
key positions for hybrid generation (above) and designed hybrid molecules
(below).</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="jm5c00974_0003.jpg"/></fig><p>For the yellow highlighted position, two hybrids
were designed
whereby the tetrahydropyrazolopyridone ring was opened and the tertiary
amide was either extended by one CH<sub>2</sub> unit (hybrid <bold>31</bold>) or directly attached (hybrid <bold>32</bold>). In both
instances, we targeted synthesis of the methylene cyclopropyl-containing
amide as we previously observed a consistent 10-fold LIMK1/2 potency
improvement compared to the propyl substituent.<xref rid="ref39" ref-type="bibr"/> A further two hybrids were proposed based on the second
overlaid position highlighted in red; hybrid <bold>33</bold> that
replaces the benzyl substituent of <bold>30</bold> with the benzoxazepin-4-one
of <bold>7</bold>, and the reversed hybrid <bold>34</bold>, where
the tertiary carbon of <bold>7</bold> was replaced with the benzyl
group of <bold>30</bold>.</p><p>The synthesis of hybrid <bold>31</bold> proved challenging, with
first attempts focused on installing the primary amide prior to formation
of the tertiary amide bond (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>). Benzylation of 3,5-dibromopyrazole <bold>35</bold> proceeded cleanly, followed by a reported selective lithiation-quenching
with carbon dioxide,<xref rid="ref51" ref-type="bibr"/> which gave single
regioisomer <bold>37</bold>. Generation of the primary amide <bold>38</bold> via the acid chloride followed by a Suzuki reaction with
(<italic toggle="yes">E</italic>)-(2-ethoxyvinyl)&#173;boronic acid pinacol ester gave <bold>39</bold>, from which a single crystal was grown to confirm the regioselectivity
of the lithiation step (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>). Unfortunately, acidic deprotection to give the aldehyde <bold>40</bold> was unsuccessful due to intermolecular attack of the primary
amide on the aldehyde. Several different strategies to install the
CH<sub>2</sub>CO<sub>2</sub>H via bromo intermediate <bold>38</bold> also failed. A change in strategy to unveil the primary amide at
the end of the synthesis proved fruitful. Ester formation followed
by Suzuki reaction gave intermediate <bold>42</bold> in satisfactory
yield. This time, acidic deprotection to give the aldehyde was successful
and following oxidation (<bold>44</bold>), <italic toggle="yes">N</italic>-benzyl-1-cyclopropylmethanamine
was introduced via amide coupling to afford key intermediate <bold>45</bold>. Finally, ester hydrolysis (<bold>46</bold>) and primary
amide formation gave the target compound <bold>31</bold>.</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthesis
of Hybrid 31<xref rid="s1fn1" ref-type="fn"/>
</title></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c00974_0008.jpg"/><p>
<fn id="s1fn1"><label>a</label><p>Reagents and conditions:
(a)
(i) K<sub>2</sub>CO<sub>3</sub> (1.3 equiv), DMF, 0 &#176;C, (ii)
BnBr (1.0 equiv), 0 &#176;C &#8594; rt, 40 min, 96%; (b) (i) iPrMgCl&#183;LiCl
(1.2 equiv), THF, &#8722;78 &#176;C, 30 min, (ii) CO<sub>2</sub>,
20 min, 94%; (c) MeOH, SOCl<sub>2</sub> (3.0 equiv), rt, 18 h &#8594;
50 &#176;C, 18 h, 98%; (d) (<italic toggle="yes">E</italic>)-(2-ethoxyvinyl)&#173;boronic
acid pinacol ester (1.3 equiv), Pd&#173;(dppf)<sub>2</sub>Cl<sub>2</sub> (0.1 equiv), Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv), monoglyme/H<sub>2</sub>O, 80 &#176;C, 18 h, 39%; (e) 4 M HCl in 1:1 dioxane/DCM (8.0
equiv), rt, 1 h, quantitative; (f) oxone (1.0 equiv), DMF, rt, 1 h,
61%; (g) <italic toggle="yes">N</italic>-benzyl-1-cyclopropylmethanamine (1.0 equiv),
HOBt (1.1 equiv), EDC&#183;HCl (1.3 equiv), Et<sub>3</sub>N (1.5 equiv),
DCM, rt, 18 h, 22%; (h) LiOH&#183;H<sub>2</sub>O (1.3 equiv), 1:1:1
MeOH/THF/H<sub>2</sub>O, rt, 2 h, 98%; (i) PyBOP (1.4 equiv), HOBt
(1.4 equiv), DIPEA (3.9 equiv), NH<sub>4</sub>Cl (1.9 equiv), DMF,
rt, 1 h, 48%; (j) (i) SOCl<sub>2</sub> (19.6 equiv), 65 &#176;C, 2
h, (ii) NH<sub>4</sub>OH (5.9 equiv), DCM, rt, 5 min, 86% (over two
steps); (k) (<italic toggle="yes">E</italic>)-(2-ethoxyvinyl)&#173;boronic acid pinacol
ester (1.7 equiv), Pd&#173;(dppf)<sub>2</sub>Cl<sub>2</sub> (1.0 equiv),
Cs<sub>2</sub>CO<sub>3</sub> (1.2 equiv), monoglyme/H<sub>2</sub>O,
90 &#176;C, 18 h, 89%; (l) 4 M HCl in 1:1 dioxane (5.0 equiv)/DCM,
rt, 1 h.</p></fn>
</p></fig><p>Hybrid <bold>32</bold> was synthesized
according to <xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>. Benzylation of bis ester <bold>47</bold>, followed by a
partially selective monoester hydrolysis/primary amide formation sequence
as previously reported<xref rid="ref52" ref-type="bibr"/> gave intermediate <bold>49</bold>, initially as a mixture of regioisomers (4:1 ratio). The
major regioisomer was isolated and a single crystal grown for X-ray
analysis, confirming the desired regiochemistry (<xref rid="sch2" ref-type="fig">Scheme <xref rid="sch2" ref-type="fig"/>
</xref>). Subsequent ester hydrolysis
to form <bold>50</bold> and primary amide formation yielded the target
compound <bold>32</bold>.</p><fig position="float" id="sch2" fig-type="scheme" orientation="portrait"><label>2</label><caption><title>Synthesis of Hybrid 32<xref rid="s2fn1" ref-type="fn"/>
</title></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c00974_0009.jpg"/><p>
<fn id="s2fn1"><label>a</label><p>Reagents and conditions:
(a)
(i) K<sub>2</sub>CO<sub>3</sub> (1.3 equiv), DMF, 0 &#176;C, (ii)
BnBr (1.0 equiv), 0 &#176;C &#8594; rt, 1 h, 93%; (b) (i) LiOH&#183;H<sub>2</sub>O (1.0 equiv), 1:1:1 MeOH/THF/H<sub>2</sub>O, 0 &#176;C, 2
h, (ii) SOCl<sub>2</sub> (21.0 equiv), 65 &#176;C, 2 h, (iii) DCM,
NH<sub>4</sub>OH (4.0 equiv), rt, 5 min, 63%; (c) LiOH&#183;H<sub>2</sub>O (3 equiv), 1:1:1 MeOH/THF/H<sub>2</sub>O, rt, 30 min, 80%;
(d) (i) SOCl<sub>2</sub> (34.3 equiv), 65 &#176;C, 2 h, (ii) DCM,
Et<sub>3</sub>N (2.5 equiv), <italic toggle="yes">N</italic>-benzyl-1-cyclopropylmethanamine
(1.0 equiv), rt, 5 min, 21%.</p></fn>
</p></fig><p>Hybrid <bold>33</bold> was easily accessible through a one-step
amide coupling from the key amine intermediate <bold>51</bold> (<xref rid="sch3" ref-type="fig">Scheme <xref rid="sch3" ref-type="fig"/>
</xref>), synthesized as
previously described.<xref rid="ref29" ref-type="bibr"/> The final hybrid <bold>34</bold> was synthesized as shown in <xref rid="sch4" ref-type="fig">Scheme <xref rid="sch4" ref-type="fig"/>
</xref>. Iodination in the presence of ceric ammonium
nitrate followed by benzylation gave intermediate <bold>53</bold> in
high yield. Suzuki reaction and successful enol ether deprotection
gave the key aldehyde intermediate <bold>27</bold> in good yield.
Reductive cyclization using 2-methylpyridine-2-borane complex proceeded
cleanly, giving the expected two regioisomers <bold>55</bold> and <bold>56</bold> arising from cyclization onto either methyl ester. The
mixture of regioisomers were hydrolyzed and amide coupled to afford
primary amides <bold>34</bold> and <bold>57</bold> that were isolated
in 17% and 9% yields, respectively. Initially, we relied upon the
presence or absence of unique HMBC cross-peaks between the benzyl
CH<sub>2</sub>, amide NH<sub>2</sub> and lactam benzyl CH<sub>2</sub> for confirmation of the regiochemistry. However, we subsequently
noted consistent patterns in the <sup>1</sup>H NMR, specifically differences
in the peak position and splitting of the primary amide protons between
the two regioisomers (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>). Therefore,
regiochemical assignment was possible in the absence of HMBC experiments.</p><fig position="float" id="sch3" fig-type="scheme" orientation="portrait"><label>3</label><caption><title>Synthesis of Hybrid 33<xref rid="s3fn1" ref-type="fn"/>
</title></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c00974_0010.jpg"/><p>
<fn id="s3fn1"><label>a</label><p>Reagents and conditions:
(a)
4-(phenylsulfamoyl)&#173;benzoic acid (1.0 equiv), HOBt (1.1 equiv), EDC&#183;HCl
(1.2 equiv), DIPEA (2.6 equiv), DCM, rt, 5 min, 94%.</p></fn>
</p></fig><fig position="float" id="sch4" fig-type="scheme" orientation="portrait"><label>4</label><caption><title>Synthesis of Hybrid 34 and Regioisomer 57<xref rid="s4fn1" ref-type="fn"/>
</title></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c00974_0011.jpg"/><p>
<fn id="s4fn1"><label>a</label><p>Reagents and conditions:
(a)
I<sub>2</sub> (1.3 equiv), CAN (1.1 equiv), MeCN, rt, 48 h, 89%; (b)
(i) K<sub>2</sub>CO<sub>3</sub> (1.3 equiv), DMF, 0 &#176;C, (ii)
BnBr (1.0 equiv), 0 &#176;C &#8594; rt, 1 h, 90%; (c) (<italic toggle="yes">E</italic>)-(2-ethoxyvinyl)&#173;boronic acid pinacol ester (1.7 equiv), Pd&#173;(dppf)<sub>2</sub>Cl<sub>2</sub> (1.0 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2.1
equiv), monoglyme/water, 90 &#176;C, 48 h, 77%; (d) 6 M HCl in 1:1
dioxane/THF (18.1 equiv), 0 &#176;C &#8594; rt, 1 h, 66%; (e) benzylamine&#183;HCl
(1.3 equiv), 2-methylpyridine&#183;BH<sub>3</sub> complex (1.5 equiv),
AcOH (0.3 equiv), MeOH, 0 &#176;C, 3 h, 42% (<bold>55</bold>), 22%
(<bold>56</bold>); (f) (i) LiOH&#183;H<sub>2</sub>O (1.2 equiv), 1:1:1
MeOH/THF/H<sub>2</sub>O, rt, 18 h, (ii) HOBt (1.1 equiv), EDC&#183;HCl
(1.3 equiv), DIPEA (2.4 equiv), NH<sub>4</sub>Cl (3 equiv), DCM, rt,
18 h, 9% (for <bold>34</bold>); (g) 7 M NH<sub>3</sub> in MeOH (87.5
equiv), 70 &#176;C, 18 h, sealed tube, 17% (for <bold>57</bold>).</p></fn>
</p></fig><p>All four hybrid targets <bold>31</bold>-<bold>34</bold> and regioisomer <bold>57</bold> were subsequently tested
in a range of LIMK1/2 <italic toggle="yes">in vitro</italic> assays (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). LIMK1/2 binding dissociation
constants (<italic toggle="yes">K</italic>
<sub>d</sub>) were measured using the <italic toggle="yes">K</italic>
<sub>d</sub>ELECT platform (provided by Eurofins/DiscoverX)
and inhibitory
activity assessed using our previously reported RapidFire mass spectrometry
assay.<xref rid="ref29" ref-type="bibr"/> Cellular target engagement and
LIMK selectivity was measured using LIMK1 and LIMK2 NanoBRET assays
in HEK293 cells, while cellular proof-of-mechanism was assessed by
measuring p-cofilin levels in SH-SY5Y cells using the AlphaLISA platform.
Since cofilin is a substrate of both LIMK1 and LIMK2, our assay is
unable to assess selectivity against these enzymes in contrast to
the NanoBRET assay. Hybrids <bold>31</bold> and <bold>32</bold> did
not show any inhibition across the various assays and <bold>33</bold> showed only weak inhibition in the LIMK1/2 RapidFire assay (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). We were excited
to observe, however, that 1-benzylpyrazolo-5-carboxamide <bold>34</bold> showed potent LIMK1/2 binding and good inhibitory activity in both
RapidFire and cellular assays, showing a pIC<sub>50</sub> value of
6.20 in the AlphaLISA <italic toggle="yes">p</italic>-cofilin assay. On the other
hand, its 1-benzylpyrazolo-3-carboxamide regioisomer <bold>57</bold> was inactive in all <italic toggle="yes">in vitro</italic> assays (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). This result was corroborated
when we assessed all 1-benzylpyrazolo-3-carboxamides isomers that
were isolated during the course of synthesizing the active 5-carboxamides
(data not shown).</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Evaluation against LIMK1 and LIMK2
in Binding, Enzymatic and Cellular Target Engagement Assays Values
to Explore Structure&#8211;Activity Relationship (SAR) of Hybrids
31-34 and Regioisomer 57<xref rid="t2fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" rowspan="1">binding
affinity (p<italic toggle="yes">K</italic>
<sub>d</sub>)<xref rid="t2fn2" ref-type="table-fn"/>
<hr/></th><th colspan="2" align="center" rowspan="1">enzymatic
pIC<sub>50</sub>
<hr/></th><th colspan="2" align="center" rowspan="1">nanoBRET
pIC<sub>50</sub>
<hr/></th><th align="center" colspan="1" rowspan="1">&#160;</th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">LIMK1</th><th align="center" colspan="1" rowspan="1">LIMK2</th><th align="center" colspan="1" rowspan="1">LIMK1</th><th align="center" colspan="1" rowspan="1">LIMK2</th><th align="center" colspan="1" rowspan="1">LIMK1</th><th align="center" colspan="1" rowspan="1">LIMK2</th><th align="center" colspan="1" rowspan="1">alphaLISA pIC<sub>50</sub>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>7</bold>
</td><td align="left" colspan="1" rowspan="1">7.21<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.06<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.17<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.82<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">6.74&#160;&#177;&#160;0.15</td><td align="left" colspan="1" rowspan="1">7.02&#160;&#177;&#160;0.07</td><td align="left" colspan="1" rowspan="1">7.06&#160;&#177;&#160;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>21</bold>
</td><td align="left" colspan="1" rowspan="1">7.73&#160;&#177;&#160;0.04<xref rid="t2fn4" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.25&#160;&#177;&#160;0.04<xref rid="t2fn4" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">6.98&#160;&#177;&#160;0.03<xref rid="t2fn4" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.95&#160;&#177;&#160;0.09<xref rid="t2fn4" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">6.15<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">6.29<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">6.58&#160;&#177;&#160;0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>31</bold>
</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>32</bold>
</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>33</bold>
</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">5.01<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">5.22<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>34</bold>
</td><td align="left" colspan="1" rowspan="1">6.80&#160;&#177;&#160;0.11</td><td align="left" colspan="1" rowspan="1">7.29&#160;&#177;&#160;0.05</td><td align="left" colspan="1" rowspan="1">6.16<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">7.03<xref rid="t2fn3" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">5.77&#160;&#177;&#160;0.13</td><td align="left" colspan="1" rowspan="1">6.04&#160;&#177;&#160;0.01</td><td align="left" colspan="1" rowspan="1">6.20&#160;&#177;&#160;0.43<xref rid="t2fn4" ref-type="table-fn"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>57</bold>
</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">nd</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Data are reported as mean &#177;
SEM of at least three independent experiments, unless otherwise stated.</p></fn><fn id="t2fn2"><label>b</label><p>Screened at DiscoverX, Eurofins
(San Diego).</p></fn><fn id="t2fn3"><label>c</label><p>
<italic toggle="yes">n</italic> = 1.</p></fn><fn id="t2fn4"><label>d</label><p>Mean of two independent
experiments.
nd, not determined.</p></fn></table-wrap-foot></table-wrap><p>Based on novel analogue <bold>34</bold>, a series
of benzylic substituted
analogues and replacements <bold>58</bold>&#8211;<bold>72</bold> were
synthesized in an effort to increase LIMK1 potency (<xref rid="sch5" ref-type="fig">Schemes <xref rid="sch5" ref-type="fig"/>
</xref> and <xref rid="sch6" ref-type="fig">
<xref rid="sch6" ref-type="fig"/>
</xref>). Again, we leveraged SAR knowledge gained
from <bold>6</bold> where the cPr moiety increased LIMK1 inhibition
by at least 10-fold<xref rid="ref39" ref-type="bibr"/> and molecular docking
studies revealed that the benzylic position was the most suitable
position to incorporate this group. Intermediates <bold>73a</bold>&#8211;<bold>i</bold> were synthesized using a similar three-step
reductive amination, ester hydrolysis and amide coupling route of
a benzyl substituted or nonaromatic amine (<xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>), as previously discussed. However, we observed
the majority of reductive aminated intermediates underwent spontaneous
cyclization to form two regioisomers (in approximately 1:1 ratio)
upon storage that negated the requirement for a conventional intramolecular
amide coupling. Primary amide formation was accomplished by refluxing
in methanolic NH<sub>3</sub> to afford final compounds <bold>58</bold>&#8211;<bold>66</bold> (<xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>). Hydrolysis product <bold>67</bold> was also isolated
as a side product from synthesis of <bold>58</bold>. As expected,
sterically hindered amines leading to <bold>68</bold>&#8211;<bold>71</bold> and <bold>79</bold> failed to undergo ring cyclization
spontaneously, and instead were prepared according to <xref rid="sch6" ref-type="fig">Scheme <xref rid="sch6" ref-type="fig"/>
</xref> through a two-step, one-pot
amide coupling of dicarboxylic acid <bold>78a</bold>&#8211;<bold>c</bold> with the respective amine and NH<sub>4</sub>Cl. Compound <bold>71</bold> was afforded from reductive amination of elaborated amine <bold>76</bold>, itself synthesized through a two-step S<sub>N</sub>Ar
and Grignard addition from <bold>74</bold> (<xref rid="sch6" ref-type="fig">Scheme <xref rid="sch6" ref-type="fig"/>
</xref>). A putative hinge-binding hybrid <bold>72</bold> was also synthesized through Boc deprotection of intermediate <bold>79</bold> and subsequent amide coupling of <bold>80</bold> (<xref rid="sch6" ref-type="fig">Scheme <xref rid="sch6" ref-type="fig"/>
</xref>), as we noted significant
LIMK1 potency improvements when hybridized with our MDI-114215 series
(data not shown) in line with previous reports with the Type II kinase
inhibitor TH-470.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>,<xref rid="ref33" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="sch5" fig-type="scheme" orientation="portrait"><label>5</label><caption><title>Synthesis of Substituted
Tetrahydropyridinone Analogues <bold>58&#8211;67</bold>
<xref rid="s5fn1" ref-type="fn"/>
</title></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c00974_0012.jpg"/><p>
<fn id="s5fn1"><label>a</label><p>Reagents and conditions:
(a)
R<sup>1</sup>R <sup>2</sup>NH<sub>2</sub>&#183;HCl (1.3&#8211;1.5
equiv), Pic-BH<sub>3</sub> (0.9 equiv), AcOH (0.7&#8211;2.1 equiv),
MeOH, 0 &#176;C, 3 h; 19&#8211;61%; (b) R<sup>1</sup>R<sup>2</sup>NH<sub>2</sub> (1.0&#8211;1.5 equiv), STAB (2.5 equiv), AcOH (0.8&#8211;2.4
equiv), DCE, rt, 18 h; 13&#8211;51% (for <bold>73g</bold> and <bold>73h</bold>); (c) 2 M AlMe<sub>3</sub> in toluene (3.4 equiv), 100
&#176;C, 3 h, 53% (for <bold>73i</bold>); (d) 7 M NH<sub>3</sub> in
MeOH (32.4&#8211;148.9 equiv), 70 &#176;C, 18 h, sealed tube, 6&#8211;21%.</p></fn>
</p></fig><fig position="float" id="sch6" fig-type="scheme" orientation="portrait"><label>6</label><caption><title>Synthesis of Substituted Tetrahydropyridinone Analogues
68&#8211;72<xref rid="s6fn1" ref-type="fn"/>
</title></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c00974_0013.jpg"/><p>
<fn id="s6fn1"><label>a</label><p>Reagents and conditions:
(a)
2-methoxyethylamine (2.0 equiv), MeCN, 100 &#176;C, 18 h, sealed tube,
34%; (b) cPrMgBr (3.0 equiv), THF, 100 &#176;C, 15 min then NaBH<sub>4</sub> (5.0 equiv), MeOH, 0 &#176;C, 30 min, 47%; (c) R<sup>1</sup>R<sup>2</sup>NH<sub>2</sub>&#183;HCl (1.0 equiv), Pic-BH<sub>3</sub> (1.0&#8211;1.5 equiv), AcOH (1.1&#8211;1.9 equiv), MeOH, 0 &#176;C,
3 h, 22&#8211;45%; (d) LiOH&#183;H<sub>2</sub>O (3.0&#8211;5.0 equiv),
THF/MeOH/H<sub>2</sub>O, rt, 18 h, 78&#8211;91%; (e) NH<sub>4</sub>Cl (5.0 equiv), HOBt (1.1 equiv), EDC&#183;HCl (1.3 equiv), DIPEA
(2.4 equiv), DCM, rt, 18 h, 5&#8211;48%; (f) chiral separation; (g) <bold>79</bold>, 4 M HCl in 1,4-dioxane (33.3 equiv), DCM, rt, 2 h, quantitative;
(h) thiazole-5-carboxylic acid (1.0 equiv), HOBt (1.1 equiv), EDC&#183;HCl
(1.3 equiv), DIPEA (2.4 equiv), DCM, rt, 18 h, 42%.</p></fn>
</p></fig><p>The synthesized analogues <bold>58&#8211;72</bold> were
screened
for binding dissociation constants (<italic toggle="yes">K</italic>
<sub>d</sub>). Although not a measure of inhibition, we previously observed that
apparent <italic toggle="yes">K</italic>
<sub>d</sub> and RapidFire pIC<sub>50</sub> values were comparable across these <italic toggle="yes">in vitro</italic> assays
(see <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref> and previously
described<xref rid="ref39" ref-type="bibr"/>). The LIMK1/2 <italic toggle="yes">K</italic>
<sub>d</sub> binding data are shown in <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>. The benzyl ring was found to be largely
sensitive to substitutions with the most tolerated analogue <bold>60</bold> leading to an approximate 5-fold drop in LIMK1 potency
with LIMK2 potency unchanged. Further attempts to extend the benzyl
ring position (<bold>62</bold> and <bold>63</bold>) or replace with
nonaromatic groups resulted in even greater loss of LIMK1/2 potency
(<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>). Based on
a similar binding mode of <bold>7</bold> with LIMK1 compared to the
TH-300 (<bold>30</bold>)-LIMK2 structure, we hypothesize that the
benzyl ring forms a key &#960;-cation interaction with the protonated
K368, similar to other allosteric LIMK inhibitors. We and others have
demonstrated the importance of benzyl positioning and aromaticity
to maintain this interaction.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref41" ref-type="bibr"/>
</named-content> Turning attention to the benzylic position, pleasingly our rationale
to incorporate a racemic cPr group increased potency (<bold>68</bold>) and chiral resolution led to a significant potency gain against
LIMK1 for the <italic toggle="yes">R</italic>-enantiomer (<bold>69</bold>, <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>), whose absolute
configuration was confirmed by X-ray crystallography (<xref rid="sch6" ref-type="fig">Scheme <xref rid="sch6" ref-type="fig"/>
</xref>). Various alternative substituents
previously reported that project past the gatekeeper residue T316
toward the hinge region did not lead to any noticeable potency gain
(such as <bold>66</bold>), including the hinge-binding hybrid <bold>72</bold>.<xref rid="ref39" ref-type="bibr"/> Attempts to merge compound <bold>69</bold> with <bold>6</bold> conferred nonbinding hybrids such as <bold>71</bold> (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>), which was consistent with our benzyl SAR. Therefore, through our
SAR assessment, we identified <bold>69</bold> as a novel, highly potent
dual LIMK1/2 binder that could be suitable as a tool inhibitor to
explore LIMK biology.</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>3</label><caption><title>LIMK1 and LIMK2 <italic toggle="yes">K</italic>
<sub>d</sub> Values to Explore Structure&#8211;Activity Relationship
(SAR) of Substituted Tetrahydropyridinone Analogues 58&#8211;72</title></caption><graphic id="fx2" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00974_0016.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" rowspan="1">binding
affinity (p<italic toggle="yes">K</italic>
<sub>d</sub>)<xref rid="t3fn1" ref-type="table-fn"/>
<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">R<sup>1</sup>
</th><th align="center" colspan="1" rowspan="1">R<sup>2</sup>
</th><th align="center" colspan="1" rowspan="1">LIMK1</th><th align="center" colspan="1" rowspan="1">LIMK2</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>34</bold>
</td><td align="left" colspan="1" rowspan="1">Ph</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">6.80&#160;&#177;&#160;0.11</td><td align="left" colspan="1" rowspan="1">7.29&#160;&#177;&#160;0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>58</bold>
</td><td align="left" colspan="1" rowspan="1">Bn</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">5.31&#160;&#177;&#160;0.01</td><td align="left" colspan="1" rowspan="1">6.29&#160;&#177;&#160;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>59</bold>
</td><td align="left" colspan="1" rowspan="1">PhOCH<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">5.87&#160;&#177;&#160;0.09</td><td align="left" colspan="1" rowspan="1">7.02&#160;&#177;&#160;0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>60</bold>
</td><td align="left" colspan="1" rowspan="1">4-OH-Ph</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">6.08&#160;&#177;&#160;0.09</td><td align="left" colspan="1" rowspan="1">7.28&#160;&#177;&#160;0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>61</bold>
</td><td align="left" colspan="1" rowspan="1">4-OMe-Ph</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">5.95&#160;&#177;&#160;0.23</td><td align="left" colspan="1" rowspan="1">6.69&#160;&#177;&#160;0.21</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>62</bold>
</td><td align="left" colspan="1" rowspan="1">3-OH-Bn</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">5.31&#160;&#177;&#160;0.04</td><td align="left" colspan="1" rowspan="1">5.92&#160;&#177;&#160;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>63</bold>
</td><td align="left" colspan="1" rowspan="1">3-OMe-Bn</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">6.24&#160;&#177;&#160;0.23</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>64</bold>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>OMe</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">5.13&#160;&#177;&#160;0.14</td><td align="left" colspan="1" rowspan="1">5.90&#160;&#177;&#160;0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>65</bold>
</td><td align="left" colspan="1" rowspan="1">CON(Me)<sub>2</sub>
</td><td align="left" colspan="1" rowspan="1">H</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">5.28&#160;&#177;&#160;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>66</bold>
<xref rid="t3fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">Ph</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>CH<sub>2</sub>OH</td><td align="left" colspan="1" rowspan="1">6.73&#160;&#177;&#160;0.01</td><td align="left" colspan="1" rowspan="1">6.65&#160;&#177;&#160;0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>67</bold>
</td><td colspan="2" align="left" rowspan="1">see <xref rid="sch5" ref-type="fig">Scheme <xref rid="sch5" ref-type="fig"/>
</xref>
</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>68</bold>
<xref rid="t3fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">Ph</td><td align="left" colspan="1" rowspan="1">cPr</td><td align="left" colspan="1" rowspan="1">7.37&#160;&#177;&#160;0.11</td><td align="left" colspan="1" rowspan="1">6.87&#160;&#177;&#160;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>69</bold>
</td><td align="left" colspan="1" rowspan="1">Ph</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>-cPr</td><td align="left" colspan="1" rowspan="1">7.80&#160;&#177;&#160;0.20</td><td align="left" colspan="1" rowspan="1">7.12&#160;&#177;&#160;0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>70</bold>
</td><td align="left" colspan="1" rowspan="1">Ph</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">S</italic>-cPr</td><td align="left" colspan="1" rowspan="1">6.87&#160;&#177;&#160;0.05</td><td align="left" colspan="1" rowspan="1">6.73&#160;&#177;&#160;0.12</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>71</bold>
<xref rid="t3fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">2-((CH<sub>2</sub>)<sub>2</sub>OMe)-Ph</td><td align="left" colspan="1" rowspan="1">cPr</td><td align="left" colspan="1" rowspan="1">&lt;5</td><td align="left" colspan="1" rowspan="1">&lt;5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>72</bold>
</td><td colspan="2" align="left" rowspan="1">see <xref rid="sch6" ref-type="fig">Scheme <xref rid="sch6" ref-type="fig"/>
</xref>
</td><td align="left" colspan="1" rowspan="1">6.27&#160;&#177;&#160;0.05</td><td align="left" colspan="1" rowspan="1">5.92&#160;&#177;&#160;0.08</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Data are reported as mean &#177;
SEM of at least two independent experiments.</p></fn><fn id="t3fn2"><label>b</label><p>Racemic.</p></fn></table-wrap-foot></table-wrap><p>Modeling of the binding mode of MDI-117740 (<bold>69</bold>) in
LIMK1 (PDB: <ext-link xlink:href="7ATU" ext-link-type="PDB">7ATU</ext-link>) shows good alignment with LIJTF500025 (<bold>7</bold>, <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>), maintaining the
key hydrogen bonding interactions with H458, D478 and L397 as described
for <bold>7</bold> (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>A). However, a difference in binding mode of the benzyl cyclopropylmethylene
moiety is predicted which projects the amide substituents of <bold>7</bold> and <bold>69</bold> into different vectors (as shown by
magenta and green arrows, respectively, <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>). The docked structure of <bold>69</bold> suggests that the <italic toggle="yes">R</italic>-cyclopropyl group pushes into
a small hydrophobic pocket enclosed by F479, the alkyl chain of K368,
V366 and L367, which occupies the same hydrophobic niche of the <italic toggle="yes">N</italic>-Me group in <bold>7</bold>. Meanwhile, the phenyl ring
is presented toward a hydrophobic tunnel comprising L370, L481, F411,
and the alkyl chain of K368 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>). This hydrophobic tunnel is the same as that exploited
by MDI-114215 (<bold>6</bold>) with an ethanolamine-substituted aromatic
pendant.<xref rid="ref39" ref-type="bibr"/>
</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Overlay of modeled <bold>69</bold> (MDI-117740,
green) superimposed
with <bold>7</bold> (LIJTF500025, magenta) in LIMK1 (PDB: <ext-link xlink:href="7ATU" ext-link-type="PDB">7ATU</ext-link>, magenta). Ligands
were extracted from LIMK1 for clarity.</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="jm5c00974_0004.jpg"/></fig><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Novel LIMK1 binding mode revealed with <bold>69</bold> (MDI-117740).
(A) <bold>69</bold> docked into the <bold>7</bold>-LIMK1 cocrystal
structure (PDB: <ext-link xlink:href="7ATU" ext-link-type="PDB">7ATU</ext-link>). The stereo configuration of the tetrahydropyrazolopyridinone core
positions the benzyl cyclopropylmethylene moiety in a different subpocket
compared to <bold>7</bold> (LIJTF500025), as detailed in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>. (B) Ligand interaction
diagram of <bold>69</bold>. Shading represents the following: hydrophobic
area (green), charged interaction (positive, blue; negative, red),
polar (teal).</p></caption><graphic id="gr12" position="float" orientation="portrait" xlink:href="jm5c00974_0005.jpg"/></fig><p>Using novel compound <bold>34</bold> as a template,
we also further
explored SAR around the primary amide through synthesis of various
amide replacements (<bold>81</bold>&#8211;<bold>91</bold>), substituted
amides (<bold>82</bold>&#8211;<bold>88</bold>) and amide isosteres
(<bold>89</bold>&#8211;<bold>90</bold>, <xref rid="sch7" ref-type="fig">Scheme <xref rid="sch7" ref-type="fig"/>
</xref>). The cocrystal structure of <bold>7</bold> bound to LIMK1 (PDB: <ext-link xlink:href="7ATU" ext-link-type="PDB">7ATU</ext-link>) shows a bidentate H-bond interaction between the
primary amide and L397/M388 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>) that we speculated was similarly important for LIMK1
potency on our new scaffold. To confirm this, a small set of secondary
and tertiary amides <bold>82</bold>&#8211;<bold>88</bold> were synthesized
through methyl ester <bold>55</bold> or carboxylic acid <bold>81</bold> that was amenable to various amide coupling conditions (<xref rid="sch7" ref-type="fig">Scheme <xref rid="sch7" ref-type="fig"/>
</xref>). 1,3,4-Oxadiazole <bold>89</bold> was synthesized from hydrazide <bold>87</bold> and triethylorthoformate
under reflux, while partially reduced oxazole <bold>90</bold> was
generated from intramolecular cyclization of compound <bold>88</bold> under Mitsunobu conditions (<xref rid="sch7" ref-type="fig">Scheme <xref rid="sch7" ref-type="fig"/>
</xref>). Attempts to oxidize the semireduced oxazole under
various oxidation conditions (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., DDQ) unfortunately failed to furnish the desired oxazole product.
Nitrile analogue <bold>91</bold> was synthesized by dehydrating primary
amide <bold>34</bold> under the action of TFAA (<xref rid="sch7" ref-type="fig">Scheme <xref rid="sch7" ref-type="fig"/>
</xref>).</p><fig position="float" id="sch7" fig-type="scheme" orientation="portrait"><label>7</label><caption><title>Synthesis of Substituted Amides 82&#8211;88,
Amide Isosteres 89&#8211;90
and Nitrile Analogue 91<xref rid="s7fn1" ref-type="fn"/>
</title></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="jm5c00974_0014.jpg"/><p>
<fn id="s7fn1"><label>a</label><p>Reagents and conditions:
(a)
NH<sub>2</sub>NH<sub>2</sub> (23.6 equiv), EtOH, 90 &#176;C, 6 h,
quantitative (when R = NH<sub>2</sub>); (b) NH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>OH, DIPEA, MeOH, 130 &#176;C, 16 h, 86% (when
R = (CH<sub>2</sub>)<sub>2</sub>OH); (c) RNH<sub>2</sub> (1.5 equiv),
T3P (3.0 equiv), DIPEA (2.6 equiv), THF, rt, 18 h, 5&#8211;35%; (d)
RNH<sub>2</sub> (1.3&#8211;1.5 equiv), HOBt (1.1 equiv), EDC&#183;HCl
(1.3 equiv), DIPEA (2.5 equiv), DCM, rt, 18 h, 15&#8211;18%; (e)
HC&#173;(OEt)<sub>3</sub> (37.6 equiv), 100 &#176;C, 18 h, 7%; (f) DEAD
(1.5 equiv), PPh<sub>3</sub> (1.5 equiv), toluene, rt, 18 h, 4%; (g)
TFAA (5.3 equiv), Et<sub>3</sub>N (7.5 equiv), DCM, rt, 18 h, 40%.</p></fn>
</p></fig><p>The synthesized substituted amides and primary
amide replacements
were then screened against LIMK1 and LIMK2 in the <italic toggle="yes">K</italic>
<sub>d</sub>ELECT assay. The results unequivocally demonstrated that
the primary amide was indispensable for LIMK1/2 binding (<xref rid="tbl4" ref-type="table">Table <xref rid="tbl4" ref-type="table"/>
</xref>). The majority of
compounds were found to be inactive with only weak binding affinities
recorded for nitrile analogue <bold>91</bold> (<xref rid="tbl4" ref-type="table">Table <xref rid="tbl4" ref-type="table"/>
</xref>). The strong requirement for an unsubstituted
primary amide is consistent with both (i) <bold>7</bold>-LIMK1 structure
which forms key H-bond interactions with the protein through each
amidic NH, and (ii) overlay of <bold>7</bold> with the TH-300 (<bold>30</bold>)-LIMK2 structure (PDB: <ext-link xlink:href="5NXD" ext-link-type="PDB">5NXD</ext-link>) that superposes the primary amide with
the sulfonamide (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A), a group which also could not be substituted or replaced.<xref rid="ref39" ref-type="bibr"/> Indeed, similar to the primary amide-sulfonamide
comparison, the benzyl ring of <bold>7</bold> superimposes very well
with the aniline ring of <bold>30</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A), which we and others showed does not tolerate
any modification.<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref41" ref-type="bibr"/>
</named-content> Therefore, we regard this region
where type III allosteric inhibitors <bold>6</bold> and <bold>7</bold> bind deep into the protein pocket as inflexible and their unique
space filling properties and H-bond interaction network as pivotal
to LIMK1/2 binding or inhibition. As a result, we decided against
further exploring modifications to the benzyl ring.</p><table-wrap position="float" id="tbl4" orientation="portrait"><label>4</label><caption><title>LIMK1 and LIMK2 <italic toggle="yes">K</italic>
<sub>d</sub> Values to Explore Structure&#8211;Activity Relationship
(SAR) of the Primary Amide of Lead Compound 34</title></caption><graphic id="fx3" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00974_0017.jpg"/><graphic id="fx4" position="float" orientation="portrait" xlink:href="jm5c00974_0018.jpg"/><table-wrap-foot><fn id="t4fn1"><label>a</label><p>Data are reported as mean &#177;
SEM of at least two independent experiments.</p></fn></table-wrap-foot></table-wrap><p>The most optimized molecule <bold>69</bold> was further
evaluated
for its suitability as an <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in
vivo</italic> tool by assessing cellular activity and DMPK properties
(<xref rid="tbl5" ref-type="table">Table <xref rid="tbl5" ref-type="table"/>
</xref>). <bold>69</bold> displayed excellent cellular target engagement and potently inhibits
p-cofilin levels in SH-SY5Y cells. The <italic toggle="yes">in vitro</italic> DMPK
properties of <bold>69</bold> were also significantly improved (<xref rid="tbl5" ref-type="table">Table <xref rid="tbl5" ref-type="table"/>
</xref>) compared to <bold>6</bold> (aqueous solubility = 11 &#956;M, rat/human microsomal
CL<sub>int</sub> = 289/98 &#956;L/min/mg), a type III allosteric
dual LIMK1/2 inhibitor that we recently disclosed where optimizing
drug clearance was challenging.<xref rid="ref39" ref-type="bibr"/> Given
its promising <italic toggle="yes">in vitro</italic> DMPK profile, we then assessed
ADME properties of <bold>69</bold> through <italic toggle="yes">in vivo</italic> PK evaluation. The low <italic toggle="yes">in vitro</italic> microsomal clearance
translated to low <italic toggle="yes">in vivo</italic> CL<sub>int</sub> in male
Sprague&#8211;Dawley rats and, again, was improved compared to <bold>6</bold> (CL<sub>int</sub> = 33 mL/min/kg). This in turn led to enhanced
drug exposure for <bold>69</bold> (654 nM), achieving &gt;40-fold
and
&gt;8-fold greater total drug concentration than LIMK1 and LIMK2 <italic toggle="yes">K</italic>
<sub>d</sub>, respectively. Other key parameters (<italic toggle="yes">V</italic>
<sub>D</sub>, <italic toggle="yes">T</italic>
<sub>1/2</sub>) were also
acceptable after i.v. dosing (<xref rid="tbl5" ref-type="table">Table <xref rid="tbl5" ref-type="table"/>
</xref>). Unfortunately, oral bioavailability of <bold>69</bold> was very low with maximal drug concentrations (<italic toggle="yes">C</italic>
<sub>max</sub>) in plasma reaching approximately 27 ng/mL after p.o.
dosing (at 3 mg/kg) and no evidence of good CNS penetration was observed
after i.p. dosing (at 10 mg/kg, <xref rid="tbl5" ref-type="table">Table <xref rid="tbl5" ref-type="table"/>
</xref>). The limited CNS penetration of <bold>69</bold>,
similar to other type III allosteric LIMK inhibitors, represents a
limitation for studies exploring the role of LIMKs in neuronal function
or synaptic regulation. Therefore, we suspected that <bold>69</bold> was a drug efflux substrate given the effect of different routes
of administration on the <italic toggle="yes">in vivo</italic> PK profile.</p><table-wrap position="float" id="tbl5" orientation="portrait"><label>5</label><caption><title>
<italic toggle="yes">In Vitro</italic> and <italic toggle="yes">In Vivo</italic> DMPK Properties of <bold>69</bold>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">69 (MDI-117740)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">nanoBRET LIMK1/2 pIC<sub>50</sub>
<xref rid="t5fn1" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">6.73&#160;&#177;&#160;0.09/7.18&#160;&#177;&#160;0.18</td></tr><tr><td align="left" colspan="1" rowspan="1">alphaLISA <italic toggle="yes">p</italic>-cofilin pIC<sub>50</sub>
<xref rid="t5fn1" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">6.89&#160;&#177;&#160;0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">aq. solubility (&#956;M, pH 7.0)<xref rid="t5fn2" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">85</td></tr><tr><td align="left" colspan="1" rowspan="1">R/H<xref rid="t5fn3" ref-type="table-fn"/> microsomal CL (&#956;L/min/mg)</td><td align="left" colspan="1" rowspan="1">96/48</td></tr><tr><td align="left" colspan="1" rowspan="1">i.v. dose (mg/kg)</td><td align="left" colspan="1" rowspan="1">0.2</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>inf</sub> (h&#183;ng/mL)</td><td align="left" colspan="1" rowspan="1">262</td></tr><tr><td align="left" colspan="1" rowspan="1">CL<sub>int</sub> (mL/min/kg)</td><td align="left" colspan="1" rowspan="1">13</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">V</italic>
<sub>D</sub> (L/kg)</td><td align="left" colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">T</italic>
<sub>1/2</sub> (h)</td><td align="left" colspan="1" rowspan="1">0.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (ng/mL)<xref rid="t5fn4" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">26.7</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub> (h)<xref rid="t5fn4" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">0.4</td></tr><tr><td align="left" colspan="1" rowspan="1">F%<xref rid="t5fn5" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">B/P ratio<xref rid="t5fn6" ref-type="table-fn"/>
</td><td align="left" colspan="1" rowspan="1">0.02</td></tr></tbody></table><table-wrap-foot><fn id="t5fn1"><label>a</label><p>Data are reported as mean &#177;
SEM of at least three independent experiments.</p></fn><fn id="t5fn2"><label>b</label><p>Average of at least two separate
experiments.</p></fn><fn id="t5fn3"><label>c</label><p>Rat and human
microsomes.</p></fn><fn id="t5fn4"><label>d</label><p>Determined after
p.o. dosing at
3 mg/kg.</p></fn><fn id="t5fn5"><label>e</label><p>Determined by comparison
with 3
mg/kg dosing p.o.</p></fn><fn id="t5fn6"><label>f</label><p>Determined
internally after i.p.
dosing at 10 mg/kg.</p></fn></table-wrap-foot></table-wrap><p>We carried out a structure-permeability relationship
study to prove <bold>69</bold> was a drug efflux substrate and identify
the chemical motifs
responsible for poor permeability. Compounds were assessed in the
Caco-2 permeability assay as it is widely used as a model of the intestinal
epithelial barrier and thus predicts human intestinal permeability.
The results are presented in <xref rid="tbl6" ref-type="table">Table <xref rid="tbl6" ref-type="table"/>
</xref>. In summary, we confirmed that <bold>69</bold> was
a drug efflux substrate (ER = 5.5). Structure-permeability relationships
also clearly showed that 1-benzylpyrazolo-5-carboxamides were exclusively
subject to high efflux (ER &gt; 2), whereas 1-benzylpyrazolo-3-carboxamides
(<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>. <bold>57</bold>), primary
amide isosteres/replacements (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., <bold>89</bold>) or ring-opened analogue <bold>32</bold> demonstrated
low ER (<xref rid="tbl6" ref-type="table">Table <xref rid="tbl6" ref-type="table"/>
</xref>). Thus,
the privileged 1-benzylpyrazolo-5-carboxamide scaffold necessary for
potent dual LIMK1/2 inhibition also leads to high drug efflux precluding
oral dosing (and most likely low CNS penetration) that could not be
separated, presenting significant challenges in developing a highly
potent, selective, CNS-penetrant series with good oral bioavailability.</p><table-wrap position="float" id="tbl6" orientation="portrait"><label>6</label><caption><title>Caco-2 Permeabilities and Efflux Ratios
of Selected Compounds</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="&#xB1;" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" char="&#xB1;" rowspan="1">caco-2
permeability<xref rid="t6fn1" ref-type="table-fn"/>
<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" char="&#xB1;" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
<sub>app(A&#8211;B)</sub> (&#215;10<sup>&#8211;6</sup>&#160;cm/s)</th><th align="center" char="." colspan="1" rowspan="1">ER<xref rid="t6fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">mean % recovery (A&#8211;B/B&#8211;A)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">antipyrine<xref rid="t6fn3" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">44.1&#160;&#177;&#160;1.59</td><td align="char" char="." colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1">86.6/92.7</td></tr><tr><td align="left" colspan="1" rowspan="1">atenolol<xref rid="t6fn4" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.28&#160;&#177;&#160;0.02</td><td align="char" char="." colspan="1" rowspan="1">1.94</td><td align="left" colspan="1" rowspan="1">87.8/93.8</td></tr><tr><td align="left" colspan="1" rowspan="1">talinolol<xref rid="t6fn5" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.31&#160;&#177;&#160;0.07</td><td align="char" char="." colspan="1" rowspan="1">37.9</td><td align="left" colspan="1" rowspan="1">79.1/92.0</td></tr><tr><td align="left" colspan="1" rowspan="1">estrone 3-sulfate<xref rid="t6fn6" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.45&#160;&#177;&#160;0.06</td><td align="char" char="." colspan="1" rowspan="1">52.3</td><td align="left" colspan="1" rowspan="1">61.4/84.4</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>7</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">5.11&#160;&#177;&#160;0.51</td><td align="char" char="." colspan="1" rowspan="1">13.9</td><td align="left" colspan="1" rowspan="1">85.9/74.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>19</bold>
<xref rid="t6fn7" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">6.84&#160;&#177;&#160;0.16</td><td align="char" char="." colspan="1" rowspan="1">1.20</td><td align="left" colspan="1" rowspan="1">36.5/25.9</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>21</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">3.06&#160;&#177;&#160;0.08</td><td align="char" char="." colspan="1" rowspan="1">14.6</td><td align="left" colspan="1" rowspan="1">91.2/85.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>32</bold>
<xref rid="t6fn8" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">18.8&#160;&#177;&#160;1.89</td><td align="char" char="." colspan="1" rowspan="1">2.00</td><td align="left" colspan="1" rowspan="1">40.5/66.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>34</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">7.00&#160;&#177;&#160;0.74</td><td align="char" char="." colspan="1" rowspan="1">6.79</td><td align="left" colspan="1" rowspan="1">85.4/85.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>55</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">40.6&#160;&#177;&#160;0.95</td><td align="char" char="." colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1">72.3/63.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>57</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">28.3&#160;&#177;&#160;1.22</td><td align="char" char="." colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1">63.2/66.5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>59</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">10.0&#160;&#177;&#160;0.52</td><td align="char" char="." colspan="1" rowspan="1">5.54</td><td align="left" colspan="1" rowspan="1">82.9/81.5</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>64</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">1.93&#160;&#177;&#160;0.30</td><td align="char" char="." colspan="1" rowspan="1">11.0</td><td align="left" colspan="1" rowspan="1">87.1/96.1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>66</bold>
<xref rid="t6fn9" ref-type="table-fn"/>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">0.38&#160;&#177;&#160;0.17</td><td align="char" char="." colspan="1" rowspan="1">86.9</td><td align="left" colspan="1" rowspan="1">84.2/84.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>68</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">8.29&#160;&#177;&#160;0.44</td><td align="char" char="." colspan="1" rowspan="1">6.32</td><td align="left" colspan="1" rowspan="1">77.2/65.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>69</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">10.1&#160;&#177;&#160;0.07</td><td align="char" char="." colspan="1" rowspan="1">5.52</td><td align="left" colspan="1" rowspan="1">81.5/82.2</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>82</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">12.8&#160;&#177;&#160;0.53</td><td align="char" char="." colspan="1" rowspan="1">4.29</td><td align="left" colspan="1" rowspan="1">76.1/85.7</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>89</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">44.5&#160;&#177;&#160;1.86</td><td align="char" char="." colspan="1" rowspan="1">1.09</td><td align="left" colspan="1" rowspan="1">84.4/85.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>90</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">38.5&#160;&#177;&#160;2.84</td><td align="char" char="." colspan="1" rowspan="1">1.04</td><td align="left" colspan="1" rowspan="1">69.8/71.0</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>91</bold>
</td><td align="char" char="&#xB1;" colspan="1" rowspan="1">35.0&#160;&#177;&#160;0.22</td><td align="char" char="." colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">72.3/64.3</td></tr></tbody></table><table-wrap-foot><fn id="t6fn1"><label>a</label><p>Data are reported as mean &#177;
SD of at least two independent experiments.</p></fn><fn id="t6fn2"><label>b</label><p>Efflux is calculated as <italic toggle="yes">P</italic>
<sub>app(A&#8211;B)</sub>/<italic toggle="yes">P</italic>
<sub>app(B&#8211;A)</sub>.</p></fn><fn id="t6fn3"><label>c</label><p>Human absorption = 97%.</p></fn><fn id="t6fn4"><label>d</label><p>Human absorption = 50%.</p></fn><fn id="t6fn5"><label>e</label><p>Known P-gp substrate.</p></fn><fn id="t6fn6"><label>f</label><p>Known BCRP substrate.</p></fn><fn id="t6fn7"><label>g</label><p>High <italic toggle="yes">C</italic>
<sub>0</sub> value
A&#8211;B direction and low recovery B&#8211;A direction.</p></fn><fn id="t6fn8"><label>h</label><p>Low <italic toggle="yes">C</italic>
<sub>0</sub> value
B&#8211;A direction was observed.</p></fn><fn id="t6fn9"><label>i</label><p>Compound concentration from basolateral
compartment below limit of quantification.</p></fn></table-wrap-foot></table-wrap><p>As exquisite kinome selectivity is an essential requirement
for
developing a LIMK selective tool compound, we assessed the wider kinome
selectivity of <bold>69</bold> using the Eurofins/DiscoverX scanMAX
panel of 468 kinases (which employs the KINOMEscan Technology, further
details at <uri xlink:href="https://www.eurofinsdiscovery.com/solution/kinomescan-technology">https://www.eurofinsdiscovery.com/solution/kinomescan-technology</uri>, full kinome screening data are reported in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). We chose to screen at a single concentration of
300 nM as approximately 10-fold LIMK1 <italic toggle="yes">K</italic>
<sub>d</sub> (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>) and a selectivity
score, S(35)-score, was calculated by dividing the number of kinases
that bind by &gt;35% with the total number of kinases tested in the
panel.
Smaller scores indicate higher selectivity and was used to facilitate
comparison with reported literature LIMK inhibitors. The selectivity
screen revealed an S(35)-score of 0.005 (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>), making <bold>69</bold> the most selective
dual LIMK1/2 inhibitor reported to date.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>,<xref rid="ref33" ref-type="bibr"/>
</named-content> Importantly, no binding to RIPK1 was observed, a known off-target
of <bold>7</bold>.<named-content content-type="bibref-group">
<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref43" ref-type="bibr"/>
</named-content> In addition, <bold>69</bold> does
not bind PAK1&#8211;2/4, ROCK1/2, MRCK&#945; or CAMK4 that are known
to activate LIMK1/2 through phosphorylation.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref53" ref-type="bibr"/>
</named-content> Such a selective
LIMK inhibitor is critical to prevent assay misinterpretation for
researchers wanting to investigate LIMKs in health and disease, similar
to previous observations with the now known dual LIMK/PAK inhibitor
FRAX486.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>,<xref rid="ref34" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Kinome selectivity profiling of MDI-117740 (<bold>69</bold>). Selectivity
profile using the scanMAX kinome wide selectivity assay (Eurofins),
screened at 300 nM. Data are illustrated using the TREE<sub>spot</sub> interaction map (DiscoverX). <sup>a</sup>Number of nonmutant kinases
that <bold>69</bold> binds to with %Ctrl &lt;35 divided by the total
number of distinct kinases tested.</p></caption><graphic id="gr13" position="float" orientation="portrait" xlink:href="jm5c00974_0006.jpg"/></fig><p>To assess the functional impact of <bold>69</bold> on cell motility,
an <italic toggle="yes">in vitro</italic> wound healing assay was performed in
MDA-MB-231 cells for 48 h. A scratch was induced to confluent monolayers
and cells were treated with <bold>69</bold>, FRAX486 (<bold>2</bold>) or a structurally related negative control (<bold>57</bold>, enzymatic
LIMK1/2 pIC<sub>50</sub> &lt; 5, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) at three separate concentrations (0.25 &#956;M,
1 &#956;M, and 3 &#956;M) or untreated control. <bold>2</bold> was
selected as the positive control as it was previously shown to significantly
inhibit TNBC MDA-MB-231 cell migration in wound healing assays.<xref rid="ref54" ref-type="bibr"/> Wound closure was measured over 48 h and the
percentage wound closure was quantified relative to the initial wound
area. Treatment with compound <bold>69</bold> significantly inhibited
wound closure compared to untreated control at 0.25 &#956;M and 1
&#956;M concentrations (<italic toggle="yes">p</italic> = 0.049 and <italic toggle="yes">p</italic> = 0.019, respectively) and had a more pronounced effect observed
at 3 &#956;M (<italic toggle="yes">p</italic> = 0.006, <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>A). LIMK inhibitor <bold>2</bold> also induced
significant effects on cell migration (0.25 &#956;M <italic toggle="yes">p</italic> = 0.015, 1 &#956;M <italic toggle="yes">p</italic> = 0.002 and 3 &#956;M <italic toggle="yes">p</italic> = 0.001, <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>B), consistent with previous literature.<xref rid="ref54" ref-type="bibr"/> No significant effect was observed for <bold>57</bold> (<italic toggle="yes">p</italic> = 0.46, <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>A/B). It should be noted that cells treated at higher concentrations
of compound <bold>2</bold> appear more rounded which may indicate
mitotic arrest, a phenotype not observed upon treatment with compounds <bold>57</bold> or <bold>69</bold>. Given that <bold>2</bold> has broader
kinome promiscuity than <bold>69</bold>,<xref rid="ref29" ref-type="bibr"/> this suggests that <bold>2</bold> might act on additional targets
involved in cell division beyond LIMK1 or LIMK2. Further cell cycle
analysis is warranted to confirm these observations. Taken together,
these data strongly suggest that <bold>69</bold> is a potent and highly
selective dual-LIMK1/2 inhibitor that demonstrates cellular target
engagement, potent inhibition of cofilin phosphorylation, and positive
LIMK-dependent downstream phenotypic effects on cell migration.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Effect of MDI-117740
(<bold>69</bold>) and FRAX486 (<bold>2</bold>) on cell migration in
a wound healing assay in MDA-MB-231 cells.
Confluent monolayers were scratched and treated with either compound <bold>69</bold> (A) or <bold>2</bold> (B) at 0.25, 1, or 3 &#956;M. Wound
closure was assessed after 48 h. Representative images and quantification
of wound area are shown. Scale bar: 100 &#956;m. Compound <bold>69</bold> inhibited wound closure at all tested concentrations in this experiment.
Data are from four independent experiments.</p></caption><graphic id="gr14" position="float" orientation="portrait" xlink:href="jm5c00974_0007.jpg"/></fig></sec><sec id="sec3"><title>Conclusions</title><p>In summary, we have discovered and characterized
tetrahydropyrazolopyridinones
as a novel class of LIMK1/2 inhibitors. Structure-based drug design
using the Takeda RIPK1 inhibitor <bold>7</bold>-LIMK1 structure, together
with our prior understanding of similar type III allosteric inhibitors,
led to discovery of MDI-117740 (<bold>69</bold>) as a potent LIMK1/2
inhibitor that demonstrates good <italic toggle="yes">in vivo</italic> PK properties
suitable as both an <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> probe when dosed intravenously. A structure-permeability relationships
study confirmed that the indispensable 1-benzylpyrazolo-5-carboxamide
scaffold is responsible for low oral bioavailability in this series
due to high drug efflux. Importantly, we show that <bold>69</bold> is the most selective LIMK1/2 inhibitor currently available in the
literature, eliminating any pre-existing RIPK1 activity associated
with <bold>7</bold>. The highly selective and potent dual LIMK1/2
inhibitor <bold>69</bold> described herein will facilitate understanding
of the mechanistic roles of LIMK in disease and their application
toward therapies targeting LIMK pathologies.</p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>General Methods</title><p>All commercial materials were used
as received without further purification. Identity and purity checks
were carried out prior to use in biological experiments using <sup>1</sup>H NMR spectroscopy and UPLC-MS analysis on the instruments
as described below that are presented in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link> for reference. All final compounds were &#8805;95%
purity as determined by <sup>1</sup>H NMR and/or UPLC-MS analyses.</p></sec><sec id="sec4.2"><title>Materials</title><p>LIJTF500125 (<bold>7</bold>), (3<italic toggle="yes">S</italic>)-3-amino-8-chloro-5-methyl-2,3-dihydro-1,5-benzoxazepin-4-one (as
the hydrochloride or trifluoroacetate salt) and 4-(phenylsulfamoyl)&#173;benzoic
acid were prepared as previously described.<xref rid="ref29" ref-type="bibr"/>
<italic toggle="yes">N</italic>-benzyl-1-cyclopropylmethanamine was synthesized
as previously described.<xref rid="ref39" ref-type="bibr"/>
</p></sec><sec id="sec4.3"><title>Synthetic Procedures and Compound Characterization</title><p>An example stacked <sup>1</sup>H NMR spectrum permitting regiochemical
assignment of 1-benzylpyrazolo-carboxamides in the absence of HMBC
experiments can be found in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker
Avance III HD 500 or 400 MHz equipped with a Prodigy cryoprobe. Chemical
shifts (&#948;) are defined in parts per million (ppm). <sup>1</sup>H NMR spectra were referenced to tetramethylsilane (TMS, &#948;
= 0.00 ppm) or residual undeuterated solvent (CDCl<sub>3</sub>, &#948;
= 7.26 ppm; MeOH-<italic toggle="yes">d</italic>
<sub>4</sub>, &#948; = 3.31 ppm;
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, &#948; = 2.50 ppm). <sup>13</sup>C NMR spectra were referenced to undeuterated solvent (CDCl<sub>3</sub>, &#948; = 77.16 ppm; DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>, &#948;
= 39.52 ppm). Multiplicities are abbreviated as follows: s, singlet;
d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet
of triplets; m, multiplet; br, broad, or combinations thereof. Coupling
constants were measured in Hertz (Hz). Liquid chromatography&#8211;mass
spectrometry (LCMS) was primarily carried out on a Waters Acquity
Hclass plus UPLC coupled to a Waters Acquity HPLC PDA detector and
a Waters Acquity QDa API-ES mass detector. Samples were eluted through
a BEH C<sub>18</sub> 2.1 mm &#215; 50 mm, 1.7 &#956;m column using
H<sub>2</sub>O and MeCN acidified by 0.1% formic acid. The gradient
runs H<sub>2</sub>O/MeCN/formic acid at 90:10:0.1&#8211;10:90:0.1
for 3 min at 1.5 mL/min and detected at 254 nm. LCMS for key intermediates
were also carried out on either a: (i) Waters HPLC equipped with XSelect
CSH C<sub>18</sub> 3.0 mm &#215; 50 mm &#215; 2.5 &#956;m column
with samples eluting using a gradient of 95:5&#8211;1:49 2.5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub>/MeCN for 5 min at 1 mL/min, or (ii) Waters
HPLC equipped with XBridge CSH C<sub>18</sub> 3.0 mm &#215; 50 mm
&#215; 2.5 &#956;m with sample eluting using a gradient of 95:5&#8211;1:49
H<sub>2</sub>O/MeCN acidified by 0.05% formic acid for 4 min at 1.2
mL/min, or (iii) LCMS EW21065&#8211;214-P1B1, or (iv) Shimadzu LC-20AB
&amp; MS 2020 with HALO C<sub>18</sub> 3 mm &#215; 30 mm, 5 uM using
0.04% TFA in water and 0.02% TFA in MeCN at a flow rate of 2.0 mL/min.
Accurate mass determination was performed on a Waters Synapt G2 SI
with ESI probe. Molecular ion peaks are defined as mass/charge (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>) ratios. Melting point analysis was
carried out using an Electrothermal IA9100 digital melting point apparatus.
Analytical thin-layer chromatography (TLC) was performed using VWR
silica gel 60 on aluminum plates coated with F<sub>254</sub> indicator.
All spots were visualized with ultraviolet light using a UVP C-10
Chromato-Vue cabinet or stained using KMnO<sub>4</sub>. Normal-phase
purifications were completed using a Teledyne ISCO CombiFlash NEXTGEN
300+ using silica gel with particle size 40&#8211;63 &#956;m; reverse-phase
purifications were completed using a Teledyne ACCQPrep system equipped
with a 20 mm &#215; 150 mm C<sub>18</sub> column, or Waters system
equipped with a 30 mm &#215; 250 mm C<sub>18</sub> column, and eluted
with a 10&#8211;100% MeOH/H<sub>2</sub>O, 10&#8211;100% MeCN/0.1%
formic acid in H<sub>2</sub>O, or MeCN/5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> gradient. Evaporation of solvents was conducted on a Buchi
Rotavapor R-300.</p><sec id="sec4.3.1"><title>General Procedure A&#8211;Reductive Amination</title><p>Unless
otherwise stated, a suspension of a primary or secondary amine (1.1&#8211;1.5
equiv) and dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>27</bold>, 1 equiv) in MeOH (5&#8211;10 mL) was added acetic
acid (0.1&#8211;0.3 mL, catalytic). The reaction mixture was cooled
to 0 &#176;C and stirred for 5 min until a solution resulted. 2-Methylpyridine
borane complex (0.9&#8211;1.5 equiv) was then added and the resultant
solution stirred at 0 &#176;C for 3 h, allowing to warm to room temperature.
Saturated NaHCO<sub>3</sub> (5&#8211;10 mL) was added and the mixture
extracted with EtOAc (2 &#215; 10&#8211;20 mL). The organic layers
were combined, dried over NaSO<sub>4</sub>, filtered and concentrated
under reduced pressure. The crude mixture was purified by flash column
chromatography and fractions containing product were combined and
concentrated under reduced pressure to afford the reductive aminated
product.</p></sec><sec id="sec4.3.2"><title>General Procedure B&#8211;Ester Hydrolysis</title><p>Unless
otherwise stated, a solution of a methyl 7-oxo-4,5,6,7-tetrahydropyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine carboxylate in either THF/water (1:1) or MeOH/THF/water
(1:1:1) was added LiOH&#183;H<sub>2</sub>O (3&#8211;5 equiv). The
reaction mixture was stirred at room temperature overnight. The reaction
mixture was concentrated under reduced pressure. One M HCl (&#8764;5
mL) was added and a solid immediately precipitated. The precipitate
was filtered, washed with water (10 mL) and dried thoroughly to afford
the 7-oxo-4,5,6,7-tetrahydropyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine
carboxylic acid.</p></sec><sec id="sec4.3.3"><title>General Procedure C&#8211;Amide Coupling</title><p>Unless otherwise
stated, DIPEA (1.5&#8211;2.4 equiv) was added to a solution of a
7-oxo-4,5,6,7-tetrahydropyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine carboxylic
acid (1 equiv), HOBt hydrate (1.1 equiv), EDC&#183;HCl (1.2&#8211;1.3
equiv) in DCM (2&#8211;8 mL). The reaction mixture was stirred at
room temperature for 30 min. A (un)&#173;substituted amine (1&#8211;5 equiv)
was then added. The reaction mixture was further stirred at room temperature
overnight. Saturated NaHCO<sub>3</sub> (10 mL) was added and the reaction
mixture stirred for 15 min at room temperature. The organic phase
was separated using a phase separator and the filtrate concentrated
under reduced pressure with silica. The crude mixture was purified
by flash column chromatography and fractions containing product were
combined and concentrated under reduced pressure to afford the substituted
7-oxo-4,5,6,7-tetrahydropyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine carboxamide.</p></sec><sec id="sec4.3.4"><title>General Procedure D&#8211;Primary Amide Synthesis</title><p>Unless otherwise stated, a methyl 7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine carboxylate (1
equiv) was dissolved in 7 M NH<sub>3</sub> in MeOH (5&#8211;15 mL).
The reaction mixture heated to 70 &#176;C and stirred overnight in
a sealed tube. The reaction mixture was concentrated under reduced
pressure. The crude mixture was purified by reverse-phase column chromatography
and fractions containing product were combined and concentrated under
reduced pressure to afford the primary 7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine carboxamide.</p></sec><sec id="sec4.3.5"><title>Ethyl 1-Benzyl-5-bromo-4-formyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate
(<bold>14</bold>)</title><p>To the solution of ethyl 1-benzyl-5-hydroxy-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate (3.00 g, 12.1 mmol, 1.00 equiv)
and POBr<sub>3</sub> (30.8 g, 107 mmol, 8.83 equiv) in DCE (45 mL)
was added DMF (1.66 g, 22.7 mmol, 1.87 equiv) at room temperature
under N<sub>2</sub>. Upon completion of addition, the mixture was
heated to 90 &#176;C and stirred for 72 h. The reaction mixture was
poured carefully onto ice water (500 mL), then stirred at room temperature
for 30 min. The mixture was extracted with EtOAc (500 mL), and the
organic layer washed with brine (500 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure
to afford the crude product, which was purified by column chromatography
(silica, 99:1 petrol/EtOAc to 9:1 petrol/EtOAc) to afford ethyl 1-benzyl-5-bromo-4-formyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate (<bold>14</bold>, 1.50 g, 4.44
mmol, 37% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 10.24 (s, 1H), 7.48&#8211;7.15 (m,
5H), 5.57 (s, 2H), 4.36 (q, <italic toggle="yes">J</italic> = 7.1 Hz, 2H), 1.32
(t, <italic toggle="yes">J</italic> = 7.1 Hz, 3H). LCMS: EW21065&#8211;214-P1B1:
Rt = 0.88 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 337.1 [M + H, <sup>79</sup>Br]<sup>+</sup>.</p></sec><sec id="sec4.3.6"><title>Ethyl 1-Benzyl-5-bromo-4-(2-methoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate (<bold>15</bold>)</title><p>To a solution
of (methoxymethyl)&#173;triphenylphosphonium chloride (10.9 g, 32.0 mmol,
2.00 equiv) in THF (50 mL) was added <italic toggle="yes">t</italic>-BuOK (3.59
g, 31.9 mmol, 2.00 equiv) at 0 &#176;C under N<sub>2</sub>. The reaction
mixture was stirred at 0 &#176;C for 5 min, before a solution of ethyl
1-benzyl-5-bromo-4-formyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate
(5.40 g, 16.0 mmol, 1.00 equiv) in THF (100 mL) was added. The mixture
was stirred at room temperature for 12 h. The reaction mixture was
poured onto ice water (200 mL), then extracted with EtOAc (100 mL).
The organic layer was washed with brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure
to afford the crude product, which was purified by column chromatography
(silica, 49:1 petrol/EtOAc to 9:1 petrol/EtOAc) to afford ethyl 1-benzyl-5-bromo-4-(2-methoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate (<bold>15</bold>, 5.02 g, 13.5
mmol, 61% yield) as a mixture of diastereomers (83% <italic toggle="yes">trans</italic> by coupling constant observed at 6.02 ppm compared to 6.16 ppm for
minor <italic toggle="yes">cis</italic> isomer) as a light yellow solid. Major
isomer (<italic toggle="yes">trans</italic>) reported: <sup>1</sup>H NMR (500 MHz,
CDCl<sub>3</sub>) &#948; 7.35&#8211;7.26 (m, 4H), 7.22&#8211;7.19
(m, 2H), 6.02 (d, <italic toggle="yes">J</italic> = 13.3 Hz, 1H), 5.47 (s, 2H),
4.42 (q, <italic toggle="yes">J</italic> = 7.1 Hz, 2H), 3.69 (s, 3H), 1.41 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.85 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 387.0 [M + Na, <sup>79</sup>Br]<sup>+</sup>, 389.0 [M + Na <sup>81</sup>Br]<sup>+</sup>.</p></sec><sec id="sec4.3.7"><title>Ethyl 1-Benzyl-5-bromo-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate
(<bold>16</bold>)</title><p>Ethyl 1-benzyl-5-bromo-4-[(<italic toggle="yes">E</italic>)-2-methoxyvinyl]&#173;pyrazole-3-carboxylate (131 mg, 0.34 mmol) was dissolved
in 4 M HCl in 1,4-dioxane (1.2 mL). UPLC analysis after 5 min indicated
reaction was complete. The mixture was taken to pH 9 by addition of
a saturated aqueous solution of NaHCO<sub>3</sub> (10 mL) and extracted
with EtOAc (2 &#215; 30 mL). The organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give
ethyl 1-benzyl-5-bromo-4-(2-oxoethyl)&#173;pyrazole-3-carboxylate (<bold>16</bold>, 106 mg, 0.287 mmol, 88% yield) as a colorless oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 9.67 (t, <italic toggle="yes">J</italic> = 1.4 Hz, 1H), 7.35&#8211;7.28 (m, 3H), 7.25&#8211;7.21
(m, 2H), 5.48 (s, 2H), 4.39 (q, <italic toggle="yes">J</italic> = 7.1 Hz, 2H),
3.80 (s, 2H), 1.37 (t, <italic toggle="yes">J</italic> = 7.1 Hz, 3H). ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.77 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 373.0 [M + Na, <sup>79</sup>Br]<sup>+</sup>,
375.0 [M + Na, <sup>81</sup>Br]<sup>+</sup>.</p></sec><sec id="sec4.3.8"><title>Ethyl 1-Benzyl-5-bromo-4-[2-[[(3<italic toggle="yes">S</italic>)-8-chloro-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]&#173;amino]&#173;ethyl]&#173;pyrazole-3-carboxylate
(<bold>17</bold>)</title><p>Synthesized according to General Procedure
A using ethyl 1-benzyl-5-bromo-4-(2-oxoethyl)&#173;pyrazole-3-carboxylate
(100 mg, 0.27 mmol), [(3<italic toggle="yes">S</italic>)-8-chloro-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]&#173;ammonium
trifluoroacetate (97 mg, 0.27 mmol), acetic acid (0.50 mL, 8.73 mmol)
and borane-2-methylpyridine complex (38 mg, 0.35 mmol). Purified by
flash column chromatography (silica, 12 g, 1:0 petrol/EtOAc to 0:1
petrol/EtOAc containing 1% Et<sub>3</sub>N over 25 CV&#8217;s) to
give ethyl 1-benzyl-5-bromo-4-[2-[[(3<italic toggle="yes">S</italic>)-8-chloro-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]&#173;amino]&#173;ethyl]&#173;pyrazole-3-carboxylate
(<bold>17</bold>, 134 mg, 0.22 mmol, 88% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.26&#8211;7.17
(m, 3H), 7.13&#8211;7.08 (m, 3H), 7.08&#8211;7.01 (m, 2H), 5.35
(s, 2H), 4.32&#8211;4.26 (m, 3H), 4.03&#8211;3.98 (m, 1H), 3.48
(dd, <italic toggle="yes">J</italic> = 11.6, 7.3 Hz, 1H), 3.28 (s, 3H), 2.81&#8211;2.61
(m, 3H), 2.38 (ddd, <italic toggle="yes">J</italic> = 10.3, 8.4, 5.9 Hz, 1H), 1.32&#8211;1.27
(m, 3H). NH not observed. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.67 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 563.1 [M + H, <sup>81</sup>Br, <sup>35</sup>Cl]<sup>+</sup>.</p></sec><sec id="sec4.3.9"><title>1-Benzyl-5-bromo-4-[2-[[(3<italic toggle="yes">S</italic>)-8-chloro-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]&#173;amino]&#173;ethyl]&#173;pyrazole-3-carboxylic
Acid (<bold>18</bold>)</title><p>Synthesized according to General Procedure
B using ethyl 1-benzyl-5-bromo-4-[2-[[(3<italic toggle="yes">S</italic>)-8-chloro-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]&#173;amino]&#173;ethyl]&#173;pyrazole-3-carboxylate
(134 mg, 0.24 mmol) and LiOH&#183;H<sub>2</sub>O (60 mg, 1.43 mmol)
to give 1-benzyl-5-bromo-4-[2-[[(3<italic toggle="yes">S</italic>)-8-chloro-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]&#173;amino]&#173;ethyl]&#173;pyrazole-3-carboxylic
acid (<bold>18</bold>, 127 mg, 0.22 mmol, quantitative yield) as a
colorless solid. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.57 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 535.0 [M + H, <sup>81</sup>Br, <sup>35</sup>Cl]<sup>+</sup>.</p></sec><sec id="sec4.3.10"><title>(<italic toggle="yes">S</italic>)-3-(2-Benzyl-3-bromo-7-oxo-2,4,5,7-tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-6-yl)-8-chloro-5-methyl-2,3-dihydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-4&#173;(5<italic toggle="yes">H</italic>)-one (<bold>19</bold>)</title><p>Synthesized according to General Procedure C using 1-benzyl-5-bromo-4-[2-[[(3<italic toggle="yes">S</italic>)-8-chloro-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]&#173;amino]&#173;ethyl]&#173;pyrazole-3-carboxylic
acid (127 mg, 0.24 mmol), HOBt hydrate (40 mg, 0.26 mmol), and EDC&#183;HCl
(55 mg, 0.29 mmol). Purified by flash column chromatography (silica,
12 g, 1:0 petrol/EtOAc to 0:1 petrol/EtOAc over 30 CV&#8217;s) to
afford (<italic toggle="yes">S</italic>)-3-(2-benzyl-3-bromo-7-oxo-2,4,5,7-tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-6-yl)-8-chloro-5-methyl-2,3-dihydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-4&#173;(5<italic toggle="yes">H</italic>)-one (<bold>19</bold>, 84 mg, 0.16 mmol, 68% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.34&#8211;7.27 (m, 3H),
7.27&#8211;7.22 (m, 3H), 7.19&#8211;7.15 (m, 2H), 5.90 (dd, <italic toggle="yes">J</italic> = 11.8, 8.1 Hz, 1H), 5.43 (s, 2H), 4.63 (dd, <italic toggle="yes">J</italic> = 11.8, 10.0 Hz, 1H), 4.41 (dd, <italic toggle="yes">J</italic> = 10.0, 8.1 Hz,
1H), 4.23 (dt, <italic toggle="yes">J</italic> = 12.0, 5.2 Hz, 1H), 3.55 (ddd, <italic toggle="yes">J</italic> = 12.0, 10.5, 4.4 Hz, 1H), 3.35 (s, 3H), 3.04 (ddd, <italic toggle="yes">J</italic> = 15.6, 10.4, 5.1 Hz, 1H), 2.64 (ddd, <italic toggle="yes">J</italic> = 15.6, 5.3, 4.4 Hz, 1H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.85 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 539.0 [M + Na, <sup>81</sup>Br, <sup>35</sup>Cl]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR
purity: 100/94/90%.</p></sec><sec id="sec4.3.11"><title>(<italic toggle="yes">S</italic>)-1-Benzyl-6-(8-chloro-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>20</bold>)</title><p>Synthesized exactly as described for LIJTF500025
(<bold>7</bold>) in Collins et al.,<xref rid="ref29" ref-type="bibr"/> Step
5 through separation of the other regioisomer. The semipurified product
collected after flash column chromatography (silica, 24 g, 1:0 petrol/EtOAc
to 0:1 petrol/EtOAc over 25 CV&#8217;s) was additionally purified
by reverse-phase chromatography (9:1 H<sub>2</sub>O/MeOH to 0:1 H<sub>2</sub>O/MeOH over 25 min) to afford (<italic toggle="yes">S</italic>)-1-benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>20</bold>, 7 mg, 0.01 mmol, 9% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
7.61 (s, 1H), 7.52 (d, <italic toggle="yes">J</italic> = 8.6 Hz, 1H), 7.42&#8211;7.37
(m, 3H), 7.35&#8211;7.22 (m, 3H), 7.19&#8211;7.15 (m, 2H), 5.67&#8211;5.58
(m, 2H), 5.48 (dd, <italic toggle="yes">J</italic> = 12.0, 7.7 Hz, 1H), 4.89 (dd, <italic toggle="yes">J</italic> = 12.0, 10.1 Hz, 1H), 4.41 (dd, <italic toggle="yes">J</italic> = 10.0,
7.7 Hz, 1H), 4.00 (ddd, <italic toggle="yes">J</italic> = 12.7, 7.4, 5.4 Hz, 1H),
3.69&#8211;3.60 (m, 1H), 3.28 (s, 3H), 3.11&#8211;2.93 (m, 2H).
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.77 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 480.1 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/89/97%.</p></sec><sec id="sec4.3.12"><title>Dimethyl 1-Benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>27</bold>)</title><p>A solution of dimethyl (<italic toggle="yes">E</italic>)-1-benzyl-4-(2-ethoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(0.57 g, 1.66 mmol) in THF (5 mL) at 0 &#176;C was added slowly to
an ice-cold solution of hydrochloric acid (6M, 5 mL, 30.0 mmol). The
reaction mixture was stirred at 0 &#176;C for 1 h, allowing to warm
to room temperature. The reaction mixture was poured onto saturated
NaHCO<sub>3</sub> solution (50 mL) and extracted with EtOAc (3 &#215;
25 mL). The organic phases were combined, dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to afford dimethyl
1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>27</bold>, 0.49 g, 1.09 mmol, 66% yield, 70% purity) as a yellow
oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948; 9.71 (s,
1H), 7.35&#8211;7.16 (m, 5H), 5.85 (s, 2H), 4.27 (s, 2H), 3.95 (s,
3H), 3.84 (s, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.66 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 317.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.13"><title>Dimethyl (<italic toggle="yes">S</italic>)-1-Benzyl-4-(2-((5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>28a</bold>)</title><p>Synthesized according to General Procedure
A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(235 mg, 0.74 mmol, <bold>27</bold>), (3<italic toggle="yes">S</italic>)-3-amino-5-methyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-4-one
hydrochloride (180 mg, 0.79 mmol, 1.1 equiv), acetic acid (0.3 mL)
and 2-methylpyridine borane complex (119 mg, 1.11 mmol, 1.5 equiv).
Purified by flash column chromatography (silica, 24 g, 7:3 petrol/EtOAc
to 0:1 petrol/EtOAc) to afford dimethyl (<italic toggle="yes">S</italic>)-1-benzyl-4-(2-((5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>28a</bold>, 220 mg, 0.42 mmol, 52% yield) as a colorless glass. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.35&#8211;7.25
(m, 3H), 7.24&#8211;7.19 (m, 3H), 7.19&#8211;7.14 (m, 3H), 5.79
(s, 2H), 4.38 (dd, <italic toggle="yes">J</italic> = 10.1, 7.4 Hz, 1H), 4.09 (dd, <italic toggle="yes">J</italic> = 11.6, 10.1 Hz, 1H), 3.91 (s, 3H), 3.81 (s, 3H), 3.59
(dd, <italic toggle="yes">J</italic> = 11.6, 7.4 Hz, 1H), 3.41 (s, 3H), 3.18&#8211;3.03
(m, 2H), 2.87 (ddd, <italic toggle="yes">J</italic> = 11.2, 9.2, 5.4 Hz, 1H), 2.47
(ddd, <italic toggle="yes">J</italic> = 11.2, 9.0, 6.5 Hz, 1H). NH not observed.
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.46 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 493.2 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/87/95%.</p></sec><sec id="sec4.3.14"><title>(<italic toggle="yes">S</italic>)-2-Benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>21</bold>)</title><p>Synthesized in a three-step telescope according
to (i) General Procedure B using dimethyl (<italic toggle="yes">S</italic>)-1-benzyl-4-(2-((5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(140 mg, 0.27 mmol) and LiOH&#183;H<sub>2</sub>O (57 mg, 1.35 mmol,
5 equiv). Product taken forward as crude to the next step. (ii) General
Procedure C using (<italic toggle="yes">S</italic>)-1-benzyl-4-(2-((5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic
acid (as crude), HOBt hydrate (45 mg, 0.29 mmol, 1.1 equiv), EDC&#183;HCl
(70 mg, 0.37 mmol, 1.3 equiv), DIPEA (0.11 mL, 0.64 mmol, 2.4 equiv).
Formation of (<italic toggle="yes">S</italic>)-2-benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid and its regioisomer were observed in approximately 1:1 ratio.
Product taken forward as crude to the next step. (iii) General Procedure
C using (<italic toggle="yes">S</italic>)-2-benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (as crude mixture of two regioisomers), HOBt hydrate (45 mg,
0.29 mmol, 1.1 equiv), EDC&#183;HCl (70 mg, 0.37 mmol, 1.3 equiv),
DIPEA (0.11 mL, 0.64 mmol, 2.4 equiv) and NH<sub>4</sub>Cl (60 mg,
1.12 mmol). The reaction mixture was heated to 45 &#176;C and stirred
for 24 h. Purified by flash column chromatography (silica, 24 g, 1:0
petrol/EtOAc to 0:1 petrol/EtOAc over 25 CV&#8217;s) to afford (<italic toggle="yes">S</italic>)-2-benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>21</bold>, 38 mg, 0.08 mmol, 28% yield) as acolorless solid.
m.p.: 190 &#176;C (dec). <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.83 (br s, 1H), 7.73 (br s, 1H),
7.50 (dd, <italic toggle="yes">J</italic> = 7.9, 1.6 Hz, 1H), 7.35&#8211;7.23
(m, 6H), 7.19&#8211;7.15 (m, 2H), 5.63 (s, 2H), 5.55 (dd, <italic toggle="yes">J</italic> = 12.0, 7.9 Hz, 1H), 4.85 (dd, <italic toggle="yes">J</italic> = 12.0,
10.1 Hz, 1H), 4.34 (dd, <italic toggle="yes">J</italic> = 10.0, 7.9 Hz, 1H), 4.00
(ddd, <italic toggle="yes">J</italic> = 12.1, 6.9, 5.0 Hz, 1H), 3.59 (ddd, <italic toggle="yes">J</italic> = 12.4, 8.9, 4.6 Hz, 1H), 3.30 (s, 3H), 3.05 (ddd, <italic toggle="yes">J</italic> = 15.9, 8.9, 5.0 Hz, 1H), 2.84 (ddd, <italic toggle="yes">J</italic> = 15.9, 6.9, 4.6 Hz, 1H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (125
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 168.9, 161.1, 160.2,
149.5, 141.0, 137.2, 136.7, 133.1, 128.6, 127.8, 127.6, 127.2, 125.9,
123.4, 122.6, 121.4, 74.4, 54.1, 50.7, 44.9, 34.8, 20.5. A HMBC cross
peak is shared between the benzyl CH<sub>2</sub>, amide NH<sub>2</sub> and lactam benzyl CH<sub>2</sub> which is only consistent with isomer
as drawn. 97% purity by <sup>1</sup>H NMR despite residual MeOH present.
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.54 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 468.1 [M + Na]<sup>+</sup>. HRMS calculated
for C<sub>24</sub>H<sub>24</sub>N<sub>5</sub>O<sub>4</sub>: 446.1828;
found 446.1817 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/92/97%. Characterization data was consistent with previously published
data.<xref rid="ref43" ref-type="bibr"/>
</p></sec><sec id="sec4.3.15"><title>(<italic toggle="yes">S</italic>)-1-Benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>22</bold>)</title><p>Synthesized according to the synthesis
of <bold>21</bold>, Step iii through separation of the other regioisomer.
The semipurified product collected after flash column chromatography
(silica, 24 g, 1:0 petrol/EtOAc to 0:1 petrol/EtOAc over 25 CV&#8217;s)
was additionally purified by reverse-phase chromatography (9:1 H<sub>2</sub>O/MeOH to 0:1 H<sub>2</sub>O/MeOH over 25 min) to afford (<italic toggle="yes">S</italic>)-1-benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>22</bold>, 18 mg, 0.04 mmol, 15% yield) as a colorless solid.
m.p.: 212&#8211;213 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.61 (s, 1H), 7.51&#8211;7.46 (m,
1H), 7.40 (d, <italic toggle="yes">J</italic> = 1.7 Hz, 1H), 7.36&#8211;7.21 (m,
6H), 7.19&#8211;7.13 (m, 2H), 5.67&#8211;5.57 (m, 2H), 5.49 (dd, <italic toggle="yes">J</italic> = 12.0, 7.8 Hz, 1H), 4.86 (dd, <italic toggle="yes">J</italic> = 12.0,
10.1 Hz, 1H), 4.35 (dd, <italic toggle="yes">J</italic> = 10.1, 7.8 Hz, 1H), 4.02
(ddd, <italic toggle="yes">J</italic> = 12.6, 7.3, 5.4 Hz, 1H), 3.65 (ddd, <italic toggle="yes">J</italic> = 12.6, 8.4, 5.3 Hz, 1H), 3.29 (s, 3H), 3.09&#8211;2.93
(m, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (125 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 168.6 (Cq), 163.1 (Cq), 158.2 (Cq),
149.4 (Cq), 140.8 (Cq), 136.9 (Cq), 136.6 (Cq), 131.7 (Cq), 128.6
(CH), 127.7 (CH), 127.4 (CH), 127.2 (CH), 125.9 (CH), 124.3 (CH),
123.4 (CH), 122.5 (Cq), 74.4 (CH<sub>2</sub>), 53.9 (CH<sub>2</sub>), 50.6 (CH), 45.3 (CH<sub>2</sub>), 34.8 (CH<sub>3</sub>), 20.7
(CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.66 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 468.1 [M + Na]<sup>+</sup>. HRMS calculated for C<sub>24</sub>H<sub>24</sub>N<sub>5</sub>O<sub>4</sub>: 446.1828, found: 446.1819 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 98/91/98%.</p></sec><sec id="sec4.3.16"><title>(<italic toggle="yes">S</italic>)-2-Benzyl-<italic toggle="yes">N</italic>-methyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>23</bold>)</title><p>Synthesized according to the synthesis
of <bold>21</bold> using MeNH<sub>2</sub>&#183;HCl in place of NH<sub>4</sub>Cl in the last step. (<italic toggle="yes">S</italic>)-2-Benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (177 mg, as crude mixture of two regioisomers), HOBt hydrate
(60 mg, 0.39 mmol), EDC&#183;HCl (95 mg, 0.50 mmol), DIPEA (1.45 mL,
0.85 mmol), MeNH<sub>2</sub>&#183;HCl (60 mg, 2.47 mmol). The semipurified
product collected after flash column chromatography (silica, 24 g,
1:0 petrol/EtOAc to 0:1 petrol/EtOAc over 25 CV&#8217;s) was additionally
purified by reverse-phase chromatography (9:1 H<sub>2</sub>O/MeOH
to 0:1 H<sub>2</sub>O/MeOH over 25 min) to afford (<italic toggle="yes">S</italic>)-2-benzyl-<italic toggle="yes">N</italic>-methyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>23</bold>, 10 mg, 0.02 mmol, 6% yield) as a colorless glass. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
8.23 (q, <italic toggle="yes">J</italic> = 4.5 Hz, 1H), 7.50 (dd, <italic toggle="yes">J</italic> = 7.9, 1.6 Hz, 1H), 7.35&#8211;7.23 (m, 6H), 7.20&#8211;7.15 (m,
2H), 5.59 (s, 2H), 5.55 (dd, <italic toggle="yes">J</italic> = 12.0, 7.9 Hz, 1H),
4.84 (dd, <italic toggle="yes">J</italic> = 12.0, 10.1 Hz, 1H), 4.34 (dd, <italic toggle="yes">J</italic> = 10.1, 7.9 Hz, 1H), 4.00 (ddd, <italic toggle="yes">J</italic> = 12.1,
6.8, 5.0 Hz, 1H), 3.59 (ddd, <italic toggle="yes">J</italic> = 12.3, 9.0, 4.6 Hz,
1H), 3.30 (s, 3H), 3.03 (ddd, <italic toggle="yes">J</italic> = 15.8, 9.0, 5.0
Hz, 1H), 2.82 (ddd, <italic toggle="yes">J</italic> = 15.9, 6.8, 4.6 Hz, 1H), 2.76
(d, <italic toggle="yes">J</italic> = 4.6 Hz, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.71 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 460.2 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 98/95/90%.</p></sec><sec id="sec4.3.17"><title>(<italic toggle="yes">S</italic>)-1-Benzyl-<italic toggle="yes">N</italic>-methyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>24</bold>)</title><p>Synthesized according to the synthesis
of <bold>23</bold> through separation of the other regioisomer. Purified
by flash column chromatography (silica, 24 g, 7:3 petrol/EtOAc to
0:1 petrol/EtOAc over 25 CV&#8217;s) followed by reverse-phase chromatography
(9:1 H<sub>2</sub>O/MeOH to 0:1 H<sub>2</sub>O/MeOH over 25 min) to
afford (<italic toggle="yes">S</italic>)-1-benzyl-<italic toggle="yes">N</italic>-methyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>24</bold>, 6 mg, 0.01 mmol, 3% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
8.17 (q, <italic toggle="yes">J</italic> = 4.6 Hz, 1H), 7.51&#8211;7.45 (m, 1H),
7.34&#8211;7.22 (m, 6H), 7.17&#8211;7.14 (m, 2H), 5.68&#8211;5.57
(m, 2H), 5.49 (dd, <italic toggle="yes">J</italic> = 12.0, 7.8 Hz, 1H), 4.86 (dd, <italic toggle="yes">J</italic> = 12.0, 10.1 Hz, 1H), 4.36 (dd, <italic toggle="yes">J</italic> = 10.1,
7.8 Hz, 1H), 4.03 (ddd, <italic toggle="yes">J</italic> = 12.7, 7.4, 5.4 Hz, 1H),
3.70&#8211;3.61 (m, 1H), 3.29 (s, 3H), 3.10&#8211;2.94 (m, 2H),
2.72 (d, <italic toggle="yes">J</italic> = 4.7 Hz, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.83 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 460.2 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/91/94%.</p></sec><sec id="sec4.3.18"><title>(<italic toggle="yes">S</italic>)-2-Benzyl-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>25</bold>)</title><p>Synthesized according to the synthesis of <bold>21</bold> using Me<sub>2</sub>NH in place of NH<sub>4</sub>Cl in the last
step. (<italic toggle="yes">S</italic>)-2-Benzyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (177 mg, as crude mixture of two regioisomers), HOBt hydrate
(60 mg, 0.39 mmol), EDC&#183;HCl (95 mg, 0.50 mmol), DIPEA (1.45 mL,
0.85 mmol), Me<sub>2</sub>NH (0.10 mL, 0.56 mmol). The semipurified
product collected after flash column chromatography (silica, 24 g,
1:0 petrol/EtOAc to 0:1 petrol/EtOAc over 25 CV&#8217;s) was additionally
purified by reverse-phase chromatography (9:1 H<sub>2</sub>O/MeOH
to 0:1 H<sub>2</sub>O/MeOH over 25 min) to afford (<italic toggle="yes">S</italic>)-2-benzyl-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>25</bold>, 6 mg, 0.01 mmol, 3% yield) as a colorless glass. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
7.50 (dd, <italic toggle="yes">J</italic> = 7.7, 1.8 Hz, 1H), 7.36&#8211;7.22
(m, 6H), 7.19&#8211;7.12 (m, 2H), 5.57 (dd, <italic toggle="yes">J</italic> =
12.0, 7.9 Hz, 1H), 5.37 (s, 2H), 4.82 (dd, <italic toggle="yes">J</italic> = 12.0,
10.1 Hz, 1H), 4.33 (dd, <italic toggle="yes">J</italic> = 10.1, 7.9 Hz, 1H), 4.01
(ddd, <italic toggle="yes">J</italic> = 12.1, 6.9, 4.9 Hz, 1H), 3.60 (ddd, <italic toggle="yes">J</italic> = 12.8, 8.8, 4.6 Hz, 1H), 3.30 (s, 3H), 2.90 (s, 3H),
2.80 (ddd, <italic toggle="yes">J</italic> = 14.4, 8.9, 4.9 Hz, 1H), 2.71&#8211;2.65
(m, 4H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.72 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 474.2 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 99/94/94%.</p></sec><sec id="sec4.3.19"><title>(<italic toggle="yes">S</italic>)-1-Benzyl-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>26</bold>)</title><p>Synthesized according to the synthesis of <bold>25</bold> through separation of the other regioisomer. Purified by flash column
chromatography (silica, 24 g, 7:3 petrol/EtOAc to 0:1 petrol/EtOAc
over 25 CV&#8217;s) followed by reverse-phase chromatography (9:1
H<sub>2</sub>O/MeOH to 0:1 H<sub>2</sub>O/MeOH over 25 min) to afford
(<italic toggle="yes">S</italic>)-1-benzyl-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethyl-6-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>26</bold>, 7 mg, 0.01 mmol, 4% yield) as a colorless solid. <sup>1</sup>H
NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.49 (dd, <italic toggle="yes">J</italic> = 7.7, 1.8 Hz, 1H), 7.35&#8211;7.22 (m, 6H), 7.18&#8211;7.15
(m, 2H), 5.66&#8211;5.58 (m, 2H), 5.50 (dd, <italic toggle="yes">J</italic> =
12.0, 7.8 Hz, 1H), 4.86 (dd, <italic toggle="yes">J</italic> = 12.0, 10.1 Hz, 1H),
4.36 (dd, <italic toggle="yes">J</italic> = 10.1, 7.8 Hz, 1H), 4.02 (ddd, <italic toggle="yes">J</italic> = 12.7, 7.4, 5.3 Hz, 1H), 3.64 (ddd, <italic toggle="yes">J</italic> = 12.6, 8.5, 5.2 Hz, 1H), 3.30 (s, 3H), 3.20 (s, 3H), 3.00&#8211;2.80
(m, 5H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.85 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 474.2 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/92/90%.</p></sec><sec id="sec4.3.20"><title>(<italic toggle="yes">S</italic>)-1-Benzyl-<italic toggle="yes">N</italic>
<sup>3</sup>-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxamide (<bold>29</bold>)</title><p>Synthesized according to General Procedure C using 1-benzyl-5-carbamoyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylic acid (80 mg, 0.33 mmol), HOBt hydrate
(55 mg, 0.36 mmol, 1.1 equiv), EDC&#183;HCl (75 mg, 0.39 mmol, 1.2
equiv), DIPEA (84 &#956;L, 0.49 mmol, 1.5 equiv) and (S)-3-amino-5-methyl-2,3-dihydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-4&#173;(5<italic toggle="yes">H</italic>)-one hydrochloride
(82 mg, 0.36 mmol, 1.1 equiv). Purified by flash column chromatography
(silica, 4 g, 1:0 petrol/EtOAc to 0:1 petrol/EtOAc over 25 CV&#8217;s)
to afford (<italic toggle="yes">S</italic>)-1-benzyl-<italic toggle="yes">N</italic>
<sup>3</sup>-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxamide (<bold>29</bold>, 70 mg, 0.16
mmol, 49% yield) as a colorless solid. m.p.: 146&#8211;147 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.86 (d, <italic toggle="yes">J</italic> = 7.1 Hz, 1H), 7.32&#8211;7.30 (m, 4H), 7.30&#8211;7.17
(m, 5H), 7.12 (s, 1H), 6.06 (s, 1H), 5.84 (d, <italic toggle="yes">J</italic> =
14.3 Hz, 1H), 5.77 (d, <italic toggle="yes">J</italic> = 14.3 Hz, 1H), 5.35 (s,
1H), 5.03 (dt, <italic toggle="yes">J</italic> = 11.2, 7.2 Hz, 1H), 4.72 (dd, <italic toggle="yes">J</italic> = 9.8, 7.4 Hz, 1H), 4.29 (dd, <italic toggle="yes">J</italic> = 11.2,
9.8 Hz, 1H), 3.45 (s, 3H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (101
MHz, CDCl<sub>3</sub>) &#948; 169.1 (Cq), 161.0 (Cq), 160.6 (Cq),
150.2 (Cq), 144.3 (Cq), 136.6 (Cq), 136.3 (Cq), 135.6 (Cq), 128.7
(CH), 128.1 (CH), 128.0 (CH), 126.0 (CH), 123.5 (CH), 123.0 (CH),
109.1 (CH), 77.3 (CH<sub>2</sub>), 55.6 (CH<sub>2</sub>), 49.3 (CH),
35.6 (CH<sub>3</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.73 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 420.2 [M + H]<sup>+</sup>. HRMS calculated for C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub>: 420.1672, found: 420.1669 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 99/91/96%.</p></sec><sec id="sec4.3.21"><title>1-Benzyl-3,5-dibromo-1<italic toggle="yes">H</italic>-pyrazole (<bold>36</bold>)</title><p>A suspension of 3,5-dibromo-1<italic toggle="yes">H</italic>-pyrazole
(2.50 g, 11.07 mmol) and K<sub>2</sub>CO<sub>3</sub> (2.06 g, 14.68
mmol) in DMF (15 mL) was cooled in an ice-bath. Benzyl bromide (1.34
mL, 11.27 mmol) was added slowly over 5 min. The bath was removed
and the mixture stirred at room temperature for 40 min, whereupon
UPLC showed complete conversion to product. The reaction mixture was
poured onto 350 mL ice-cold water, extracted with EtOAc (3 &#215;
40 mL) and washed with brine (5 &#215; 20 mL), dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give
1-benzyl-3,5-dibromo-1<italic toggle="yes">H</italic>-pyrazole (<bold>36</bold>, 3.34 g, 10.04 mmol, 96% yield) as a light-yellow thick oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.41&#8211;7.31
(m, 3H), 7.30&#8211;7.22 (m, 2H), 6.36 (s, 1H), 5.35 (s, 2H). ACQUITY
UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.83 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 316.8 [M + H, <sup>79</sup>Br, <sup>81</sup>Br]<sup>+</sup>.</p></sec><sec id="sec4.3.22"><title>1-Benzyl-3-bromo-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylic Acid
(<bold>37</bold>)</title><p>To a cooled (&#8722;78 &#176;C) solution
of <bold>36</bold> (3.29 g, 10.4 mmol) in anhydrous THF (80 mL) was
added dropwise iPrMgCl&#183;LiCl (1.3 M in THF, 9.60 mL, 12.48 mmol).
The solution took on a light-yellow color and was left to stir for
30 min. CO<sub>2</sub> was bubbled through the solution <italic toggle="yes">via</italic> cannula over a period of 20 min before removal of the cooling bath.
The reaction mixture was concentrated under reduced pressure and redissolved
in saturated aqueous solution of NaHCO<sub>3</sub> (50 mL) and extracted
with DCM (20 mL). This extract was discarded and the aqueous brought
to pH 3 and extracted with EtOAc (4 &#215; 30 mL). The combined EtOAc
extract was dried over MgSO<sub>4</sub>, filtered and concentrated
under reduced pressure to give 1-benzyl-3-bromo-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylic acid (<bold>37</bold>, 2.61 g, 9.30 mmol,
94% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) &#948; 7.33&#8211;7.23 (m, 3H), 7.22 (ddd, <italic toggle="yes">J</italic> = 8.1, 1.4, 0.7 Hz, 2H), 6.89 (s, 1H), 5.72 (s, 2H). ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.54 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 282.9 [M + H, <sup>81</sup>Br]<sup>+</sup>.</p></sec><sec id="sec4.3.23"><title>1-Benzyl-3-bromo-1<italic toggle="yes">H</italic>-pyrazole-5-carboxamide
(<bold>38</bold>)</title><p>A mixture of <bold>37</bold> (198 mg, 0.70
mmol) and SOCl<sub>2</sub> (1.0 mL, 13.71 mmol) was heated to 65 &#176;C
for 2 h. Once cooled, the mixture was concentrated under reduced pressure
in a fumehood to give the acid chloride (colorless oil), which was
used directly without further purification. The acid chloride was
dissolved in DCM (5 mL) and cooled in an ice bath. Ammonia solution
(0.20 mL, 35% by w/w aqueous solution) was added slowly dropwise.
The cooling bath was removed and the reaction left to stir at room
temperature overnight. The mixture was diluted with DCM (20 mL) and
poured into a separating funnel containing a saturated aqueous solution
of NaHCO<sub>3</sub> (20 mL). The layers were separated and the organic
extract washed with additional NaHCO<sub>3</sub> solution (20 mL).
The organic phase was dried over MgSO<sub>4</sub>, filtered and concentrated
under reduced pressure to give 1-benzyl-3-bromo-1<italic toggle="yes">H</italic>-pyrazole-5-carboxamide (<bold>38</bold>, 171 mg, 0.58 mmol, 86%
yield) as a colorless viscous oil. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) &#948; 7.29&#8211;7.19 (m, 5H), 6.86 (s, 1H), 5.72 (s,
2H), 4.93 (s, 2H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.42 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 281.9 [M + H, <sup>81</sup>Br]<sup>+</sup>.</p></sec><sec id="sec4.3.24"><title>(<italic toggle="yes">E</italic>)-1-Benzyl-3-(2-ethoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxamide (<bold>39</bold>)</title><p>A mixture of (<italic toggle="yes">E</italic>)-(2-ethoxyvinyl)&#173;boronic pinacol ester (0.22 mL, 1.04 mmol), <bold>38</bold> (171 mg, 0.61 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (0.42
g, 1.29 mmol) in monoglyme (4 mL) and water (0.4 mL) was degassed
with N<sub>2</sub> for 15 min. [1,1&#8242;-Bis&#173;(diphenylphosphino)&#173;ferrocene]&#173;dichloropalladium&#173;(II)
(0.04 g, 0.06 mmol) was added, the mixture degassed for a further
10 min before being heated to 90 &#176;C overnight. The mixture was
diluted with EtOAc (20 mL), washed with a saturated aqueous solution
of NaHCO<sub>3</sub> (20 mL), the aqueous back-extracted with EtOAc
(20 mL), the combined organics dried over MgSO<sub>4</sub>, filtered
and concentrated under reduced pressure to give the crude product,
which was purified by automated column chromatography on silica (ISCO,
12 g, slow gradient from DCM to 20% MeOH in DCM with 1% Et<sub>3</sub>N) to give (<italic toggle="yes">E</italic>)-1-benzyl-3-(2-ethoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxamide (<bold>39</bold>, 162 mg, 0.54
mmol, 89% yield) as a light brown solid. <sup>1</sup>H NMR (500 MHz,
CDCl<sub>3</sub>) &#948; 7.32&#8211;7.19 (m, 5H), 7.07 (d, <italic toggle="yes">J</italic> = 13.2 Hz, 1H), 6.44 (s, 1H), 5.86 (s, 1H), 5.77 (d, <italic toggle="yes">J</italic> = 13.2 Hz, 1H), 5.70 (s, 2H), 5.64 (s, 1H), 3.87 (q, <italic toggle="yes">J</italic> = 7.0 Hz, 2H), 1.33 (t, <italic toggle="yes">J</italic> = 7.0 Hz, 3H).
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.42 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 272.0 [M + H]<sup>+</sup>. Regiochemistry
shown by small X-ray crystal structure analysis.</p></sec><sec id="sec4.3.25"><title>Methyl 1-Benzyl-3-bromo-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate
Hydrochloride (<bold>41</bold>)</title><p>To an ice-cold solution of <bold>37</bold> (2.00 g, 6.76 mmol) in MeOH (15 mL) was added dropwise
SOCl<sub>2</sub> (1.48 mL, 20.28 mmol). Upon completion of addition,
the cooling bath was removed and the mixture allowed to stir at room
temperature for 1 h, overnight at room temperature, and finally at
50 &#176;C for a further 12 h. The mixture was concentrated under
reduced pressure in a fumehood to give methyl 1-benzyl-3-bromo-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate hydrochloride (<bold>41</bold>,
2.20 g, 6.30 mmol, 98% yield) as a brown solid. <sup>1</sup>H NMR
(500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>
<italic toggle="yes">6</italic>
</sub>) &#948;
7.36&#8211;7.24 (m, 3H), 7.17 (d, <italic toggle="yes">J</italic> = 7.3 Hz, 2H),
7.06 (s, 1H), 5.67 (s, 2H), 3.81 (s, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.80 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 297.1 [M-HCl + H, <sup>81</sup>Br]<sup>+</sup>.</p></sec><sec id="sec4.3.26"><title>Methyl (<italic toggle="yes">E</italic>)-1-Benzyl-3-(2-ethoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate (<bold>42</bold>)</title><p>A mixture
of (<italic toggle="yes">E</italic>)-(2-ethoxyvinyl)&#173;boronic pinacol ester (0.58
mL, 2.73 mmol) Cs<sub>2</sub>CO<sub>3</sub> (2.03 g, 6.18 mmol) and <bold>41</bold> (683 mg, 2.06 mmol) in monoglyme (6.2 mL) and water (0.62
mL) was degassed with N<sub>2</sub> for 15 min. [1,1&#8242;-Bis&#173;(diphenylphosphino)&#173;ferrocene]&#173;dichloropalladium&#173;(II)
(0.12 g, 0.16 mmol) was added, the mixture degassed again for 10 min
before heating overnight at 80 &#176;C. The reaction mixture was diluted
with EtOAc (40 mL), washed with water (15 mL), the organic phase dried
over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure
to give the crude product, which was purified by automated column
chromatography on silica (ISCO, 12 g, gradient from petroleum ether
to EtOAc with 1% Et<sub>3</sub>N) to give methyl (<italic toggle="yes">E</italic>)-1-benzyl-3-(2-ethoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate
(<bold>42</bold>, 230 mg, 0.76 mmol, 39% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.31&#8211;7.26
(m, 2H), 7.26&#8211;7.21 (m, 3H), 7.10 (d, <italic toggle="yes">J</italic> = 13.2
Hz, 1H), 6.74 (s, 1H), 5.80 (d, <italic toggle="yes">J</italic> = 13.2 Hz, 1H),
5.70 (s, 2H), 3.88 (q, <italic toggle="yes">J</italic> = 7.0 Hz, 2H), 3.81 (s,
3H), 1.33 (t, <italic toggle="yes">J</italic> = 7.0 Hz, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.78 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 287.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.27"><title>Methyl 1-Benzyl-3-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate
(<bold>43</bold>)</title><p>
<bold>42</bold> (230 mg, 0.8 mmol) was
dissolved in DCM (2 mL) and 4 M HCl in dioxane (2 mL) was added. UPLC
analysis after 1 h indicated reaction was complete. The mixture was
taken to pH 9 by portion-wise addition of a saturated aqueous solution
of NaHCO<sub>3</sub> (30 mL) and extracted with EtOAc (3 &#215; 30
mL). The organic phase was dried over MgSO<sub>4</sub>, filtered and
concentrated under reduced pressure to give methyl 1-benzyl-3-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate (<bold>43</bold>, 208 mg, 0.77
mmol, quantitative yield) as a colorless oil, which was used immediately
in the next step due to stability concerns. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.54 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 259.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.28"><title>2-(1-Benzyl-5-(methoxycarbonyl)-1<italic toggle="yes">H</italic>-pyrazol-3-yl)&#173;acetic
Acid (<bold>44</bold>)</title><p>To a solution of <bold>43</bold> (222
mg, 0.86 mmol) in DMF (8 mL) was added oxone (528 mg, 0.86 mmol).
UPLC analysis after stirring at room temperature for 1 h showed complete
conversion to the acid. Aqueous 1 M HCl (15 mL) and EtOAc (50 mL)
were added to the mixture. The layers were separated and the aqueous
back-extracted with EtOAc (20 mL). The combined organic extracts were
dried over MgSO<sub>4</sub>, filtered and concentrated under reduced
pressure to give the crude product, which was triturated with petroleum
ether (3 &#215; 35 mL) to give 2-(1-benzyl-5-(methoxycarbonyl)-1<italic toggle="yes">H</italic>-pyrazol-3-yl)&#173;acetic acid (<bold>44</bold>, 143 mg, 0.47
mmol, 61% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz,
CDCl<sub>3</sub>) &#948; 7.32&#8211;7.26 (m, 2H), 7.26&#8211;7.19
(m, 3H), 6.85 (s, 1H), 5.73 (s, 2H), 3.84 (s, 3H), 3.78 (s, 2H). CO<sub>2</sub>H not observed. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.52 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 275.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.29"><title>Methyl 1-Benzyl-3-(2-(benzyl&#173;(cyclopropylmethyl)&#173;amino)-2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate (<bold>45</bold>)</title><p>To a
mixture of HOBt (69.7 mg, 0.45 mmol), EDC&#183;HCl (103 mg, 0.54 mmol),
Et<sub>3</sub>N (0.09 mL, 0.62 mmol) and <bold>44</bold> (126 mg,
0.41 mmol) in DCM (2 mL) was added a solution of <italic toggle="yes">N</italic>-benzyl-1-cyclopropylmethanamine (66.7 mg, 0.41 mmol) in DCM (2 mL).
The mixture was left to stir overnight at room temperature. UPLC analysis
showed the desired product, along with an unknown side-product. Saturated
aqueous NaHCO<sub>3</sub> (5 mL) was added and the mixture stirred
vigorously for 5 min before being passed through a phase separator.
The filtrate was purified by normal phase automated column chromatography
(12 g silica, ISCO, gradient from petroleum ether to EtOAc) to give
methyl 1-benzyl-3-(2-(benzyl&#173;(cyclopropylmethyl)&#173;amino)-2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylate (<bold>45</bold>, 39 mg, 0.09 mmol,
22% yield) as a light-yellow oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.27&#8211;6.97 (m, 10H), 6.81 (s, 0.5H), 6.77
(s, 0.5H), 5.61 (s, 1H), 5.56 (s, 1H), 4.64 (s, 1H), 4.61 (s, 1H),
3.76 (s, 1H), 3.71 (s, 1.5H), 3.70 (s, 1.5H), 3.65 (s, 1H), 3.19 (d, <italic toggle="yes">J</italic> = 6.9 Hz, 1H), 3.07 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 1H),
0.90&#8211;0.81 (m, 0.5H), 0.78&#8211;0.68 (m, 0.5H), 0.40&#8211;0.35
(m, 1H), 0.35&#8211;0.29 (m, 1H), 0.09&#8211;0.03 (m, 1H), 0.02
to &#8722;0.04 (m, 1H). Rotamers observed in approximately 1:1 ratio.
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.84 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 418.3 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.30"><title>1-Benzyl-3-(2-(benzyl&#173;(cyclopropylmethyl)&#173;amino)-2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylic Acid (<bold>46</bold>)</title><p>
<bold>45</bold> (39 mg, 0.09 mmol) was dissolved in MeOH (0.25 mL),
water (0.25 mL) and THF (0.25 mL). LiOH&#183;H<sub>2</sub>O (5.0 mg,
0.12 mmol) was added and the mixture stirred for 2 h at room temperature.
The mixture was concentrated under reduced pressure and aqueous 1
M HCl (5.0 mL) was added. The product precipitated out, the supernatant
was removed by pipet and the solid washed twice with water (5 mL).
The solid was dried in a vacuum oven overnight at 40 &#176;C to give
1-benzyl-3-(2-(benzyl&#173;(cyclopropylmethyl)&#173;amino)-2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxylic acid (<bold>46</bold>, 39 mg, 0.09
mmol, 98% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz,
CDCl<sub>3</sub>) &#948; 7.35&#8211;7.10 (m, 10H), 6.96 (s, 0.5H),
6.91 (s, 0.5H), 5.71 (s, 1H), 5.66 (s, 1H), 4.78 (s, 1H), 4.76 (s,
1H), 3.92 (s, 1H), 3.81 (s, 1H), 3.33 (d, <italic toggle="yes">J</italic> = 6.9
Hz, 1H), 3.21 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 1H), 0.97 (dddd, <italic toggle="yes">J</italic> = 11.9, 7.0, 4.0, 1.6 Hz, 0.5H), 0.90&#8211;0.80 (m,
0.5H), 0.51&#8211;0.46 (m, 1H), 0.46&#8211;0.40 (m, 1H), 0.19&#8211;0.14
(m, 1H), 0.13&#8211;0.08 (m, 1H). CO<sub>2</sub>H not observed. Rotamers
observed in approximately 1:1 ratio. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.68 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 404.3 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.31"><title>1-Benzyl-3-(2-(benzyl&#173;(cyclopropylmethyl)&#173;amino)-2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxamide (<bold>31</bold>)</title><p>To a
solution of PyBOP (54 mg, 0.14 mmol), HOBt (22.2 mg, 0.14 mmol) and <bold>46</bold> (39 mg, 0.1 mmol) in DMF (0.4 mL) was added DIPEA (0.07
mL, 0.39 mmol) followed by NH<sub>4</sub>Cl (10.3 mg, 0.19 mmol).
The mixture was left to stir for 1 h, after which it was diluted in
EtOAc (20 mL) and washed with a saturated solution of NaHCO<sub>3</sub> (3 &#215; 30 mL). The organic fraction was dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give the crude
product, which was purified by automated reverse-phase column chromatography
(ACCQPrep, 30 min run from water to MeOH) to afford 1-benzyl-3-(2-(benzyl&#173;(cyclopropylmethyl)&#173;amino)-2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-5-carboxamide (<bold>31</bold>, 19 mg, 0.05 mmol,
48% yield) as a colorless viscous oil, which solidified upon standing.
m.p.: 109&#8211;110 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.32 (dd, <italic toggle="yes">J</italic> = 8.1, 6.5 Hz, 1H),
7.29&#8211;7.18 (m, 7H), 7.18&#8211;7.15 (m, 1H), 7.15&#8211;7.11
(m, 1H), 6.75 (s, 0.5H), 6.70 (s, 0.5H), 6.19 (s, 1H), 5.74 (s, 1H),
5.68 (s, 1H), 5.51 (s, 1H), 4.73 (s, 2H), 3.86 (s, 1H), 3.75 (s, 1H),
3.29 (d, <italic toggle="yes">J</italic> = 6.9 Hz, 1H), 3.20 (d, <italic toggle="yes">J</italic> = 6.6 Hz, 1H), 1.00&#8211;0.91 (m, 0.5H), 0.86 (dddd, <italic toggle="yes">J</italic> = 13.1, 9.7, 5.8, 1.5 Hz, 0.5H), 0.52&#8211;0.46 (m, 1H), 0.46&#8211;0.41
(m, 1H), 0.16 (dt, <italic toggle="yes">J</italic> = 6.1, 4.7 Hz, 1H), 0.11 (dt, <italic toggle="yes">J</italic> = 6.0, 4.8 Hz, 1H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR
(101 MHz, CDCl<sub>3</sub>) &#948; 170.6 (Cq), 170.1 (Cq), 161.2
(Cq), 145.7 (Cq), 145.6 (Cq), 137.5 (Cq), 137.5 (Cq), 136.9 (Cq),
135.1 (Cq), 135.0 (Cq), 129.0 (CH), 128.7 (CH), 128.6 (CH), 128.6
(CH), 127.8 (CH), 127.8 (CH), 127.7 (CH), 127.7 (CH), 127.7 (CH),
127.4 (CH), 126.4 (CH), 108.1 (CH), 108.0 (CH), 54.6 (CH<sub>2</sub>), 54.5 (CH<sub>2</sub>), 51.9 (CH<sub>2</sub>), 51.5 (CH<sub>2</sub>), 50.4 (CH<sub>2</sub>), 48.5 (CH<sub>2</sub>), 47.8 (CH<sub>2</sub>), 47.8 (CH<sub>2</sub>), 34.0 (CH<sub>2</sub>), 33.8 (CH<sub>2</sub>), 10.2 (CH), 9.6 (CH), 3.9 (CH<sub>2</sub>), 3.7 (CH<sub>2</sub>). Rotamers observed in approximately 1:1 ratio. ACQUITY UPLC BEH
C<sub>18</sub> 1.7 &#956;m: Rt = 1.63 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 403.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub>, 403.2134, found 403.2136
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: nd/96/95%.</p></sec><sec id="sec4.3.32"><title>Dimethyl 1-Benzyl-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>48</bold>)</title><p>A suspension of dimethyl 1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (5.00 g, 27.15 mmol) and K<sub>2</sub>CO<sub>3</sub> (5.05 g, 36 mmol) in DMF (50 mL) was cooled in an
ice-bath. Benzyl bromide (3.28 mL, 27.64 mmol) was added slowly over
5 min. The bath was removed and the mixture stirred at room temperature
for 1 h, whereupon UPLC showed complete conversion to product. The
reaction mixture was poured onto 2 L ice-cold water, which precipitated
the desired product. The solid was collected by filtration under vacuum
and dried in a vacuum oven overnight to give dimethyl 1-benzylpyrazole-3,5-dicarboxylate
(<bold>48</bold>, 6.954 g, 24.087 mmol, 93% yield) as a colorless
solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.31
(s, 1H), 7.25&#8211;7.16 (m, 5H), 5.77 (s, 2H), 3.88 (s, 3H), 3.79
(s, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.65 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 275.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.33"><title>Methyl 1-Benzyl-5-carbamoyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylate
(<bold>49</bold>)</title><p>Synthesized according to method described
in US 10,966,961 B2.<xref rid="ref52" ref-type="bibr"/> To an ice-cold solution
of dimethyl 1-benzylpyrazole-3,5-dicarboxylate (5.00 g, 17.32 mmol)
in MeOH (40 mL), THF (40 mL) and water (16 mL) was added LiOH&#183;H<sub>2</sub>O (727 mg, 17.3 mmol). UPLC analysis after 2 h showed a mixture
of starting material (30% by UV), monohydrolyzed material (66% by
UV) and bis-hydrolyzed material (4%). The reaction mixture was concentrated
under reduced pressure to give a basic aqueous mixture, which was
diluted with water (40 mL) and extracted with DCM (2 &#215; 40 mL).
The aqueous phase was acidified and extracted with DCM (5 &#215; 40
mL). The combined second extract was dried over MgSO<sub>4</sub>,
filtered, and concentrated under reduced pressure to give the crude
products of monohydrolysis, which was used directly in the next step.
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.48 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 261.0 [M + H]<sup>+</sup>.</p><p>The
monohydrolyzed material from above (3.25 g, 12.48 mmol) was heated
in thionyl chloride (19.15 mL, 262.55 mmol) for 2 h. Excess thionyl
chloride was removed under reduced pressure in a fumehood and the
residue dissolved in DCM (10 mL) and added dropwise to a solution
of ammonia solution (35% by weight solution in water, 0.32 mL, 49.92
mmol). UPLC analysis showed reaction completion with both regioisomers
were present (80:20 ratio). Additional DCM (20 mL) was added and the
mixture washed with aqueous saturated NaHCO<sub>3</sub> solution (2
&#215; 30 mL). The organic phase was dried over MgSO<sub>4</sub>,
filtered and concentrated under reduced pressure to give the crude
product, which was purified by flash column chromatography (silica,
12 g, 1:0 petrol/EtOAc to 0:1 petrol/EtOAc containing 5% Et<sub>3</sub>N over 25 CV&#8217;s) to afford methyl 1-benzyl-5-carbamoyl-pyrazole-3-carboxylate
(<bold>49</bold>, 3.00 g, 10.99 mmol, 63% yield over two steps) as
a colorless solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) &#948;
7.34 (s, 1H), 7.31&#8211;7.22 (m, 5H), 5.83 (s, 2H), 3.90 (s, 3H).
CONH<sub>2</sub> not observed. ACQUITY UPLC BEH C<sub>18</sub> 1.7
&#956;m: Rt = 1.42 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 260.0
[M + H]<sup>+</sup>. Regioselectivity of monohydrolysis proven by
single crystal analysis.</p></sec><sec id="sec4.3.34"><title>1-Benzyl-5-carbamoyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylic
Acid (<bold>50</bold>)</title><p>Synthesized according to General Procedure
B using methyl 1-benzyl-5-carbamoyl-pyrazole-3-carboxylate (600 mg,
2.31 mmol) and LiOH&#183;H<sub>2</sub>O (291 mg, 6.93 mmol) to give
1-benzyl-5-carbamoyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylic acid
(<bold>50</bold>, 454 mg, 1.75 mmol, 80% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
12.96 (s, 1H), 8.11 (s, 1H), 7.66 (s, 1H), 7.40 (s, 1H), 7.36&#8211;7.24
(m, 3H), 7.20&#8211;7.14 (m, 2H), 5.82 (s, 2H). ACQUITY UPLC BEH
C<sub>18</sub> 1.7 &#956;m: Rt = 1.23 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 244.0 [M&#8211;H]<sup>&#8722;</sup>.</p></sec><sec id="sec4.3.35"><title>
<italic toggle="yes">N</italic>
<sup>3</sup>,1-Dibenzyl-<italic toggle="yes">N</italic>
<sup>3</sup>-(cyclopropylmethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxamide
(<bold>32</bold>)</title><p>1-Benzyl-5-carbamoyl-1<italic toggle="yes">H</italic>-pyrazole-3-carboxylic acid (49 mg, 0.20 mmol, <bold>50</bold>) was
heated in thionyl chloride (0.50 mL, 6.85 mmol) at 65 &#176;C for
2 h. The mixture was concentrated under reduced pressure and dissolved
in DCM (2 mL). Et<sub>3</sub>N (0.07 mL, 0.50 mmol) was added followed
by the dropwise addition of a solution of <italic toggle="yes">N</italic>-benzyl-1-cyclopropylmethanamine
(35 mg, 0.20 mmol) in DCM (2 mL). UPLC analysis after 5 min indicated
reaction completion. A saturated aqueous solution of NaHCO<sub>3</sub> was added and the mixture stirred vigorously for 5 min before being
passed through a phase separator. The filtrate was concentrated under
reduced pressure and purified by flash column chromatography (silica,
12 g, 1:0 petrol/EtOAc to 0:1 petrol/EtOAc containing 1% Et<sub>3</sub>N over 20 CV&#8217;s) to afford <italic toggle="yes">N</italic>
<sup>3</sup>,1-dibenzyl-<italic toggle="yes">N</italic>
<sup>3</sup>-(cyclopropylmethyl)&#173;pyrazole-3,5-dicarboxamide
(<bold>32</bold>, 16 mg, 0.04 mmol, 21% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) &#948; 7.35&#8211;7.10
(m, 11H), 5.81 (s, 1H), 5.71 (s, 1H), 5.16 (s, 1H), 3.56 (d, <italic toggle="yes">J</italic> = 6.9 Hz, 1H), 3.37&#8211;3.32 (m, 1H), 1.14&#8211;1.04
(m, 1H), 0.51&#8211;0.45 (m, 1H), 0.44&#8211;0.39 (m, 1H), 0.25&#8211;0.19
(m, 1H), 0.09&#8211;0.03 (m, 1H). Rotamers observed in approximately
1:1 ratio. One benzyl proton is missing as underneath HDO peak. ACQUITY
UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.78 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 389.2 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/94/90%.</p></sec><sec id="sec4.3.36"><title>(<italic toggle="yes">S</italic>)-<italic toggle="yes">N</italic>-(8-Chloro-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-4-(<italic toggle="yes">N</italic>-phenylsulfamoyl)&#173;benzamide
(<bold>33</bold>)</title><p>Synthesized according to General Procedure
C using 4-(phenylsulfamoyl)&#173;benzoic acid (42 mg, 0.14 mmol), (3<italic toggle="yes">S</italic>)-3-amino-8-chloro-5-methyl-2,3-dihydro-1,5-benzoxazepin-4-one
hydrochloride salt (40 mg, 0.14 mmol), HOBt hydrate (24 mg, 0.16 mmol),
EDC&#183;HCl (33 mg, 0.17 mmol) and DIPEA (0.06 mL, 0.36 mmol). Purified
by flash column chromatography (silica, 12 g, 1:0 petrol/EtOAc to
0:1 petrol/EtOAc containing 1% Et<sub>3</sub>N over 30 CV&#8217;s)
to afford (<italic toggle="yes">S</italic>)-<italic toggle="yes">N</italic>-(8-chloro-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo&#173;[<italic toggle="yes">b</italic>]&#173;[1,4]&#173;oxazepin-3-yl)-4-(<italic toggle="yes">N</italic>-phenylsulfamoyl)&#173;benzamide
(<bold>33</bold>, 66 mg, 0.13 mmol, 94% yield) as a beige solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.78&#8211;7.73
(m, 4H), 7.41 (d, <italic toggle="yes">J</italic> = 6.9 Hz, 1H), 7.26&#8211;7.21
(m, 4H), 7.17 (dd, <italic toggle="yes">J</italic> = 8.4, 0.5 Hz, 1H), 7.12 (ddt, <italic toggle="yes">J</italic> = 8.0, 6.9, 1.2 Hz, 1H), 7.09&#8211;7.06 (m, 2H), 5.07
(dt, <italic toggle="yes">J</italic> = 11.3, 7.1 Hz, 1H), 4.73 (dd, <italic toggle="yes">J</italic> = 9.8, 7.4 Hz, 1H), 4.30 (dd, <italic toggle="yes">J</italic> = 11.3, 9.9 Hz,
1H), 3.42 (s, 3H). NH not observed. <sup>13</sup>C&#173;{<sup>1</sup>H}
NMR (101 MHz, CDCl<sub>3</sub>) &#948; 169.5 (Cq), 165.6 (Cq), 150.6
(Cq), 142.3 (Cq), 137.4 (Cq), 136.3 (Cq), 134.7 (Cq), 132.9 (Cq),
129.6 (CH), 128.1 (CH), 127.5 (CH), 126.2 (CH), 125.9 (CH), 124.3
(CH), 123.7 (CH), 121.9 (CH), 77.3 (CH<sub>2</sub>), 49.8 (CH), 35.9
(CH<sub>3</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.76 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 486.2 [M + H, <sup>35</sup>Cl]<sup>+</sup>. HRMS calculated for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>SCl: 486.0890, found: 486.0887
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/97/88%.</p></sec><sec id="sec4.3.37"><title>Dimethyl 4-Iodo-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>52</bold>)</title><p>To a solution of dimethyl 1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (10.0 g, 54.3 mmol) in MeCN (1 L) under
inert atmosphere were added CAN (32.7 g, 59.8 mmol) and I<sub>2</sub> (17.9 g, 70.7 mmol). The reaction mixture was stirred at room temperature
for 48 h. The reaction mixture was concentrated under reduced pressure,
diluted with EtOAc (500 mL) and washed with 5% aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (200 mL). The organic layer was separated,
dried over NaSO<sub>4</sub> and concentrated under <italic toggle="yes">vacuo</italic> to obtain the crude which was triturated with heptane (150 mL) and
dried to afford dimethyl 4-iodo-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(<bold>52</bold>, 15.0 g, 48.4 mmol, 89% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948; 3.98 (s, 6H). NH
not observed. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.39
min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 311.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.38"><title>Dimethyl 1-Benzyl-4-iodo-pyrazole-3,5-dicarboxylate (<bold>53</bold>)</title><p>K<sub>2</sub>CO<sub>3</sub> (3.00 g, 21.4 mmol) was added
to a solution of 4-iodo-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(5.00 g, 16.1 mmol) in DMF (30 mL). The reaction mixture was cooled
to 0 &#176;C and benzyl bromide (1.95 mL, 16.4 mmol) was slowly added
over 5 min. The reaction mixture was stirred at 0 &#176;C for 1 h,
allowing to warm to room temperature. The mixture was poured onto
ice-cold water (350 mL) and the resultant precipitate filtered, washed
with additional cold water (100 mL) and dried thoroughly to afford
dimethyl 1-benzyl-4-iodo-pyrazole-3,5-dicarboxylate (<bold>53</bold>, 6.10 g, 14.5 mmol, 90% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.37&#8211;7.27 (m, 3H),
7.25&#8211;7.18 (m, 2H), 5.84 (s, 2H), 3.99 (s, 3H), 3.89 (s, 3H).
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.78 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 401.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.39"><title>Dimethyl (<italic toggle="yes">E</italic>)-1-Benzyl-4-(2-ethoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>54</bold>)</title><p>A 20 mL microwave vial was charged dimethyl 1-benzyl-4-iodo-pyrazole-3,5-dicarboxylate
(2.00 g, 4.75 mmol), (<italic toggle="yes">E</italic>)-(2-ethoxyvinyl)&#173;boronic acid
pinacol ester (1.71 mL, 8.08 mmol), CsCO<sub>3</sub> (3.30 g, 10.07
mmol), Pd&#173;(dppf)<sub>2</sub>Cl<sub>2</sub> (0.33 g, 0.45 mmol), monoglyme
(20 mL) and water (2 mL). The reaction mixture was degassed with N<sub>2</sub> for 10 min before heating to 90 &#176;C and stirring overnight.
The reaction mixture was diluted with EtOAc (60 mL) and filtered,
separated and aqueous phase extracted with further EtOAc (20 mL).
The organic phases were combined, dried over NaSO<sub>4</sub>, filtered
and concentrated under reduced pressure with Celite. The crude mixture
was purified by flash column chromatography (silica, 40 g, 1:0 petrol/EtOAc
to 7:3 petrol/EtOAc over 25 CV&#8217;s). Fractions containing product
were combined and concentrated under reduced pressure to afford dimethyl
(<italic toggle="yes">E</italic>)-1-benzyl-4-(2-ethoxyvinyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>54</bold>, 1.40 g, 3.66 mmol,
77% yield) as a brown oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.40 (d, <italic toggle="yes">J</italic> = 12.9 Hz, 1H), 7.34&#8211;7.21
(m, 3H), 7.20&#8211;7.14 (m, 2H), 6.20 (d, <italic toggle="yes">J</italic> = 12.9
Hz, 1H), 5.77 (s, 2H), 3.97&#8211;3.92 (m, 5H), 3.83 (s, 3H), 1.35
(t, <italic toggle="yes">J</italic> = 7.0 Hz, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.82 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 367.1 [M + Na]<sup>+</sup>.</p></sec><sec id="sec4.3.40"><title>Methyl 2,6-Dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate (<bold>55</bold>)</title><p>Synthesized according to General Procedure A using dimethyl
1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(5 g, 15.8 mmol, <bold>27</bold>), benzylamine hydrochloride (2.20
g, 20.6 mmol, 1.3 equiv), acetic acid (0.3 mL) and 2-methylpyridine
borane complex (2.56 g, 23.7 mmol, 1.5 equiv), MeOH (50 mL). Purified
by flash column chromatography (silica, 24 g, 1:0 heptane/EtOAc to
1:1 heptane/EtOAc over 25 CV&#8217;s) to give methyl 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>55</bold>, 2.50 g, 6.66 mmol, 42% yield) as a colorless solid.
m.p.: 157&#8211;159 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.40&#8211;7.23 (m, 10H), 5.83 (s, 2H), 4.78 (s,
2H), 3.85&#8211;3.81 (m, 3H), 3.48 (t, <italic toggle="yes">J</italic> = 6.7 Hz,
2H), 2.97 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 160.9 (Cq), 159.9
(Cq), 142.4 (Cq), 137.3 (Cq), 136.4 (Cq), 128.8 (CH), 128.6 (CH),
128.3 (CH), 128.14 (Cq), 128.12 (CH), 128.1 (CH), 127.7 (CH), 125.9
(Cq), 56.2 (CH<sub>2</sub>), 52.1 (CH<sub>3</sub>), 49.7 (CH<sub>2</sub>), 46.6 (CH<sub>2</sub>), 21.5 (CH<sub>2</sub>). ACQUITY UPLC BEH
C<sub>18</sub> 1.7 &#956;m: Rt = 1.78 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 376.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>: 376.1661, found: 376.1665
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/93/99%.</p></sec><sec id="sec4.3.41"><title>Methyl 1,6-Dibenzyl-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate (<bold>56</bold>)</title><p>Synthesized according to the synthesis of <bold>55</bold> through separation of the other regioisomer to give methyl 1,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>56</bold>, 1.30 g, 3.46 mmol, 22% yield) as a colorless solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.39&#8211;7.34
(m, 2H), 7.29&#8211;7.20 (m, 8H), 5.81 (s, 2H), 4.63 (s, 2H), 3.85
(s, 3H), 3.43 (t, <italic toggle="yes">J</italic> = 6.9 Hz, 2H), 2.97 (t, <italic toggle="yes">J</italic> = 6.9 Hz, 2H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.82 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 376.3 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.42"><title>2,6-Dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>34</bold>)</title><p>Synthesized
according to General Procedure C using 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (150 mg, 0.41 mmol, <bold>80</bold>), HOBt hydrate (61 mg, 0.45
mmol, 1.1 equiv), EDC&#183;HCl (103 mg, 0.54 mmol, 1.3 equiv), DIPEA
(0.18 mL, 1.03 mmol, 2.4 equiv) and NH<sub>4</sub>Cl (66 mg, 1.24
mmol, 3 equiv). Purified by reverse-phase column chromatography (9:1
0.1% TFA in water/MeCN to 0:1 0.1% TFA in water/MeCN over 30 min)
to afford 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>34</bold>, 14 mg, 0.04 mmol, 9% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.77
(br s, 1H), 7.62 (br s, 1H), 7.39&#8211;7.16 (m, 10H), 5.64 (s, 2H),
4.65 (s, 2H), 3.48 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H), 2.89 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (101
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 161.0, 160.0, 141.3,
137.7, 137.1, 132.9, 128.48, 127.64, 127.61, 127.57, 127.1, 125.3,
120.6, 54.0, 48.7, 46.7, 19.9. A HMBC correlation (in DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) of amidic NH<sub>2</sub> (7.62 and 7.77 ppm)
with C5 (132.9 ppm) and benzyl CH<sub>2</sub> (5.65 ppm) with C5 (132.9
ppm) was observed. Additionally, NOESY correlation was observed between
amidic NH<sub>2</sub> (7.62 and 7.77 ppm) with benzyl CH<sub>2</sub> (5.65 ppm), which altogether is only consistent with isomer as drawn.
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.52 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 361.2 [M + H]<sup>+</sup>. HRMS calculated
for C<sub>21</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub>, 361.1665,
found 361.1675. ELSD/UV/<sup>1</sup>H NMR purity: 100/100/94%.</p></sec><sec id="sec4.3.43"><title>1,6-Dibenzyl-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>57</bold>)</title><p>Synthesized
according to General Procedure D using methyl 1,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(150 mg, 0.40 mmol, 1 equiv) and 7 M NH<sub>3</sub> in MeOH (5 mL).
Purified by reverse-phase column chromatography (9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to 1,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>57</bold>, 25 mg, 0.07 mmol, 17% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.40&#8211;7.27
(m, 10H), 6.76 (s, 1H), 5.82 (s, 2H), 5.35 (s, 1H), 4.71 (s, 2H),
3.50 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 3.10 (t, <italic toggle="yes">J</italic> = 6.9 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 163.1, 158.0, 140.6, 137.3, 137.0,
131.9, 130.0, 128.53, 128.47, 127.49, 127.45, 127.2, 123.5, 53.8,
48.6, 47.3, 20.1. A HMBC correlation (in DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) of benzyl CH<sub>2</sub> (5.77 ppm) and C5 (131.9 ppm) was
identified only and no NOESY was observed between amidic NH<sub>2</sub> and benzyl CH<sub>2</sub>, which is only consistent with isomer
as drawn. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.81
min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 361.2 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/89/98%.</p></sec><sec id="sec4.3.44"><title>Methyl 2-Benzyl-7-oxo-6-phenethyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73a</bold>)</title><p>Synthesized according to General Procedure
A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(0.90 g, 2.84 mmol, <bold>27</bold>), phenethylamine hydrochloride
(0.67 g, 4.27 mmol, 1.5 equiv), acetic acid (0.3 mL) and 2-methylpyridine
borane complex (0.27 g, 2.56 mmol, 0.9 equiv). The crude uncyclized
product after workup was kept at room temperature overnight, resulting
in two cyclized regioisomers. Purified by flash column chromatography
(silica, 12 g, 1:0 heptane/EtOAc to 1:1 heptane/EtOAc) to give methyl
2-benzyl-7-oxo-6-phenethyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate (<bold>73a</bold>, 240 mg, 0.62
mmol, 22% yield) as a pale yellow oil. X-Select LCMS CSH C<sub>18</sub> 2.5 &#956;m: Rt = 2.08 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 390.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.45"><title>2-Benzyl-7-oxo-6-phenethyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>58</bold>)</title><p>Synthesized according to General Procedure D using methyl
2-benzyl-7-oxo-6-phenethyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate (100 mg, 0.25 mmol) and 7 M NH<sub>3</sub> in MeOH (5 mL). Purified by reverse-phase column chromatography
(9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM
(NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to give
2-benzyl-7-oxo-6-phenethyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>58</bold>, 20 mg, 0.05 mmol,
21% yield) as an off-white solid. m.p.: 169&#8211;171 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.38&#8211;7.33
(m, 2H), 7.33&#8211;7.19 (m, 8H), 5.78 (s, 2H), 5.58 (br s, 2H),
3.78 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 3.37 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 2.95 (t, <italic toggle="yes">J</italic> = 7.1 Hz, 2H), 2.75 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126
MHz, CDCl<sub>3</sub>) &#948; 161.2 (Cq), 160.8 (Cq), 142.0 (Cq),
139.2 (Cq), 136.4 (Cq), 130.9 (CH), 129.0 (CH), 128.7 (CH), 128.3
(CH), 128.2 (CH), 126.7 (CH), 121.1 (Cq), 55.8 (CH<sub>2</sub>), 49.2
(CH<sub>2</sub>), 48.6 (CH<sub>2</sub>), 34.5 (CH<sub>2</sub>), 21.1
(CH<sub>2</sub>). A HMBC correlation (in DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) of amidic NH<sub>2</sub> (7.71 and 7.82 ppm) with C5 (132.8
ppm) and benzyl CH<sub>2</sub> (5.69 ppm) with C5 (132.8 ppm) was
observed, which is only consistent with isomer as drawn. ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.57 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 375.3 [M + H]<sup>+</sup>. HRMS calculated for
C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>: 375.1821,
found: 375.1817 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/92/100%.</p></sec><sec id="sec4.3.46"><title>Methyl 2-Benzyl-7-oxo-6-(2-phenoxyethyl)-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73b</bold>)</title><p>Synthesized according to General Procedure
A but reversed limiting reagent. Dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (0.80 g, 2.53 mmol, <bold>27</bold>), 2-phenyoxyethylamine (0.50 mL, 3.79 mmol, 1.5 equiv), acetic acid
(0.2 mL), 2-methylpyridine borane complex (243 mg, 2.27 mmol, 0.9
equiv). 4 M HCl in 1,4-dioxane (0.7 mL) was added to generate amine
hydrochloride prior to reductive amination. The crude uncyclized product
after workup was kept at room temperature overnight, resulting in
two cyclized regioisomers. Purified by flash column chromatography
(silica, 24 g, 7:3 heptane/EtOAc to 0:1 heptane/EtOAc) to give methyl
2-benzyl-7-oxo-6-(2-phenoxyethyl)-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate (<bold>73b</bold>, 200 mg, 0.49 mmol, 20% yield) as an off-white solid. X-Select LCMS
CSH C<sub>18</sub> 1.5 &#956;m: Rt = 2.17 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 406.2 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.47"><title>2-Benzyl-7-oxo-6-(2-phenoxyethyl)-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>59</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-7-oxo-6-(2-phenoxyethyl)-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(150 mg, 0.37 mmol) and 7 M NH<sub>3</sub> in MeOH (5 mL). Purified
by reverse-phase column chromatography (9:1 0.1% TFA in water/MeCN
to 1:9 0.1% TFA in water/MeCN over 30 min) to give 2-benzyl-7-oxo-6-(2-phenoxyethyl)-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>59</bold>, 20 mg, 0.05 mmol, 14% yield) as an off-white solid.
m.p.: 95&#8211;97 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.77 (s, 1H), 7.65 (s, 1H), 7.35&#8211;7.24
(m, 5H), 7.21&#8211;7.17 (m, 2H), 6.97&#8211;6.91 (m, 3H), 5.63
(s, 2H), 4.14 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 2H), 3.80 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 2H), 3.69 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H),
2.91 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 161.0 (Cq), 158.6 (Cq),
142.1 (Cq), 136.5 (Cq), 130.9 (Cq), 129.7 (CH), 128.7 (CH), 128.2
(CH), 128.1 (CH), 121.4 (Cq), 121.2 (CH), 114.5 (CH), 67.3 (CH<sub>2</sub>), 55.8 (CH<sub>2</sub>), 49.8 (CH<sub>2</sub>), 47.0 (CH<sub>2</sub>), 21.4 (CH<sub>2</sub>). A HMBC correlation of amidic NH<sub>2</sub> (7.65 and 7.77 ppm) with C5 (132.9 ppm) and benzyl CH<sub>2</sub> (5.63 ppm) with C5 (132.9 ppm) was observed, which is only
consistent with isomer as drawn. ACQUITY UPLC BEH C<sub>18</sub> 1.7
&#956;m: Rt = 1.57 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 389.2
[M &#8211; H]<sup>&#8722;</sup>. HRMS calculated for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>: 389.1616, found: 389.1598
[M &#8211; H]<sup>&#8722;</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/93/100%.</p></sec><sec id="sec4.3.48"><title>Methyl 2-Benzyl-6-(4-hydroxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
and Methyl 1-Benzyl-6-(4-hydroxybenzyl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73c</bold>)</title><p>Synthesized according to General Procedure
A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(0.80 g, 2.53 mmol, <bold>27</bold>), 4-hydroxybenzylamine (0.47 g,
3.79 mmol, 1.5 equiv), acetic acid (0.3 mL) and 2-methylpyridine borane
complex (243 mg, 2.27 mmol, 0.9 equiv). 4 M HCl in 1,4-dioxane (0.7
mL) was added to generate amine hydrochloride prior to reductive amination.
The crude uncyclized product after workup was kept at room temperature
overnight, resulting in two cyclized regioisomers. Purified by flash
column chromatography (silica, 24 g, 1:0 heptane/EtOAc to 1:1 heptane/EtOAc)
to afford a mixture of two regioisomers methyl 2-benzyl-6-(4-hydroxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
and methyl 1-benzyl-6-(4-hydroxybenzyl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73c</bold>, 0.60 g, 1.53 mmol, 61% yield) as a pale yellow
solid. X-Select LCMS CSH C<sub>18</sub> 2.5 &#956;m: Rt = 2.32 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 392.1 [M + H]<sup>+</sup>, Rt = 2.43; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 392.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.49"><title>2-Benzyl-6-(4-hydroxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>60</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-6-(4-hydroxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(0.50 g, 1.27 mmol, as mixture of two regioisomers) and 7 M NH<sub>3</sub> in MeOH (15 mL). Purified by reverse-phase column chromatography
(9:1 10 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 10
mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to give
2-benzyl-6-(4-hydroxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamid<italic toggle="yes">e</italic> (<bold>60</bold>, 28 mg, 0.07 mmol, 6% yield) as an off-white solid.
m.p.: 148&#8211;149 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 9.33 (s, 1H), 7.76 (s, 1H), 7.61
(s, 1H), 7.36&#8211;7.25 (m, 3H), 7.23&#8211;7.18 (m, 2H), 7.13&#8211;7.07
(m, 2H), 6.73&#8211;6.69 (m, 2H), 5.64 (s, 2H), 4.52 (s, 2H), 3.43
(t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H), 2.85 (t, <italic toggle="yes">J</italic> =
6.7 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 161.1 (Cq), 159.8 (Cq), 156.6 (Cq),
141.5 (Cq), 137.2 (Cq), 132.9 (Cq), 129.1 (CH), 128.5 (CH), 127.8
(Cq), 127.7 (CH), 127.6 (CH), 120.6 (Cq), 115.2 (CH), 54.0 (CH<sub>2</sub>), 48.1 (CH<sub>2</sub>), 46.4 (CH<sub>2</sub>), 19.9 (CH<sub>2</sub>). A HMBC correlation of amidic NH (7.76 ppm) with C5 (132.9
ppm) and benzyl CH<sub>2</sub> (5.64 ppm) with C5 (132.9 ppm) was
observed, which is only consistent with isomer as drawn. ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.39 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 377.2 [M + H]<sup>+</sup>. HRMS calculated for
C<sub>21</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>: 377.1614,
found: 377.1599 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/100/100%.</p></sec><sec id="sec4.3.50"><title>Methyl 2-Benzyl-6-(4-methoxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73d</bold>)</title><p>Synthesized according to General Procedure
A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(0.80 g, 2.53 mmol, <bold>27</bold>), 4-methoxybenzylamine (0.50 g,
3.79 mmol, 1.5 equiv), acetic acid (0.3 mL) and 2-methylpyridine borane
complex (0.24 g, 2.27 mmol, 0.9 equiv). 4 M HCl in 1,4-dioxane (0.8
mL) was added to generate amine hydrochloride prior to reductive amination.
The crude uncyclized product after workup was kept at room temperature
overnight, resulting in two cyclized regioisomers. Purified by flash
column chromatography (silica, 24 g, 1:0 heptane/EtOAc to 1:1 heptane/EtOAc)
to give methyl 2-benzyl-6-(4-methoxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73d</bold>, 0.20 g, 0.49 mmol, 20% yield) as a pale yellow
solid. X-Select LCMS CSH C<sub>18</sub> 2.5 &#956;m: Rt = 1.87 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 406.2 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.51"><title>2-Benzyl-6-(4-methoxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>61</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-6-(4-methoxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(200 mg, 0.49 mmol) and 7 M NH<sub>3</sub> in MeOH (10 mL). Purified
by reverse-phase column chromatography (9:1 0.1% TFA in water/MeCN
to 0:1 0.1% TFA in water/MeCN over 30 min) to give 2-benzyl-6-(4-methoxybenzyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>61</bold>, 14 mg, 0.04 mmol, 7% yield) as an off-white solid.
m.p.: 195&#8211;196 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.76 (s, 1H), 7.61 (s, 1H), 7.36&#8211;7.25
(m, 3H), 7.24&#8211;7.19 (m, 4H), 6.92&#8211;6.86 (m, 2H), 5.64
(s, 2H), 4.57 (s, 2H), 3.73 (s, 3H), 3.44 (t, <italic toggle="yes">J</italic> =
6.7 Hz, 2H), 2.86 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 160.9 (Cq),
160.8 (Cq), 159.3 (Cq), 142.1 (Cq), 136.6 (Cq), 130.9 (Cq), 129.7
(CH), 129.3 (Cq), 128.7 (CH), 128.3 (CH), 128.1 (CH), 120.9 (Cq),
114.2 (CH), 55.8 (CH<sub>2</sub>), 55.4 (CH<sub>3</sub>), 49.0 (CH<sub>2</sub>), 46.3 (CH<sub>2</sub>), 21.2 (CH<sub>2</sub>). ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.54 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 391.3 [M + H]<sup>+</sup>. HRMS calculated for
C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>: 391.1770,
found: 391.1765 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/95/100%.</p></sec><sec id="sec4.3.52"><title>Methyl 2-Benzyl-6-(3-hydroxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
and Methyl 1-Benzyl-6-(3-hydroxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73e</bold>)</title><p>Synthesized according to General Procedure
A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(0.80 g, 2.53 mmol, <bold>27</bold>), 3-(2-aminoethyl)&#173;phenol (0.52
mL, 3.79 mmol, 1.5 equiv), acetic acid (0.3 mL) and 2-methylpyridine
borane complex (0.24 g, 2.27 mmol, 0.9 equiv). 4 M HCl in 1,4-dioxane
(0.7 mL) was added to generate amine hydrochloride prior to reductive
amination. The crude uncyclized product after workup was kept at room
temperature overnight, resulting in two cyclized regioisomers. Purified
by flash column chromatography (silica, 24 g, 1:0 heptane/EtOAc to
3:7 heptane/EtOAc) to give methyl 2-benzyl-6-(3-hydroxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
and methyl 1-benzyl-6-(3-hydroxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-1<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73e</bold>, 0.40 g, 0.98 mmol, 39% yield) as a pale yellow
solid. X-Select LCMS CSH C<sub>18</sub> 2.5 &#956;m: Rt = 1.13 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 406.3 [M + H]<sup>+</sup>, Rt = 1.16
min, <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 406.3 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.53"><title>2-Benzyl-6-(3-hydroxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>62</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-6-(3-hydroxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(400 mg, 0.98 mmol, as mixture of two regioisomers) and 7 M NH<sub>3</sub> in MeOH (15 mL). Purified by reverse-phase column chromatography
(9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM
(NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to give
2-benzyl-6-(3-hydroxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>62</bold>, 30 mg, 0.08 mmol, 8% yield) as an off-white solid.
m.p.: 184&#8211;186 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 9.27 (s, 1H), 7.76 (s, 1H), 7.65
(s, 1H), 7.35&#8211;7.25 (m, 3H), 7.21&#8211;7.17 (m, 2H), 7.07
(t, <italic toggle="yes">J</italic> = 7.7 Hz, 1H), 6.67&#8211;6.63 (m, 2H), 6.59
(ddd, <italic toggle="yes">J</italic> = 8.0, 2.5, 1.0 Hz, 1H), 5.63 (s, 2H), 3.64&#8211;3.57
(m, 2H), 3.48 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 2.84 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 2.73 (t, <italic toggle="yes">J</italic> = 7.5 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (101 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 161.1 (Cq), 159.6 (Cq), 157.3 (Cq), 141.6 (Cq),
140.5 (Cq), 137.2 (Cq), 132.8 (Cq), 129.3 (CH), 128.5 (CH), 127.61
(CH), 127.57 (CH), 120.6 (Cq), 119.3 (CH), 115.5 (CH), 113.2 (CH),
54.0 (CH<sub>2</sub>), 47.6 (CH<sub>2</sub>), 47.3 (CH<sub>2</sub>), 33.5 (CH<sub>2</sub>), 20.0 (CH<sub>2</sub>). A HMBC correlation
of amidic NH<sub>2</sub> (7.65 and 7.76 ppm) with C5 (132.8 ppm) was
observed, similarly benzyl CH<sub>2</sub> (5.63 ppm) with C5 (132.8
ppm) and lactam CH<sub>2</sub> (2.84 ppm) with C5 (132.8 ppm) was
observed, which is only consistent with isomer as drawn. ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.44 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 391.3 [M + H]<sup>+</sup>. HRMS calculated for
C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>: 391.1770,
found: 391.1770 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/87/97%.</p></sec><sec id="sec4.3.54"><title>Methyl 2-Benzyl-6-(3-methoxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73f</bold>)</title><p>Synthesized according to General Procedure
A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(0.80 g, 2.53 mmol, <bold>27</bold>), 3-methoxyphenethylamine (0.55
mL, 3.79 mmol, 1.5 equiv), acetic acid (0.3 mL) and 2-methylpyridine
borane complex (0.24 g, 2.27 mmol, 0.9 equiv). 4 M HCl in 1,4-dioxane
(0.7 mL) was added to generate amine hydrochloride prior to reductive
amination. The crude uncyclized product after workup was kept at room
temperature overnight, resulting in two cyclized regioisomers. Purified
by flash column chromatography (silica, 24 g, 7:3 heptane/EtOAc to
1:4 heptane/EtOAc) to give methyl 2-benzyl-6-(3-methoxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73f</bold>, 0.20 g, 0.48 mmol, 19% yield) as a brown oil. X-Select
LCMS CSH C<sub>18</sub> 2.5 &#956;m: Rt = 2.65 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 420.2 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.55"><title>2-Benzyl-6-(3-methoxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>63</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-6-(3-methoxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(200 mg, 0.47 mmol) and 7 M NH<sub>3</sub> in MeOH (10 mL). Purified
by reverse-phase column chromatography (9:1 10 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 10 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to give 2-benzyl-6-(3-methoxyphenethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>63</bold>, 21 mg, 0.05 mmol, 11% yield) as an off-white solid.
m.p.: 162&#8211;163 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.76 (s, 1H), 7.65 (s, 1H), 7.36&#8211;7.24
(m, 3H), 7.23&#8211;7.17 (m, 3H), 6.85&#8211;6.80 (m, 2H), 6.78&#8211;6.74
(m, 1H), 5.63 (s, 2H), 3.72 (s, 3H), 3.67&#8211;3.62 (m, 2H), 3.49
(t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 2.88&#8211;2.78 (m, 4H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948;
160.9 (Cq), 160.6 (Cq), 159.9 (Cq), 142.2 (Cq), 140.9 (Cq), 136.6
(Cq), 130.9 (Cq), 129.7 (CH), 128.7 (CH), 128.3 (CH), 128.1 (CH),
121.4 (CH), 121.0 (Cq), 114.6 (CH), 112.1 (CH), 55.8 (CH<sub>2</sub>), 55.4 (CH<sub>3</sub>), 49.0 (CH<sub>2</sub>), 48.5 (CH<sub>2</sub>), 34.6 (CH<sub>2</sub>), 21.2 (CH<sub>2</sub>). ACQUITY UPLC BEH
C<sub>18</sub> 1.7 &#956;m: Rt = 1.57 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 405.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub>: 405.1927, found: 405.1912
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/100/98%.</p></sec><sec id="sec4.3.56"><title>Methyl 2-Benzyl-6-(2-methoxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73g</bold>)</title><p>To a solution of dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (0.70 g, 2.21 mmol) in DCE
(10 mL) were added 2-methoxyethylamine (0.29 mL, 3.32 mmol), Na&#173;(OAc)<sub>3</sub>BH (1.17 g, 5.53 mmol) and AcOH (0.3 mL). The reaction mixture
was stirred at room temperature overnight. The reaction mixture was
diluted with DCM (50 mL) and washed with saturated NaHCO<sub>3</sub> solution (30 mL). The organic layer was dried over NaSO<sub>4</sub>, filtered and concentrated under reduced pressure to obtain the
crude uncyclized product which was kept at room temperature overnight,
resulting in formation of two cyclized regioisomers. The crude mixture
was purified by flash column chromatography (silica, 24 g, 1:0 heptane/EtOAc
to 0:1 heptane/EtOAc over 25 CV&#8217;s). Fractions containing product
were combined and concentrated under reduced pressure to afford methyl
2-benzyl-6-(2-methoxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate (<bold>73g</bold>, 100 mg, 0.29 mmol, 13% yield) as a pale yellow solid. X-Select
LCMS CSH C<sub>18</sub> 2.5 &#956;m: Rt = 2.80 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 344.2 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.57"><title>2-Benzyl-6-(2-methoxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>64</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-6-(2-methoxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(100 mg, 0.29 mmol) and 7 M NH<sub>3</sub> in MeOH (5 mL). Purified
by reverse-phase column chromatography (9:1 10 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 10 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to give 2-benzyl-6-(2-methoxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>64</bold>, 15 mg, 0.05 mmol, 16% yield) as an off-white solid.
m.p.: 143&#8211;145 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.77 (s, 1H), 7.64 (s, 1H), 7.35&#8211;7.24
(m, 3H), 7.22&#8211;7.17 (m, 2H), 5.63 (s, 2H), 3.61&#8211;3.55
(m, 4H), 3.48 (t, <italic toggle="yes">J</italic> = 5.6 Hz, 2H), 3.25 (s, 3H),
2.89 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 161.1 (Cq), 160.8 (Cq),
142.2 (Cq), 136.6 (Cq), 131.0 (Cq), 128.7 (CH), 128.3 (CH), 128.1
(CH), 121.2 (Cq), 71.8 (CH<sub>2</sub>), 59.0 (CH<sub>3</sub>), 55.7
(CH<sub>2</sub>), 49.3 (CH<sub>2</sub>), 46.9 (CH<sub>2</sub>), 21.3
(CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.32 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 329.2 [M + H]<sup>+</sup>. HRMS calculated for C<sub>17</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>: 329.1614, found: 329.1621 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/93/100%.</p></sec><sec id="sec4.3.58"><title>Methyl 2-Benzyl-6-(2-(dimethylamino)-2-oxoethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73h</bold>)</title><p>To a solution of dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (0.70 g, 2.21 mmol) in DCE
(7 mL) were added 2-amino-<italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylacetamide
(0.31 mL, 2.21 mmol), Na&#173;(OAc)<sub>3</sub>BH (1.17 g, 5.53 mmol) and
AcOH (0.1 mL). The reaction mixture was stirred at room temperature
overnight. The reaction mixture was diluted with DCM (50 mL) and washed
with saturated NaHCO<sub>3</sub> solution (30 mL). The organic layer
was dried over NaSO<sub>4</sub>, filtered and concentrated under reduced
pressure to obtain the crude uncyclized product which was kept at
room temperature overnight, resulting in formation of two cyclized
regioisomers. The crude mixture was purified by flash column chromatography
(silica, 24 g, 1:0 DCM/MeOH to 49:1 DCM/MeOH over 25 CV&#8217;s).
Fractions containing product were combined and concentrated under
reduced pressure to afford methyl 2-benzyl-6-(2-(dimethylamino)-2-oxoethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73h</bold>, 0.42 g, 1.13 mmol, 51% yield) as an off-white solid.
X-Bridge LCMS BEH C<sub>18</sub> 2.5 &#956;m: Rt = 1.17 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 371.1 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.59"><title>2-Benzyl-6-(2-(dimethylamino)-2-oxoethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>65</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-6-(2-(dimethylamino)-2-oxoethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(0.40 g, 1.08 mmol) and 7 M NH<sub>3</sub> in MeOH (5 mL). Purified
by reverse-phase column chromatography (9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to give 2-benzyl-6-(2-(dimethylamino)-2-oxoethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>65</bold>, 15 mg, 0.04 mmol, 6% yield) as an off-white solid.
m.p.: 160&#8211;161 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.78 (s, 1H), 7.67 (s, 1H), 7.35&#8211;7.25
(m, 3H), 7.22&#8211;7.18 (m, 2H), 5.64 (s, 2H), 4.31 (s, 2H), 3.56
(t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H), 2.98 (s, 3H), 2.92 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H), 2.83 (s, 3H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 167.9 (Cq), 161.0 (Cq),
141.7 (Cq), 136.6 (Cq), 131.1 (Cq), 128.7 (CH), 128.2 (CH), 128.1
(CH), 121.7 (Cq), 55.8 (CH<sub>2</sub>), 48.5 (CH<sub>2</sub>), 47.6
(CH<sub>2</sub>), 36.7 (CH<sub>3</sub>), 35.8 (CH<sub>3</sub>), 21.1
(CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.24 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 354.1 [M-H]<sup>&#8722;</sup>. HRMS calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>3</sub>: 354.1566, found: 354.1561 [M-H]<sup>&#8722;</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/92/100%.</p></sec><sec id="sec4.3.60"><title>Methyl 2-Benzyl-6-(3-hydroxy-1-phenylpropyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73i</bold>)</title><p>Synthesized in two steps according to
(i) General Procedure A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (1.50 g, 4.74 mmol, <bold>27</bold>), 3-amino-3-phenyl-1-propanol (0.93 g, 6.17 mmol, 1.3 equiv), acetic
acid (0.2 mL) and 2-methylpyridine borane complex (0.46 g, 4.27 mmol,
0.9 equiv). Purified by flash column chromatography (silica, 24 g,
1:0 DCM/MeOH to 9:1 DCM/MeOH) to afford dimethyl 1-benzyl-4-(2-((3-hydroxy-1-phenylpropyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (0.90 g, 1.99 mmol, 42% yield)
as a yellow liquid. Product taken forward as crude to the next step.
(ii) To a solution of dimethyl 1-benzyl-4-(2-((3-hydroxy-1-phenylpropyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (0.30 g, 0.66 mmol) in toluene
(5 mL) was added AlMe<sub>3</sub> (2 M in toluene, 1.10 mL, 2.25 mmol).
The reaction mixture was heated to 100 &#176;C and stirred for 3 h.
The reaction mixture was cooled to room temperature, quenched with
saturated Rochelle salt solution (60 mL) and extracted with EtOAc
(2 &#215; 70 mL). The organic layers were combined, dried over NaSO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude
mixture was purified by flash column chromatography (silica, 12 g,
1:0 heptane/EtOAc to 3:7 heptane/EtOAc over 25 CV&#8217;s). Fractions
containing product were combined and concentrated under reduced pressure
to afford methyl 2-benzyl-6-(3-hydroxy-1-phenylpropyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(<bold>73i</bold>, 0.15 g, 0.35 mmol, 53% yield) as a brown liquid.
XSelect LCMS CSH C<sub>18</sub> 2.5 &#956;m: 2.15 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 420.3 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.61"><title>2-Benzyl-6-(3-hydroxy-1-phenylpropyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>66</bold>)</title><p>Synthesized according to General Procedure
D using methyl 2-benzyl-6-(3-hydroxy-1-phenylpropyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(150 mg, 0.35 mmol) and 7 M NH<sub>3</sub> in MeOH (5 mL). Purified
by flash column chromatography (silica, 12 g, 1:0 DCM/MeOH to 19:1
DCM/MeOH over 25 CV&#8217;s) to give 2-benzyl-6-(3-hydroxy-1-phenylpropyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>66</bold>, 29 mg, 0.07 mmol, 20% yield) as an off-white solid.
m.p.: 182&#8211;184 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.74 (s, 1H), 7.59 (s, 1H), 7.39&#8211;7.31
(m, 6H), 7.30&#8211;7.25 (m, 2H), 7.23&#8211;7.20 (m, 2H), 5.91
(dd, <italic toggle="yes">J</italic> = 9.6, 6.0 Hz, 1H), 5.67&#8211;5.58 (m, 2H),
4.50 (t, <italic toggle="yes">J</italic> = 5.1 Hz, 1H), 3.50&#8211;3.39 (m, 3H),
3.09&#8211;3.02 (m, 1H), 2.86&#8211;2.78 (m, 1H), 2.74&#8211;2.66
(m, 1H), 2.19&#8211;2.07 (m, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR
(100 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 161.5 (Cq),
160.5 (Cq), 142.1 (Cq), 140.6 (Cq), 137.6 (Cq), 133.3 (Cq), 129.0
(CH), 128.9 (CH), 128.2 (CH), 128.0 (CH), 127.8 (CH), 120.9 (Cq),
58.6 (CH<sub>2</sub>), 54.5 (CH<sub>2</sub>), 51.5 (CH), 42.1 (CH<sub>2</sub>), 33.2 (CH<sub>2</sub>), 20.6 (CH<sub>2</sub>). A HMBC correlation
of amidic NH<sub>2</sub> (7.59 and 7.74 ppm) with C5 (133.3 ppm) and
benzyl CH<sub>2</sub> (5.58&#8211;5.67 ppm) with C5 (133.3 ppm) was
observed, which is only consistent with isomer as drawn. ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.49 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 405.3 [M + H]<sup>+</sup>. HRMS calculated for
C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub>: 405.1927,
found 405.1929 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
95/95/95%.</p></sec><sec id="sec4.3.62"><title>2-Benzyl-7-oxo-6-phenethyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic acid (<bold>67</bold>)</title><p>Synthesized according to synthesis of <bold>58</bold> and isolated as a major side-product. Purified by reverse-phase
column chromatography (9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in
water/MeCN to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN
over 30 min). Fractions containing product were combined and concentrated
under reduced pressure to give 2-benzyl-7-oxo-6-phenethyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (<bold>67</bold>, 28 mg, 0.07 mmol, 30% yield) as an off-white
solid. m.p.: 80 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.36&#8211;7.19 (m, 10H), 5.78 (s, 2H), 3.84&#8211;3.77
(m, 2H), 3.39 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 2H), 2.96 (t, <italic toggle="yes">J</italic> = 7.2 Hz, 2H), 2.91 (t, <italic toggle="yes">J</italic> = 6.8 Hz, 2H).
OH not observed. <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 162.3 (Cq), 161.3 (Cq), 142.0 (Cq), 138.9 (Cq),
136.1 (Cq), 129.0 (CH), 128.8 (CH), 128.7 (CH), 128.2 (CH), 128.2
(CH), 127.9 (Cq), 127.1 (Cq), 126.8 (CH), 56.2 (CH<sub>2</sub>), 49.6
(CH<sub>2</sub>), 48.8 (CH<sub>2</sub>), 34.4 (CH<sub>2</sub>), 21.2
(CH<sub>2</sub>). The structure was assigned based on structural confirmation
by HMBC of <bold>58</bold>. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.63 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 376.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>: 376.1661, found: 376.1653 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/91/98%.</p></sec><sec id="sec4.3.63"><title>2-((2-Methoxyethyl)&#173;amino)&#173;benzonitrile (<bold>75</bold>)</title><p>To a stirred solution of 2-fluorobenzonitrile (5.00 g, 41.3 mmol)
in MeCN (50 mL) was added 2-methoxyethylamine (7.18 mL, 82.6 mmol).
The reaction mixture was heated to 100 &#176;C and stirred overnight
in a sealed tube. The reaction mixture was cooled to room temperature
and concentrated under reduced pressure. The crude mixture was purified
by flash column chromatography (silica, 24 g, 1:0 heptane/EtOAc to
9:1 heptane/EtOAc over 25 CV&#8217;s). Fractions containing product
were combined and concentrated under reduced pressure to afford 2-((2-methoxyethyl)&#173;amino)&#173;benzonitrile
(<bold>75</bold>, 2.50 g, 14.19 mmol, 34% yield) as a colorless liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948; 7.42&#8211;7.35
(m, 2H), 6.72&#8211;6.64 (m, 2H), 4.86 (br s, 1H), 3.62 (t, <italic toggle="yes">J</italic> = 5.3 Hz, 2H), 3.41 (s, 3H), 3.39&#8211;3.34 (m, 2H).
X-Select LCMS CSH C<sub>18</sub> 2.5 &#956;m: Rt = 1.43 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 177.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.64"><title>2-(Amino&#173;(cyclopropyl)&#173;methyl)-<italic toggle="yes">N</italic>-(2-methoxyethyl)&#173;aniline
(<bold>76</bold>)</title><p>To a stirred solution of 2-((2-methoxyethyl)&#173;amino)&#173;benzonitrile
(0.30 g, 1.70 mmol) in THF (3 mL) was added cyclopropylmagnesium bromide
(0.5 M in THF, 10 mL, 5.11 mmol). The reaction mixture was irradiated
in a microwave at 100 &#176;C for 15 min. After completion of the
reaction, NaBH<sub>4</sub> (0.32 g, 8.52 mmol) in MeOH (6 mL) was
added at 0 &#176;C. The reaction mixture was stirred at 0 &#176;C
for 30 min, allowing to warm to room temperature. The reaction mixture
was diluted with water (5 mL) and extracted with EtOAc (2 &#215; 5
mL). The organic layers were combined, dried over NaSO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude mixture
was purified by flash column chromatography (silica, 12 g, 1:0 heptane/EtOAc
to 3:2 heptane/EtOAc over 25 CV&#8217;s). Fractions containing product
were combined and concentrated under reduced pressure to afford 2-(amino&#173;(cyclopropyl)&#173;methyl)-<italic toggle="yes">N</italic>-(2-methoxyethyl)&#173;aniline (<bold>76</bold>, 0.70 g, 3.18
mmol, 47% yield) as a yellow liquid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) &#948; 7.23&#8211;7.13 (m, 2H), 6.71&#8211;6.61 (m, 2H),
3.66 (t, <italic toggle="yes">J</italic> = 5.4 Hz, 3H), 3.40 (s, 4H), 3.36&#8211;3.28
(m, 3H), 3.07 (br d, <italic toggle="yes">J</italic> = 9.3 Hz, 1H), 1.47&#8211;1.41
(m, 1H), 0.66&#8211;0.52 (m, 2H), 0.30&#8211;0.20 (m, 2H).</p></sec><sec id="sec4.3.65"><title>Dimethyl 1-Benzyl-4-(2-((cyclopropyl&#173;(phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>77a</bold>)</title><p>Synthesized according to General Procedure A but reversed limiting
reagent. Dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(1.11 g, 3.53 mmol, 1.3 eq, <bold>27</bold>), cyclopropyl&#173;(phenyl)&#173;methanamine
hydrochloride (0.40 g, 2.72 mmol), AcOH (0.3 mL), 2-methylpyridine
borane complex (0.44 g, 4.08 mmol, 1.5 equiv). Purified by flash column
chromatography (silica, 24 g, 1:0 heptane/EtOAc to 0:1 heptane/EtOAc
over 25 CV&#8217;s) to give dimethyl 1-benzyl-4-(2-((cyclopropyl&#173;(phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>77a</bold>, 0.55 g,
1.23 mmol, 45% yield) as a yellow gum. <sup>1</sup>H NMR (400 MHz,
CDCl<sub>3</sub>) &#948; 7.32&#8211;7.16 (m, 10H), 5.77 (s, 2H),
3.92 (s, 3H), 3.76&#8211;3.70 (m, 3H), 3.28&#8211;3.14 (m, 2H),
2.91 (d, <italic toggle="yes">J</italic> = 8.8 Hz, 1H), 2.73&#8211;2.61 (m, 2H),
2.06 (s, 1H), 1.11&#8211;1.02 (m, 1H), 0.62&#8211;0.55 (m, 1H),
0.43&#8211;0.35 (m, 1H), 0.32&#8211;0.27 (m, 1H), 0.24&#8211;0.15
(m, 1H).</p></sec><sec id="sec4.3.66"><title>1-Benzyl-4-(2-((cyclopropyl&#173;(phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic Acid (<bold>78a</bold>)</title><p>Synthesized according to General Procedure B using dimethyl 1-benzyl-4-(2-((cyclopropyl&#173;(phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (0.55 g, 1.23 mmol) and LiOH&#183;H<sub>2</sub>O (0.26 g, 6.15 mmol, 5 equiv) to give 1-benzyl-4-(2-((cyclopropyl&#173;(phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic acid (<bold>78a</bold>, 0.40
g, 0.95 mmol, 78% yield) as an off-white solid. <sup>1</sup>H NMR
(400 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 12.92 (br s,
1H), 9.94 (br s, 1H), 7.46&#8211;7.17 (m, 10H), 5.83&#8211;5.63
(m, 2H), 3.56&#8211;3.46 (m, 1H), 3.23&#8211;3.20 (m, 2H), 3.12&#8211;3.00
(m, 1H), 2.96&#8211;2.81 (m, 1H), 1.30&#8211;1.15 (m, 1H), 0.70&#8211;0.50
(m, 1H), 0.45&#8211;0.34 (m, 1H), 0.19&#8211;0.09 (m, 1H), 0.01
to &#8722;0.18 (m, 1H). CH not observed as overlapping with HDO peak.
X-Select LCMS BEH C<sub>18</sub> 2.5 &#956;m: Rt = 0.74 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 420.0 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.67"><title>2-Benzyl-6-(cyclopropyl&#173;(phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>68</bold>)</title><p>Synthesized according to General Procedure
C using 1-benzyl-4-(2-((cyclopropyl&#173;(phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic acid (400 mg, 0.95 mmol), HOBt
hydrate (142 mg, 1.04 mmol, 1.1 equiv), EDC&#183;HCl (237 mg, 1.23
mmol, 1.3 equiv), DIPEA (0.40 mL, 2.38 mmol, 2.5 equiv) and NH<sub>4</sub>Cl (254 mg, 4.75 mmol, 5 equiv). Purified by reverse-phase
column chromatography (9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in
water/MeCN to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN
over 30 min) to afford <italic toggle="yes">rac</italic>-2-benzyl-6-(cyclopropyl&#173;(phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>68</bold>) as a colorless solid. <sup>1</sup>H NMR (500 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.78 (s, 1H), 7.63 (s,
1H), 7.49&#8211;7.19 (m, 10H), 5.68&#8211;5.58 (m, 2H), 5.00&#8211;4.90
(m, 1H), 3.65&#8211;3.54 (m, 1H), 2.94&#8211;2.72 (m, 2H), 1.58&#8211;1.44
(m, 1H), 1.30&#8211;1.18 (m, 1H), 0.90&#8211;0.74 (m, 1H), 0.60&#8211;0.42
(m, 1H), 0.37&#8211;0.27 (m, 1H). 1H for CH<sub>2</sub> for one enantiomer
not observed as overlapping with HDO peak. ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.64 min, <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 401.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>: 401.1978, found: 401.1970
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/96/98%.</p></sec><sec id="sec4.3.68"><title>(<italic toggle="yes">R</italic>)-2-Benzyl-6-(cyclopropyl&#173;(phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(MDI-117740, <bold>69</bold>)</title><p>Racemate <bold>68</bold> was
resolved by chiral separation (Daicel CHIRALPAK IG 250 mm &#215; 4.6
mm, 5 &#956;m, 7:3 0.1% DEA in <italic toggle="yes">n</italic>-hexane/1:1 DCM/MeOH,
flow rate: 1 mL/min) to afford (<italic toggle="yes">R</italic>)-2-benzyl-6-(cyclopropyl&#173;(phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>69</bold>, 130 mg, 0.32 mmol, 34% yield) as a colorless solid.
m.p.: 203&#8211;205 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.46&#8211;7.43 (m, 2H, H26,30), 7.33&#8211;7.30
(m, 2H, H16,20), 7.29&#8211;7.20 (m, 6H, H17&#8211;19, H27&#8211;29),
5.79&#8211;5.72 (m, 2H, H24), 5.43 (s, 2H, NH<sub>2</sub>), 5.19
(d, <italic toggle="yes">J</italic> = 10.3 Hz, 1H, H14), 3.63&#8211;3.55 (m, 1H,
H5&#8242;), 3.30&#8211;3.22 (m, 1H, H5), 2.82&#8211;2.70 (m, 2H,
H4,4&#8217;), 1.32&#8211;1.23 (m, 1H, H21), 0.84&#8211;0.78 (m,
1H, H22&#8217;/23&#8217;), 0.65&#8211;0.58 (m, 1H, H22&#8217;/23&#8217;),
0.54&#8211;0.47 (m, 2H, H22&#8217;,H23&#8217;). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 160.86 (C1/C10),
160.80 (C1/C10) 142.4 (C2), 140.3 (C15), 136.6 (C25), 130.7 (C9),
128.7 (C27,29), 128.6 (C17,19), 128.4 (C16,20), 128.2 (C18), 127.7
(C26,30), 127.5 (C28), 120.9 (C3), 59.8 (C14), 55.9 (C24), 42.5 (C5),
21.6 (C4), 12.4 (C21), 6.3 (C22/23), 3.5 (C22/23). Absolute stereochemistry
confirmed by small X-ray crystal structure analysis. ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.67 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 401.3 [M + H]<sup>+</sup>. HRMS calculated for
C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>: 401.1978,
found: 401.1981 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/94/96%.</p></sec><sec id="sec4.3.69"><title>(<italic toggle="yes">S</italic>)-2-Benzyl-6-(cyclopropyl&#173;(phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>70</bold>)</title><p>Synthesized according to the synthesis
of <bold>68</bold> through separation of the other enantiomer to afford
(<italic toggle="yes">S</italic>)-2-benzyl-6-(cyclopropyl&#173;(phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>70</bold>, 20 mg, 0.05 mmol, 5% yield) as a colorless solid.
m.p: 204&#8211;205 &#176;C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.54&#8211;7.49 (m, 2H), 7.41&#8211;7.27 (m, 8H),
5.88&#8211;5.77 (m, 2H), 5.46 (s, 2H), 5.27 (d, <italic toggle="yes">J</italic> = 10.3 Hz, 1H), 3.70&#8211;3.61 (m, 1H), 3.38&#8211;3.29 (m, 1H),
2.91&#8211;2.76 (m, 2H), 1.38&#8211;1.29 (m, 1H), 0.93&#8211;0.84
(m, 1H), 0.73&#8211;0.64 (m, 1H), 0.63&#8211;0.52 (m, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948;
160.86 (Cq), 160.79 (Cq) 142.4 (Cq), 140.3 (Cq), 136.6 (Cq), 130.7
(Cq), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.2 (CH), 127.7 (CH),
127.5 (CH), 120.9 (Cq), 59.8 (CH), 55.9 (CH<sub>2</sub>), 42.5 (CH<sub>2</sub>), 21.5 (CH<sub>2</sub>), 12.4 (CH), 6.3 (CH<sub>2</sub>),
3.5 (CH<sub>2</sub>). Absolute stereochemistry confirmed based on
single X-ray structure analysis of <bold>69</bold>. ACQUITY UPLC BEH
C<sub>18</sub> 1.7 &#956;m: Rt = 1.66 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 401.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>: 401.1978, found: 401.1982
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/92/93%.</p></sec><sec id="sec4.3.70"><title>Dimethyl 1-Benzyl-4-(2-((cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>77b</bold>)</title><p>Synthesized according to General Procedure A but reversed limiting
reagent. Dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate
(0.55 g, 1.74 mmol, 1.1 equiv, <bold>27</bold>), 2-(amino&#173;(cyclopropyl)&#173;methyl)-<italic toggle="yes">N</italic>-(2-methoxyethyl)&#173;aniline (0.35 g, 1.59 mmol, <bold>76</bold>), AcOH (0.1 mL), 2-methylpyridine borane complex (0.19 g, 1.79 mmol,
1.2 equiv). Purified by flash column chromatography (silica, 12 g,
1:0 heptane/EtOAc to 7:3 heptane/EtOAc over 25 CV&#8217;s) to give
dimethyl 1-benzyl-4-(2-((cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>77b</bold>, 0.30 g,
0.58 mmol, 36% yield) as a yellow gum. X-Select LCMS BEH C<sub>18</sub> 2.5 &#956;m: Rt = 1.95 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 521.5 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.71"><title>1-Benzyl-4-(2-((cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic acid (<bold>78b</bold>)</title><p>Synthesized according to General Procedure B using dimethyl 1-benzyl-4-(2-((cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (300 mg, 0.58 mmol) and LiOH&#183;H<sub>2</sub>O (121 mg, 2.88 mmol, 5 equiv) to give 1-benzyl-4-(2-((cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic acid (<bold>78b</bold>, 250
mg, 0.50 mmol, 88% yield) as an off-white solid. X-Select LCMS BEH
C<sub>18</sub> 2.5 &#956;m: Rt = 0.88 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 533.6 [M + MeCN]<sup>+</sup>.</p></sec><sec id="sec4.3.72"><title>2-Benzyl-6-(cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>71</bold>)</title><p>Synthesized through two-step telescope
according to General Procedure C (for both steps) using 1-benzyl-4-(2-((cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic acid (250 mg, 0.50 mmol), HOBt
hydrate (75 mg, 0.55 mmol, 1.1 equiv), EDC&#183;HCl (126 mg, 0.66
mmol, 1.3 equiv) and DIPEA (0.22 mL, 1.27 mmol, 2.4 equiv).</p><p>After cyclization in the first step, NH<sub>4</sub>Cl (27 mg, 0.50
mmol, 5 equiv), HOBt hydrate (75 mg, 0.55 mmol, 1.1 equiv), EDC&#183;HCl
(126 mg, 0.66 mmol, 1.3 equiv) and DIPEA (0.22 mL, 1.27 mmol, 2.4
equiv) were added to the crude mixture. Purified by reverse-phase
column chromatography (9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in
water/MeCN to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN
over 30 min) to give 2-benzyl-6-(cyclopropyl&#173;(2-((2-methoxyethyl)&#173;amino)&#173;phenyl)&#173;methyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>71</bold>, 46 mg, 0.10 mmol, 19% yield) as a colorless solid.
m.p: 97&#8211;99 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.80 (d, <italic toggle="yes">J</italic> = 7.9 Hz, 0.26H), 7.67 (d, <italic toggle="yes">J</italic> = 2.3 Hz, 0.80H), 7.53 (d, <italic toggle="yes">J</italic> = 8.0 Hz,
0.24H), 7.49 (d, <italic toggle="yes">J</italic> = 2.3 Hz, 0.85H), 7.47&#8211;7.44
(m, 0.21H), 7.39&#8211;7.35 (m, 2.48H), 7.31&#8211;7.22 (m, 5H),
5.79&#8211;5.63 (m, 2H), 5.28&#8211;5.22 (m, 1H), 4.06&#8211;3.98
(m, 0.40H), 3.94&#8211;3.85 (m, 1.87H), 3.78&#8211;3.68 (m, 0.74H),
3.62&#8211;3.52 (m, 0.93H), 3.42&#8211;3.28 (m, 2.49H), 3.24 (s,
2.33H), 3.20 (s, 0.73H), 2.86 (d, <italic toggle="yes">J</italic> = 12.6 Hz, 1.27H),
1.49&#8211;1.38 (m, 1H), 0.92&#8211;0.81 (m, 2H), 0.79&#8211;0.73
(m, 1H), 0.48&#8211;0.40 (m, 1H). Atropisomers observed in approximately
3:1 ratio. <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 160.9 (Cq), 142.3 (Cq), 136.6 (Cq), 130.6 (Cq), 129.1 (CH),
128.7 (CH), 128.49 (CH), 128.47 (CH), 128.2 (CH), 121.0 (Cq), 70.9
(CH<sub>2</sub>), 58.9 (CH<sub>3</sub>), 56.3 (CH), 55.8 (CH<sub>2</sub>), 42.1 (CH<sub>2</sub>), 21.4 (CH<sub>2</sub>), 12.6 (CH), 5.0 (CH<sub>2</sub>), 4.8 (CH<sub>2</sub>). CH<sub>2</sub> and 2 x Cq not observed.
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.69 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 474.3 [M + H]<sup>+</sup>. HRMS calculated
for C<sub>27</sub>H<sub>32</sub>N<sub>5</sub>O<sub>3</sub>: 474.2505,
found: 474.2505 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/93/92%.</p></sec><sec id="sec4.3.73"><title>Dimethyl 1-Benzyl-4-(2-((2-((<italic toggle="yes">tert-</italic>butoxycarbonyl)&#173;amino)-1-phenylethyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>77c</bold>)</title><p>Synthesized according to General Procedure A using dimethyl 1-benzyl-4-(2-oxoethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (0.40 g, 1.26 mmol, <bold>27</bold>), <italic toggle="yes">tert</italic>-butyl (2-amino-2-phenylethyl)&#173;carbamate (0.30
g, 1.26 mmol, 1 equiv), AcOH (0.1 mL) and 2-methylpyridine borane
complex (0.14 g, 1.26 mmol, 1 equiv). Purified by flash column chromatography
(silica, 12 g, 1:0 heptane/EtOAc to 6:4 heptane/EtOAc over 25 CV&#8217;s)
to give dimethyl 1-benzyl-4-(2-((2-((tert-butoxycarbonyl)&#173;amino)-1-phenylethyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (<bold>77c</bold>, 0.15 g,
0.27 mmol, 22% yield) as a pale-yellow gum. X-Select LCMS BEH C<sub>18</sub> 2.5 &#956;m: Rt = 1.56 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 537.2 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.74"><title>1-Benzyl-4-(2-((2-((<italic toggle="yes">tert</italic>-butoxycarbonyl)&#173;amino)-1-phenylethyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic Acid (<bold>78c</bold>)</title><p>Synthesized according to General Procedure B using dimethyl 1-benzyl-4-(2-((2-((<italic toggle="yes">tert</italic>-butoxycarbonyl)&#173;amino)-1-phenylethyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylate (150 mg, 0.27 mmol) and LiOH&#183;H<sub>2</sub>O (35 mg, 0.83 mmol, 3 equiv) to give 1-benzyl-4-(2-((2-((tert-butoxycarbonyl)&#173;amino)-1-phenylethyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic acid (<bold>78c</bold>, 130
mg, 0.26 mmol, 91% yield) as an off-white solid. X-Select LCMS BEH
C<sub>18</sub> 2.5 &#956;m: Rt = 0.70 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 509.6 [M + H]<sup>+</sup>.</p></sec><sec id="sec4.3.75"><title>
<italic toggle="yes">tert-</italic>Butyl (2-(2-Benzyl-3-carbamoyl-7-oxo-2,4,5,7-tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-6-yl)-2-phenylethyl)&#173;carbamate
(<bold>79</bold>)</title><p>Synthesized through two-step telescope
according to General Procedure C (for both steps) using 1-benzyl-4-(2-((2-(<italic toggle="yes">(tert</italic>-butoxycarbonyl)&#173;amino)-1-phenylethyl)&#173;amino)&#173;ethyl)-1<italic toggle="yes">H</italic>-pyrazole-3,5-dicarboxylic acid (130 mg, 0.25 mmol), HOBt
hydrate (37 mg, 0.28 mmol, 1.1 equiv), EDC&#183;HCl (63 mg, 0.33 mmol,
1.3 equiv) and DIPEA (0.11 mL, 0.61 mmol, 2.4 equiv).</p><p>After
cyclization in the first step, NH<sub>4</sub>Cl (68 mg, 1.27 mmol,
5 equiv), HOBt hydrate (37 mg, 0.28 mmol, 1.1 equiv), EDC&#183;HCl
(63 mg, 0.33 mmol, 1.3 equiv) and DIPEA (0.11 mL, 0.61 mmol, 2.4 equiv)
were added to the crude mixture. Purified by reverse-phase column
chromatography (9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN
to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30
min) to give tert-butyl (2-(2-benzyl-3-carbamoyl-7-oxo-2,4,5,7-tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-6-yl)-2-phenylethyl)&#173;carbamate
(<bold>79</bold>, 60 mg, 0.12 mmol, 48% yield) as a colorless solid.
X-Select LCMS BEH C<sub>18</sub> 2.5 &#956;m: Rt = 1.33 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 488.0 [M &#8211; H]<sup>&#8722;</sup>.</p></sec><sec id="sec4.3.76"><title>6-(2-Amino-1-phenylethyl)-2-benzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
Hydrochloride (<bold>80</bold>)</title><p>To a stirred solution of <italic toggle="yes">tert</italic>-butyl (2-(2-benzyl-3-carbamoyl-7-oxo-2,4,5,7-tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-6-yl)-2-phenylethyl)&#173;carbamate
(50 mg, 0.12 mmol) in DCM (1 mL) was added 4 M HCl in 1,4 dioxane
(1 mL). The reaction mixture was stirred at room temperature for 2
h. The reaction mixture was concentrated under reduced pressure to
afford 6-(2-amino-1-phenylethyl)-2-benzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>80</bold>, 50 mg, 0.12 mmol) as a crude off-white solid, which
was taken forward to the next step.</p></sec><sec id="sec4.3.77"><title>
<italic toggle="yes">N</italic>-(2-(2-Benzyl-3-carbamoyl-7-oxo-2,4,5,7-tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-6-yl)-2-phenylethyl)&#173;thiazole-5-carboxamide
(<bold>72</bold>)</title><p>Synthesized according to General Procedure
C using 6-(2-amino-1-phenylethyl)-2-benzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
hydrochloride (50 mg, 0.12 mmol), thiazole-5-carboxylic acid (16 mg,
0.12 mmol, 1 equiv), HOBt hydrate (19 mg, 0.14 mmol, 1.1 equiv), EDC&#183;HCl
(31 mg, 0.16 mmol, 1.3 equiv) and DIPEA (66 &#956;L, 0.38 mmol, 2.4
equiv). Purified by reverse-phase column chromatography (9:1 5 mM
(NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min) to give <italic toggle="yes">N</italic>-(2-(2-benzyl-3-carbamoyl-7-oxo-2,4,5,7-tetrahydro-6<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-6-yl)-2-phenylethyl)&#173;thiazole-5-carboxamide
(<bold>72</bold>, 27 mg, 0.05 mmol, 42% yield) as an off-white solid.
m.p.: 143&#8211;145 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 9.20 (d, <italic toggle="yes">J</italic> = 0.7
Hz, 1H), 8.89 (t, <italic toggle="yes">J</italic> = 5.9 Hz, 1H), 8.36 (d, <italic toggle="yes">J</italic> = 0.7 Hz, 1H), 7.74 (s, 1H), 7.61 (s, 1H), 7.35&#8211;7.41
(m, 4H), 7.29&#8211;7.33 (m, 3H), 7.25&#8211;7.28 (m, 1H), 7.17&#8211;7.20
(m, 2H), 6.05 (t, <italic toggle="yes">J</italic> = 7.6 Hz, 1H), 5.65 (d, <italic toggle="yes">J</italic> = 14.6 Hz, 1H), 5.57 (d, <italic toggle="yes">J</italic> = 14.7 Hz,
1H), 3.91 (dd, <italic toggle="yes">J</italic> = 7.7, 5.9 Hz, 2H), 3.61 (ddd, <italic toggle="yes">J</italic> = 13.0, 8.4, 5.1 Hz, 1H), 3.09 (ddd, <italic toggle="yes">J</italic> = 12.5, 7.3, 5.3 Hz, 1H), 2.84 (ddd, <italic toggle="yes">J</italic> = 15.9,
7.3, 5.1 Hz), 2.70 (ddd, <italic toggle="yes">J</italic> = 15.8, 8.4, 5.2 Hz, 1H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 161.0 (Cq), 160.3 (Cq), 160.0 (Cq), 157.9 (CH),
143.6 (CH), 141.5 (Cq), 138.2 (Cq), 137.1 (Cq), 135.3 (Cq), 132.8
(Cq), 128.6 (CH), 128.5 (CH), 127.69 (CH), 127.67 (CH), 127.5 (CH),
120.6 (Cq), 54.1 (CH<sub>2</sub>), 53.7 (CH), 42.0 (CH<sub>2</sub>), 38.8 (CH<sub>2</sub>), 20.1 (CH<sub>2</sub>). ACQUITY UPLC BEH
C<sub>18</sub> 1.7 &#956;m: Rt = 1.50 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 501.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>26</sub>H<sub>25</sub>N<sub>6</sub>O<sub>3</sub>S: 501.1709, found: 501.1708
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/88/96%.</p></sec><sec id="sec4.3.78"><title>2,6-Dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic Acid (<bold>81</bold>)</title><p>Synthesized according to General Procedure B using methyl 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(0.80 g, 2.13 mmol, <bold>55</bold>) and LiOH&#183;H<sub>2</sub>O
(0.27 g, 6.39 mmol, 3 equiv). The reaction mixture was concentrated
under reduced pressure, diluted with water (10 mL) and acidified with
1 M HCl. The aqueous layer was extracted with EtOAc (2 &#215; 20 mL).
The organic layers were combined, dried over NaSO<sub>4</sub> and
concentrated under reduced pressure. The crude mixture was purified
by reverse-phase column chromatography (9:1 0.1% TFA in water/MeCN
to 0:1 0.1% TFA in water/MeCN over 30 min) to afford 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (<bold>81</bold>, 130 mg, 0.36 mmol, 17% yield) as an off-white
solid. m.p.: 86&#8211;88 &#176;C (dec). <sup>1</sup>H NMR (500 MHz,
DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 13.72 (br s, 1H), 7.37&#8211;7.16
(m, 10H), 5.78 (s, 2H), 4.66 (s, 2H), 2.97 (t, <italic toggle="yes">J</italic> =
6.7 Hz, 2H). CH<sub>2</sub> not observed as overlapping with HDO peak. <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 160.5 (Cq), 159.7 (Cq), 141.8 (Cq), 137.6 (Cq),
137.1 (Cq), 129.0 (Cq), 128.6 (CH), 127.64 (CH), 127.60 (CH), 127.3
(CH), 127.2 (CH), 125.6 (Cq), 54.8 (CH<sub>2</sub>), 48.9 (CH<sub>2</sub>), 46.7 (CH<sub>2</sub>), 20.7 (CH<sub>2</sub>). ACQUITY UPLC
BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.61 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 362.2 [M + H]<sup>+</sup>. HRMS calculated for
C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>, 362.1505,
found 362.1520 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/91/95%.</p></sec><sec id="sec4.3.79"><title>2,6-Dibenzyl-<italic toggle="yes">N</italic>-methyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>82</bold>)</title><p>To a solution of 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (100 mg, 0.27 mmol) in THF (1 mL) were added DIPEA (0.12 mL,
0.69 mmol) and T3P (50% in EtOAc, 0.53 g, 0.83 mmol). The reaction
mixture was stirred at room temperature for 10 min, followed by addition
of CH<sub>3</sub>NH<sub>2</sub> (2 M in THF, 0.2 mL, 0.41 mmol) and
further stirred at room temperature overnight. The reaction mixture
was diluted with water (25 mL) and extracted with EtOAc (2 &#215;
25 mL). The organic layers were combined, dried over NaSO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude mixture
was purified by reverse-phase column chromatography (9:1 0.1% TFA
in water/MeCN to 0:1 0.1% TFA in water/MeCN over 30 min). Fractions
containing product were combined and concentrated under reduced pressure
to afford 2,6-dibenzyl-<italic toggle="yes">N</italic>-methyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>82</bold>, 5 mg, 0.01 mmol, 5% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
8.16 (q, <italic toggle="yes">J</italic> = 4.5 Hz, 1H), 7.37&#8211;7.21 (m, 10H),
5.61 (s, 2H), 4.65 (s, 2H), 3.48 (t, <italic toggle="yes">J</italic> = 6.7 Hz,
2H), 2.86 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H), 2.74 (d, <italic toggle="yes">J</italic> = 4.6 Hz, 3H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt
= 1.59 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 375.3 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/43/92%.</p></sec><sec id="sec4.3.80"><title>2,6-Dibenzyl-<italic toggle="yes">N</italic>-cyclopropyl-7-oxo-4,5,6,7-tetrahydro-2H-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>83</bold>)</title><p>Synthesized
according to General Procedure C using 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (100 mg, 0.27 mmol), HOBt hydrate (10 mg, 0.30 mmol, 1.1 equiv),
EDC&#183;HCl (69 mg, 0.36 mmol, 1.3 equiv), DIPEA (0.12 mL, 0.69 mmol,
2.4 equiv) and cyclopropylamine (24 &#956;L, 0.36 mmol, 1.3 equiv).
Purified by reverse-phase column chromatography (9:1 0.1% TFA in water/MeCN
to 0:1 0.1% TFA in water/MeCN over 30 min) to give 2,6-dibenzyl-<italic toggle="yes">N</italic>-cyclopropyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>83</bold>, 20 mg, 0.05 mmol, 18% yield) as an off-white solid. m.p.: 138&#8211;140
&#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 8.31
(d, <italic toggle="yes">J</italic> = 4.1 Hz, 1H), 7.38&#8211;7.20 (m, 10H), 5.58
(s, 2H), 4.64 (s, 2H), 3.46 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H),
2.83&#8211;2.72 (m, 3H), 0.73&#8211;0.65 (m, 2H), 0.51&#8211;0.41
(m, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 160.6 (Cq), 160.0 (Cq), 141.3 (Cq),
137.8 (Cq), 136.9 (Cq), 133.1 (Cq), 128.5 (CH), 127.83 (CH), 127.80
(CH), 127.5 (CH), 127.2 (CH), 120.5 (Cq), 54.1 (CH<sub>2</sub>), 48.7
(CH<sub>2</sub>), 46.8 (CH<sub>2</sub>), 22.6 (CH), 19.8 (CH<sub>2</sub>), 5.8 (CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.66 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 401.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>: 401.1978, found: 401.1980 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/100/100%.</p></sec><sec id="sec4.3.81"><title>2,6-Dibenzyl-7-oxo-<italic toggle="yes">N</italic>-phenyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>84</bold>)</title><p>Synthesized according to General Procedure
C using 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic acid (100 mg, 0.27 mmol), HOBt hydrate
(40 mg, 0.30 mmol, 1.1 equiv), EDC&#183;HCl (69 mg, 0.36 mmol, 1.3
equiv), DIPEA (0.12 mL, 0.69 mmol, 2.4 equiv) and aniline (37 &#956;L,
0.41 mmol, 1.5 equiv). Purified by flash column chromatography (silica,
4 g, 1:0 DCM/MeOH to 9:1 DCM/MeOH over 25 CV&#8217;s) to give 2,6-dibenzyl-7-oxo-<italic toggle="yes">N</italic>-phenyl-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>84</bold>, 18 mg, 0.04 mmol,
15% yield) as an off-white solid. m.p.: 174&#8211;175 &#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
10.32&#8211;10.10 (m, 1H), 7.71&#8211;7.53 (m, 2H), 7.44&#8211;7.02
(m, 13H), 5.68&#8211;5.53 (m, 2H), 4.75&#8211;4.56 (m, 2H), 3.63&#8211;3.40
(m, 2H), 3.00&#8211;2.81 (m, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR
(126 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 159.9 (Cq),
157.9 (Cq), 141.5 (Cq), 138.2 (Cq), 137.8 (Cq), 136.8 (Cq), 133.3
(Cq), 128.9 (CH), 128.60 (CH), 128.55 (CH), 127.9 (CH), 127.8 (CH),
127.6 (CH), 127.2 (CH), 124.4 (CH), 121.2 (Cq), 120.1 (CH), 54.2 (CH<sub>2</sub>), 48.8 (CH<sub>2</sub>), 46.8 (CH<sub>2</sub>), 19.9 (CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.80
min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 437.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>27</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub>: 437.1978, found: 437.1980 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/97/98%.</p></sec><sec id="sec4.3.82"><title>2,6-Dibenzyl-<italic toggle="yes">N</italic>-(2-methoxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>85</bold>)</title><p>To a solution of 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (100 mg, 0.27 mmol) in DCM (2 mL) were added DIPEA (0.12 mL,
0.69 mmol) and T3P (50% in EtOAc, 0.53 g, 0.83 mmol). The reaction
mixture was stirred at room temperature for 10 min, followed by addition
of 2-methoxyethylamine (36 &#956;L, 0.41 mmol) and further stirred
at room temperature overnight. The reaction mixture was diluted with
water (2 mL) and extracted with DCM (2 &#215; 5 mL). The organic layers
were combined, dried over NaSO<sub>4</sub>, filtered and concentrated
under reduced pressure. The crude mixture was purified by reverse-phase
column chromatography (9:1 0.1% TFA in water/MeCN to 0:1 0.1% TFA
in water/MeCN over 30 min). Fractions containing product were combined
and concentrated under reduced pressure to afford 2,6-dibenzyl-<italic toggle="yes">N</italic>-(2-methoxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>85</bold>, 40 mg, 0.10 mmol, 35% yield) as an off-white solid. m.p.: 92&#8211;94
&#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.33 (t, <italic toggle="yes">J</italic> = 5.1 Hz, 1H), 7.36&#8211;7.22
(m, 10H), 5.59 (s, 2H), 4.65 (s, 2H), 3.48 (t, <italic toggle="yes">J</italic> =
6.7 Hz, 2H), 3.39&#8211;3.37 (m, 2H), 3.23 (s, 3H), 2.84 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H). CH<sub>2</sub> not observed as overlapping
with HDO peak. <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 160.0 (Cq), 159.5 (Cq), 141.4 (Cq),
137.8 (Cq), 137.0 (Cq), 133.2 (Cq), 128.54 (CH), 128.52 (CH), 127.9
(CH), 127.8 (CH), 127.6 (CH), 127.2 (CH), 120.5 (Cq), 70.2 (CH<sub>2</sub>), 57.9 (CH<sub>3</sub>), 54.1 (CH<sub>2</sub>), 48.8 (CH<sub>2</sub>), 46.8 (CH<sub>2</sub>), 38.7 (CH<sub>2</sub>), 19.8 (CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.63
min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 419.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>24</sub>H<sub>27</sub>N<sub>4</sub>O<sub>3</sub>: 419.2085, found: 419.2083 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 98/92/94%.</p></sec><sec id="sec4.3.83"><title>2,6-Dibenzyl-<italic toggle="yes">N</italic>-(2-(dimethylamino)&#173;ethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>86</bold>)</title><p>To a solution of 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylic
acid (0.15 g, 0.41 mmol) in DCM (1 mL) were added DIPEA (0.18 mL,
1.03 mmol) and T3P (50% in EtOAc, 0.40 g, 1.24 mmol). The reaction
mixture was stirred at room temperature for 10 min, followed by addition
of <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylethylenediamine (67
&#956;L, 0.62 mmol) and further stirred at room temperature overnight.
The reaction mixture was diluted with water (2 mL) and extracted with
DCM (2 &#215; 5 mL). The organic layers were combined, dried over
NaSO<sub>4</sub>, filtered and concentrated under reduced pressure.
The crude mixture was purified by reverse-phase column chromatography
(9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM
(NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min). Fractions
containing product were combined and concentrated under reduced pressure
to afford 2,6-dibenzyl-<italic toggle="yes">N</italic>-(2-(dimethylamino)&#173;ethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>86</bold>, 15 mg, 0.03 mmol, 8% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948;
8.17 (t, <italic toggle="yes">J</italic> = 5.8 Hz, 1H), 7.37&#8211;7.22 (m, 10H),
5.59 (s, 2H), 4.65 (s, 2H), 3.48 (t, <italic toggle="yes">J</italic> = 6.6 Hz,
2H), 2.85 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H), 2.31 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H), 2.13 (s, 6H). CH<sub>2</sub> not observed as overlapping
with HDO peak. <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 160.0 (Cq), 159.3 (Cq), 141.4 (Cq),
137.8 (Cq), 137.0 (Cq), 133.2 (Cq), 128.54 (CH), 128.51 (CH), 127.9
(CH), 127.8 (CH), 127.6 (CH), 127.2 (CH), 120.4 (Cq), 57.8 (CH<sub>2</sub>), 54.1 (CH<sub>2</sub>), 48.8 (CH<sub>2</sub>), 46.8 (CH<sub>2</sub>), 45.1 (CH<sub>3</sub>), 37.0 (CH<sub>2</sub>), 19.8 (CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.31
min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 432.3 [M + H]<sup>+</sup>. HRMS calculated for C<sub>25</sub>H<sub>30</sub>N<sub>5</sub>O<sub>2</sub>: 432.2400, found: 432.2406 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/91/97%. ELSD/UV/<sup>1</sup>H NMR purity:
96/96/97%.</p></sec><sec id="sec4.3.84"><title>2,6-Dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carbohydrazide (<bold>87</bold>)</title><p>To
a solution of methyl 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(250 mg, 0.66 mmol) in EtOH (5 mL) was added NH<sub>2</sub>NH<sub>2</sub> (50% in H<sub>2</sub>O, 1 mL). The reaction mixture was heated
to 90 &#176;C and stirred for 6 h. The reaction mixture was cooled
to room temperature and concentrated under reduced pressure to afford
2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carbohydrazide (<bold>87</bold>, 300 mg, 0.80
mmol) as a crude yellow gum, which was taken forward as crude to the
next step.</p></sec><sec id="sec4.3.85"><title>2,6-Dibenzyl-3-(1,3,4-oxadiazol-2-yl)-2,4,5,6-tetrahydro-7<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-7-one (<bold>89</bold>)</title><p>2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carbohydrazide (300 mg,
0.80 mmol) was added to triethyl orthoformate (5 mL) and the reaction
mixture heated to 100 &#176;C and stirred overnight. The reaction
mixture was cooled to room temperature and concentrated under reduced
pressure. The crude mixture was purified by reverse-phase column chromatography
(9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM
(NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min). Fractions
containing product were combined and concentrated under reduced pressure
to afford 2,6-dibenzyl-3-(1,3,4-oxadiazol-2-yl)-2,4,5,6-tetrahydro-7<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-7-one (<bold>89</bold>, 42 mg, 0.11 mmol, 7% yield) as an off-white solid. m.p.: 150&#8211;152
&#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 8.45
(s, 1H), 7.44&#8211;7.41 (m, 2H), 7.35&#8211;7.33 (m, 4H), 7.32&#8211;7.23
(m, 4H), 5.98 (s, 2H), 4.81 (s, 2H), 3.55 (t, <italic toggle="yes">J</italic> =
6.7 Hz, 2H), 3.05 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 160.6 (Cq),
157.0 (Cq), 152.1 (CH), 143.4 (Cq), 137.2 (Cq), 135.6 (Cq), 128.9
(CH), 128.8 (CH), 128.34 (CH), 128.33 (CH), 127.8 (CH), 123.7 (Cq),
123.1 (Cq), 56.2 (CH<sub>2</sub>), 49.8 (CH<sub>2</sub>), 46.7 (CH<sub>2</sub>), 20.8 (CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7
&#956;m: Rt = 1.68 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 386.3
[M + H]<sup>+</sup>. HRMS calculated for C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>: 386.1617, found: 386.1619 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/91/97%.</p></sec><sec id="sec4.3.86"><title>2,6-Dibenzyl-<italic toggle="yes">N</italic>-(2-hydroxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(<bold>88</bold>)</title><p>To a solution of methyl 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxylate
(200 mg, 0.52 mmol) and ethanolamine (0.16 mL, 2.66 mmol) in MeOH
(10 mL) was added DIPEA (0.28 mL, 1.58 mmol). The reaction mixture
was heated to 130 &#176;C and stirred overnight in a sealed tube.
The reaction mixture was cooled, concentrated under reduced pressure,
diluted with water (5 mL) and extracted with EtOAc (2 &#215; 10 mL).
The organic layers were combined, dried over NaSO<sub>4</sub>, filtered
and concentrated under reduced pressure. The crude mixture was purified
by flash column chromatography (silica, 12 g, 1:0 heptane/EtOAc to
7:3 heptane/EtOAc over 25 CV&#8217;s). Fractions containing product
were combined and concentrated under reduced pressure to afford 2,6-dibenzyl-<italic toggle="yes">N</italic>-(2-hydroxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (<bold>88</bold>, 160 mg, 0.40 mmol, 86% yield) as a pale yellow solid. m.p.: 140&#8211;142
&#176;C. <sup>1</sup>H NMR (500 MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 8.21 (t, <italic toggle="yes">J</italic> = 5.7 Hz, 1H), 7.39&#8211;7.22
(m, 10H), 5.59 (s, 2H), 4.73&#8211;4.70 (m, 1H), 4.65 (s, 2H), 3.51&#8211;3.42
(m, 4H), 3.28 (q, <italic toggle="yes">J</italic> = 6.0 Hz, 2H), 2.86 (t, <italic toggle="yes">J</italic> = 6.6 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 160.0 (Cq), 159.5
(Cq), 141.4 (Cq), 137.8 (Cq), 137.0 (Cq), 133.2 (Cq), 128.54 (CH),
128.51 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 127.2 (CH), 120.4
(Cq), 59.4 (CH<sub>2</sub>), 54.1 (CH<sub>2</sub>), 48.8 (CH<sub>2</sub>), 46.8 (CH<sub>2</sub>), 41.8 (CH<sub>2</sub>), 19.9 (CH<sub>2</sub>). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.50 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 405.3 [M + H]<sup>+</sup>. HRMS calculated
for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub>: 405.1927,
found: 405.1929 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity:
100/88/99%.</p></sec><sec id="sec4.3.87"><title>2,6-Dibenzyl-3-(4,5-dihydrooxazol-2-yl)-2,4,5,6-tetrahydro-7<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-7-one (<bold>90</bold>)</title><p>To a stirred solution of 2,6-dibenzyl-<italic toggle="yes">N</italic>-(2-hydroxyethyl)-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide (150 mg, 0.37 mmol) in toluene
(2 mL) was added PPh<sub>3</sub> (146 mg, 0.55 mmol) and DEAD (97
mg, 0.55 mmol). The reaction mixture was stirred at room temperature
overnight. The reaction mixture was concentrated under reduced pressure.
The crude mixture was diluted with ice-cold water (2 mL) and extracted
with EtOAc (2 &#215; 5 mL). The organic layers were combined, dried
over NaSO<sub>4</sub>, filtered and concentrated under reduced pressure.
The crude mixture was purified by reverse-phase column chromatography
(9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM
(NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min). Fractions
containing product were combined and concentrated under reduced pressure
to afford 2,6-dibenzyl-3-(4,5-dihydrooxazol-2-yl)-2,4,5,6-tetrahydro-7<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridin-7-one (<bold>90</bold>, 7 mg, 0.02 mmol, 4%) as an off-white solid. <sup>1</sup>H NMR (500
MHz, DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>) &#948; 7.37&#8211;7.23
(m, 8H), 7.22&#8211;7.18 (m, 2H), 5.87 (s, 2H), 4.65 (s, 2H), 4.36
(t, <italic toggle="yes">J</italic> = 9.6 Hz, 2H), 3.98 (t, <italic toggle="yes">J</italic> =
9.6 Hz, 2H), 3.50 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H), 2.95 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H). ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m:
Rt = 1.77 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 387.3 [M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/100/96%.</p></sec><sec id="sec4.3.88"><title>2,6-Dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carbonitrile (<bold>91</bold>)</title><p>To
a stirred solution of 2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carboxamide
(50 mg, 0.13 mmol) in DCM (3 mL) was added Et<sub>3</sub>N (1.35 mL,
0.97 mmol) and trifluoroacetic anhydride (96 &#956;L, 0.69 mmol).
The reaction mixture was stirred at room temperature overnight. The
reaction mixture was concentrated under reduced pressure. The crude
mixture was diluted with water (1 mL) and extracted with DCM (2 &#215;
2 mL). The organic layers were combined, dried over NaSO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude mixture
was purified by reverse-phase column chromatography (9:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN to 0:1 5 mM (NH<sub>4</sub>)&#173;HCO<sub>3</sub> in water/MeCN over 30 min). Fractions containing
product were combined and concentrated under reduced pressure to afford
2,6-dibenzyl-7-oxo-4,5,6,7-tetrahydro-2<italic toggle="yes">H</italic>-pyrazolo&#173;[3,4-<italic toggle="yes">c</italic>]&#173;pyridine-3-carbonitrile (<bold>91</bold>, 19 mg, 0.01
mmol, 40%) as an off-white solid. m.p.: 105&#8211;106 &#176;C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#948; 7.44&#8211;7.41
(m, 2H), 7.39&#8211;7.27 (m, 8H), 5.52 (s, 2H), 4.76 (s, 2H), 3.51
(dd, <italic toggle="yes">J</italic> = 7.0, 6.4 Hz, 2H), 2.86 (t, <italic toggle="yes">J</italic> = 6.7 Hz, 2H). <sup>13</sup>C&#173;{<sup>1</sup>H} NMR (126 MHz, CDCl<sub>3</sub>) &#948; 159.8 (Cq), 143.2 (Cq), 136.9 (Cq), 134.2 (Cq),
129.2 (CH), 129.1 (CH), 128.9 (CH), 128.6 (CH), 128.3 (CH), 127.9
(CH), 111.8 (Cq), 109.8 (Cq), 56.8 (CH<sub>2</sub>), 49.8 (CH<sub>2</sub>), 46.4 (CH<sub>2</sub>), 19.8 (CH<sub>2</sub>). Cq not observed.
ACQUITY UPLC BEH C<sub>18</sub> 1.7 &#956;m: Rt = 1.77 min; <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 343.2 [M + H]<sup>+</sup>. HRMS calculated
for C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>O: 343.1559, found: 343.1564
[M + H]<sup>+</sup>. ELSD/UV/<sup>1</sup>H NMR purity: 100/92/100%.</p></sec></sec><sec id="sec4.4"><title>Molecular Docking</title><p>The predicted binding mode of MDI-117740
(<bold>69</bold>) was derived using a truncated version of chain A
from protein structure 7ATU using Schrodinger software (Schrodinger,
Inc., NY 10036). Although docking took a core constraint based on
reference ligand LIJTF500025 (<bold>7</bold>) into consideration,
no fixed constraints, features or voids were imposed. The system was
then minimized to give the final pose.</p></sec><sec id="sec4.5"><title>Cell Lines and Growth Conditions</title><p>HEK293 and SH-SY5Y
cells used in this study were purchased from Sigma/Merck (Dorset,
U.K.) and were cultured in Dulbecco&#8217;s Modified Eagle&#8217;s
Medium (DMEM)/F12 (#11320033, Thermofisher Scientific, U.K.), supplemented
with 10% fetal calf serum, 1% penicillin/streptomycin (Sigma-Aldrich,
Dorset U.K.). MDA-MB-231 (human breast adenocarcinoma TNBC) cells
were purchased from the American Type Culture Collection (ATCC, Virginia)
and were cultured in DMEM containing sodium pyruvate (#11574446, Gibco,
Fisher Scientific, U.K.). Cells were cultured in a standard T75 tissue-culture
treated flask at 37 &#176;C, 5% CO<sub>2</sub> in a humidified sterile
incubator. HEK293, SH-SY5Y and MDA-MB-231 cell lines used in this
study were not obtained from animal or human participants and did
not require ethical approval or informed consent.</p></sec><sec id="sec4.6"><title>RapidFire Mass Spectrometry (RF-MS) Kinase Assays</title><p>A
50 &#956;L reaction was prepared in 384-well polypropylene plates.
First, compounds were transferred in duplicate in a 16-point 2-fold
serial dilution in DMSO (maximum inhibitor concentration of 40 &#956;M
in the LIMK1/2 assay) using an ECHO 550 acoustic dispenser (Labcyte).
To these plates, 25 &#956;L of 80 nM LIMK1<sub>330&#8211;637</sub> (for a final concentration of 40 nM) or 30 nM LIMK2<sub>347&#8211;659</sub> (final concentration of 15 nM) in assay buffer was dispensed into
each well using a COMBI multidrop dispenser and the plates were incubated
for 45 min at room temperature. Then, 25 &#956;L of 8 &#956;M CFL1
(for a final concentration of 4 &#956;M) and 4 mM ATP (final concentration
2 mM) in assay buffer was added to each well and incubated for 105
and 180 min for LIMK1 and LIMK2, respectively. The composition of
the assay buffer used for LIMK1 was 50 mM tris pH 7.5, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM MgCl<sub>2</sub>, while that of the assay buffer
used for LIMK2 was 50 mM HEPES pH 7.5, 0.1 mM EGTA, 1 mM EDTA, and
1 mM MnCl<sub>2</sub>.</p><p>The LIMK phosphorylation reactions were
halted by the addition of 5 &#956;L of 10% formic acid (final concentration
of 1%), and the assay plates were transferred onto a RapidFire RF360
instrument (Agilent). Once loaded, the samples were aspirated under
vacuum and the salts and the nonvolatile buffer components were removed
by loading onto a C4 solid-phase extraction (SPE) cartridge (Agilent
Technologies) in 0.1% formic acid in water at a flow rate of 1.5 mL/min.
Elution using 85% acetonitrile and 0.1% formic acid was then used
to elute analytes into the mass spectrometer (Agilent 6530 QTOF) at
a flow rate of 1.2 mL/min. The resulting data were analyzed using
RapidFire integrator software (Agilent), and GraphPad Prism 7 was
used to calculate IC<sub>50</sub> values.</p></sec><sec id="sec4.7"><title>Transient Transfection of HEK293 Cells</title><p>The transfection
reagent mix of 1.25 mL Opti-MEM without phenol red (Fisher Life Technologies,
U.K.) and 1.25 &#956;g NanoLuc LIMK1 or LIMK2 kinase fusion vector,
11.25 &#956;g transfection carrier DNA and 37.5 &#956;L FuGENE HD
transfection reagent (all Promega, Hampshire, U.K.) was prepared according
to manufacturer&#8217;s protocol. HEK293 cells were resuspended in
5 mL growth media following trypsinization, neutralization and sedimentation.
Cell density was calculated and adjusted to 1 &#215; 10<sup>5</sup> cells/mL for each transfection of either LIMK1 or LIMK2 in 25 mL
growth media. The transfection mix was added directly to cells and
mixed gently <italic toggle="yes">via</italic> inversion. Cells were then plated
into T75 tissue culture flasks and incubated for 20 h at 37 &#176;C,
5% CO<sub>2</sub>.</p></sec><sec id="sec4.8"><title>Cellular NanoBRET LIMK1/2 Assay</title><p>The NanoBRET cellular
target engagement assay was performed as previously described.<xref rid="ref29" ref-type="bibr"/> Briefly, white 96-well plates containing LIMK1/2
transfected HEK293 cells and extracellular NanoLuc inhibitor was added
either positive control (NanoBRET Tracer #10), negative control (DMSO)
or test compound (8-point dose&#8211;response curve in DMSO in duplicate,
final concentration of 0.5% for control wells). Following incubation
of plates under standard conditions (37 &#176;C, 5% CO<sub>2</sub>) for 2 h, plates were removed and allowed to reach RT for 15 min.
Freshly prepared Nano-Glo substrate was then added to each well and
luminescence measured using dual emission for the donor at 450 nm
and the acceptor 610 nm on a BMG Pherastar plate reader. Kit components
were purchased from Promega (Hampshire, U.K.).</p></sec><sec id="sec4.9"><title>AlphaLISA SureFire Assay</title><p>The AlphaLISA assay for detection
of p-cofilin Ser3 levels was followed as previously described.<xref rid="ref29" ref-type="bibr"/> Briefly, 96-well plates containing SH-SY5Y cells
was added either positive control (LIMKi3, 10 &#956;M), negative
control (0.5% DMSO) or test compound (8-point, 3-fold serial dilution
in DMSO from 10 &#956;M to 30 nM in duplicate). Cells were placed
in the incubator for 2 h, after which the media was removed and the
cells were lysed using 50 &#956;L AlphaLISA 1&#215; lysis buffer
(PerkinElmer) containing protease inhibitor cocktail (Sigma/Merck,
Dorset, U.K.) and Pierce phosphatase inhibitor cocktail (Thermofisher
Scientific, U.K.). The cell lysate was then transferred to a clean,
flat-bottom, white 384-well plate, to which 5 &#956;L/well of acceptor
bead solution consisting of Reaction buffer 1, Reaction buffer 2,
Activation Buffer and Acceptor Beads from pCofilin SureFire Ultra
assay kit (PerkinElmer, Cat# ALSU-PCOF-A500) was added under dim light.
After plate shaking for 2 min at 450 rpm, centrifuged briefly and
incubation at RT for 1 h, 5 &#956;L/well of donor solution consisting
of Dilution Buffer and Donor beads was added. The plate was read on
a Pherastar reader (BMD Labtech Ltd., Aylesbury, U.K.) using an AlphaLISA
cartridge and AlphaLISA plate settings. The AlphaLISA assay was robust
and reproducible (<italic toggle="yes">Z</italic>&#8242; = 0.7).</p></sec><sec id="sec4.10"><title>Binding Affinity (<italic toggle="yes">K</italic>
<sub>d</sub>) Assay</title><p>Apparent binding dissociation constants (<italic toggle="yes">K</italic>
<sub>d</sub>) were determined using <italic toggle="yes">K</italic>
<sub>d</sub>ELECT platform
provided by Eurofins/DiscoverX (San Diego). Briefly, LIMK1/2 transfected
HEK293 cells were tagged with DNA and incubated until lysis. Streptavidin-coated
magnetic beads were treated with biotinylated small molecule ligands
for 30 min at RT to generate affinity resins. Liganded beads were
blocked with excess biotin and washed with blocking buffer (SeaBlock
(Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand
and reduce nonspecific binding. Test compound (11-point, 3-fold serial
dilution from 100 &#956;M to 1 nM in duplicate, final DMSO concentration
of 0.9%) were transferred to 384-well plates containing beads and
DNA-tagged LIMK1/2 by acoustic transfer (noncontact dispensing). The
assay plates were incubated at RT with shaking for 1 h and the affinity
beads washed with wash buffer (1&#215; PBS, 0.05% Tween20). The beads
were then resuspended in elution buffer (1&#215; PBS, 0.05% Tween20,
0.5 &#956;M nonbiotinylated affinity ligand) and incubated at RT
with shaking for 30 min. The kinase concentration in the eluates was
measured by qPCR. Binding constants <italic toggle="yes">K</italic>
<sub>d</sub> were calculated from the dose&#8211;response curve using the Hill
equation<disp-formula id="ueq1"><alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00974_m001.jpg"/><mml:math id="d1e9439" display="block"><mml:mi>response</mml:mi><mml:mo>=</mml:mo><mml:mi>background</mml:mi><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mrow><mml:mi>signal</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>background</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:msup><mml:msub><mml:mi>K</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:msub><mml:mi>hillslope</mml:mi></mml:msup><mml:mrow><mml:mi>dos</mml:mi><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mi>hillslope</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula>
</p></sec><sec id="sec4.11"><title>Microsomal Stability</title><p>Five microliter microsomes (20
mg/mL, Corning BV) diluted into 95 &#956;L PBS (pH 7.4 with 0.6%
MeCN) containing 0.04% DMSO and 4 &#956;M compound were incubated
with 100 &#956;L of prewarmed 4 mM NADPH in PBS (final concentrations:
0.5 mg/mL microsomes, 2 &#956;M compound, 0.02% DMSO, 0.3% MeCN and
2 mM NADPH). After mixing thoroughly the <italic toggle="yes">T</italic> = 0 sample
(40 &#956;L) was immediately quenched into 80 &#956;L ice cold MeOH
containing 4 &#956;M internal standard (Carbemazepine). Three further
samples were quenched in the same way at <italic toggle="yes">T</italic> = 3, 9,
and 30 min. Samples were incubated on ice for 30 min before centrifugation
at 4700 rpm for 20 min. The supernatant was analyzed via LC-MS/MS
and compound/Carbemazepine peak area ratios calculated to determine
the rate of substrate depletion.</p></sec><sec id="sec4.12"><title>Thermodynamic Solubility</title><p>1&#8211;2 mg of accurately
weighed compound was suspended in 1 mL PBS (pH 7.0) and incubated
(rotating end over end) at room temperature for 24 h. The samples
were then centrifuged at &gt;10,000 rpm for 10 min to pellet any remaining
solid. The supernatant was then diluted sequentially (1:5, 1:50, 1:500,
and 1:5000) in MeCN and mixed 1:1 with MeCN containing 4 &#956;M
of carbamazepine. To prepare the standard, an 8-point, 1:3 dilution
curve was prepared in DMSO with a top concentration of 1 mM, which
was then diluted to 1:100 in MeCN containing 2 &#956;M carbamazepine.
Standards and samples were analyzed <italic toggle="yes">via</italic> LCMS/MS.
The compound carbamazepine peak area ratios were calculated, and the
test article solubility was determined by interpolation from the standard
curve.</p></sec><sec id="sec4.13"><title>Caco-2-Permeability and Efflux</title><p>Bidirectional permeabilities
and drug efflux were performed at Cyprotex (Alderley Park, U.K.).
Caco-2 cells (derived from ATCC) were seeded onto Transwell plates
at 1 &#215; 10<sup>5</sup> cells/cm<sup>2</sup> and cultured in DMEM.
The monolayers are prepared by rinsing both apical and basolateral
surfaces twice with HBSS at pH 7.4 and incubating both compartments
for 40 min to stabilize physiological parameters. For assessment of
A &#8594; B permeability, HBSS was removed from the apical compartment
and replaced with either positive control (antipyrine, atenolol, talinolol,
estrone 3-sulfate) or test compound dosing solution (10 &#956;M in
assay buffer in duplicate, final DMSO concentration of &#8804;1%).
For assessment of B &#8594; A permeability, HBSS was removed from
the basolateral compartment and replaced with positive control or
test compound dosing solution as above. After 2 h, apical compartment
inserts and companion plates are separated and apical and basolateral
samples diluted for analysis. Test and control compounds are quantified
by LCMS/MS cassette analysis using a 7-point calibration with appropriate
dilution of the samples. Permeability coefficient (<italic toggle="yes">P</italic>
<sub>app</sub>) for each compound is calculated from the following
equation<disp-formula id="ueq2"><alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00974_m002.jpg"/><mml:math id="d1e9503" display="block"><mml:msub><mml:mi>P</mml:mi><mml:mi>app</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>Q</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#215;</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula>where d<italic toggle="yes">Q</italic>/d<italic toggle="yes">T</italic> is the rate of permeation of compound across the cells, <italic toggle="yes">C</italic>
<sub>0</sub> is the donor compartment concentration at
time zero, and <italic toggle="yes">A</italic> is the area of the cell monolayer.
Only <italic toggle="yes">P</italic>
<sub>app</sub> A &#8594; B is reported for
clarity. Efflux ratio (ER) is derived from <italic toggle="yes">P</italic>
<sub>app(B&#8211;A)</sub>/<italic toggle="yes">P</italic>
<sub>app(A&#8211;B)</sub>.</p></sec><sec id="sec4.14"><title>
<italic toggle="yes">In Vivo</italic> DMPK</title><p>
<italic toggle="yes">In vivo</italic> studies were carried out under appropriate licenses at Sai Life
(India) or internally using male Sprague&#8211;Dawley rats. MDI-117740
(<bold>69</bold>) was either dosed: (i) i.v. in a formulation of 10%
DMSO, 20% Cremophor EL, 70% saline (v/v/v) at a concentration of 0.04
mg/mL with dose volume of 5 mL/kg for final dose of 0.2 mg/kg, (ii)
p.o. in a formulation of 20% hydroxypropyl-&#946;-cyclodextrin in
dH<sub>2</sub>O (w/v) at a concentration of 0.3 mg/mL with dose volume
of 10 mL/kg for final dose of 3 mg/kg, or, (iii) i.p. in a formulation
of 20% hydroxypropyl-&#946;-cyclodextrin in dH<sub>2</sub>O (w/v)
at a concentration of 2 mg/mL with dose volume 5 mL/kg for final dose
of 10 mg/kg. Serial plasma samples were obtained at predetermined
time points and then stored at &#8722;20 &#176;C. Brain samples from
a CNS satellite group were isolated at 1 h, homogenized and stored
at &#8722;20 &#176;C. Samples were then thawed, protein precipitated
with MeCN followed by LC-MS/MS quantification. No adverse effects
were noted for the duration of the <italic toggle="yes">in vivo</italic> experiments.</p></sec><sec id="sec4.15"><title>Wound Healing Assay</title><p>The wound healing or scratch assay
used for monitoring adherent cell migration over time following the
induction of a &#8220;scratched&#8221; area in the monolayer with
a 200 &#956;L pipet tip. The MDA-MB-231 breast cancer cell line was
seeded in a clear, 12-well plate, approximately 24 h prior to the
experiment to form a complete monolayer. Following wound induction,
the disrupted cells were gently removed from the wells and fresh medium
supplemented with or without compound was added. The cells were incubated
for 48 h and images were taken using the ZOE cell imager (BIO-RAD)
to monitor the wounded gap. The initial width of the wound was measured,
followed by measurements after 48 h. The images were measured using
ImageJ software and the wound closure rate, indicative of cellular
motility and migration, was calculated using GraphPad Prism 10.5.0.</p></sec><sec id="sec4.16"><title>Statistical Analysis</title><p>Statistical analysis was performed
using GraphPad Prism (v10.5.0). For wound healing assays, percentage
wound closure at 48 h was compared across treatment groups using an
ordinary one-way ANOVA followed by Dunnett&#8217;s post hoc test
to determine significance (<italic toggle="yes">p</italic> &lt; 0.05) of differences
between control sample and test samples. Data are presented as mean
&#177; SEM from <italic toggle="yes">n</italic> = 4 independent experiments. Statistical
significance was set at <italic toggle="yes">p</italic> &lt; 0.05. Details about
the multiple comparisons test can be found in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Table S2</ext-link>.</p></sec><sec id="sec4.17"><title>X-ray Crystallography</title><p>X-ray diffraction structures
of MDI-117740 (<bold>69</bold>) and intermediates <bold>39</bold> and <bold>49</bold> are deposited with Cambridge Crystallographic Data Centre
(CCDC) under deposition numbers 2467213, 2440761 and 2440762, respectively.
Thermal ellipsoids for compound <bold>69</bold> and intermediates <bold>39</bold> and <bold>49</bold> can be found in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">Figures S1&#8211;S3</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00974_si_001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00974_si_002.csv" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ACK-d14e8112-autogenerated"><p>The DMPK and chemistry teams at Sai Life are acknowledged
for their contribution to the <italic toggle="yes">in vivo</italic> PK data and
synthesis of selected compounds presented in this manuscript. We thank
Simon Waller from Analytical Services, School of Chemistry, Cardiff
University for running HRMS analyses.</p></ack><notes id="notes-1" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00974?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00974</ext-link>.<list list-type="simple" id="silist"><list-item><p>DiscoverX scanMAX panel for compound <bold>69</bold>; thermal ellipsoids for compound <bold>69</bold> and intermediates <bold>39</bold> and <bold>49</bold>; statistical data used to compare effect
of LIMK inhibitors on cell migration in the wound healing assay; <sup>1</sup>H, <sup>13</sup>C NMR, and UPLC-MS characterization data and
details of chemical synthesis of all final compounds (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item><list-item><p>Formula Strings
containing SMILES string and associated
biochemical and biological data (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00974/suppl_file/jm5c00974_si_002.csv" ext-link-type="uri">CSV</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-2" notes-type="author-present-addresses"><label>&#8741;</label><p>Tay
Therapeutics Limited, Dundee University Incubator, 3 James
Lindsay Place, Dundee DD1 5JJ, United Kingdom</p></notes><notes id="notes-3" notes-type="author-present-addresses"><label>&#8869;</label><p>Division of Structural Biology, The Institute of Cancer Research
(ICR), London SW3 6JB, United Kingdom</p></notes><notes id="notes-4" notes-type="author-present-addresses"><label>#</label><p>Recursion
plc, 155 Brook Drive, Milton Park, Abingdon OX14 4SD,
United Kingdom</p></notes><notes id="notes-5" notes-type="author-present-addresses"><label>&#8711;</label><p>Institute
of Systems, Molecular and Integrative Biology, University
of Liverpool, Biosciences Building, Crown Street, Liverpool L69 7BE,
United Kingdom</p></notes><notes id="notes-6" notes-type="author-present-addresses"><label>&#9675;</label><p>European
Cancer Stem Cell Research Institute, School of Biosciences,
Cardiff University, Haydn Ellis Building, Maindy Road, Cardiff CF24
4HQ, United Kingdom</p></notes><notes id="notes-7" notes-type="author-contributions"><p>Conceptualization:
A.G.B., D.W.F., D.H.J., J.M.E., J.R.A., S.E.W.; Methodology: A.G.B.,
D.W.F., D.H.J., J.M.E., J.R.A., S.E.W.; Investigation: A.G.B., D.W.F.,
D.H.J., H.L., R.C., B.W., J.P., L.W., M.P., L.S., G.F., B.K.; Writing&#58872;original
draft: A.G.B.; Writing&#58872;editing: D.W.F., D.H.J.; Writing&#58872;review:
all authors; Funding Acquisition: J.M.E., J.R.A., S.E.W.; Supervision:
D.W.F., J.M.E., J.R.A., S.E.W. All authors have given approval to
the final version of the manuscript.</p></notes><notes id="notes-8" notes-type="funding-statement"><p>This project
was funded through the UK&#8217;s Medical Research Council&#8217;s
Developmental Pathway Funding Scheme, grant reference MR/S005331/1.</p></notes><notes id="NOTES-d14e8117-autogenerated" notes-type="conflict-of-interest"><p>The authors declare no
competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations Used</title><def-item><term>ADF</term><def><p>actin-depolymerizing factor</p></def></def-item><def-item><term>ASD</term><def><p>autism spectrum disorder</p></def></def-item><def-item><term>AUC<sub>inf</sub>
</term><def><p>area
under the curve (to infinity)</p></def></def-item><def-item><term>B/P</term><def><p>brain-to-plasma ratio</p></def></def-item><def-item><term>BMPR2</term><def><p>bone morphogenetic protein receptor type
2</p></def></def-item><def-item><term>CaMKIV</term><def><p>calcium/calmodulin-dependent
protein kinase IV</p></def></def-item><def-item><term>CL<sub>int</sub>
</term><def><p>intrinsic clearance</p></def></def-item><def-item><term>
<italic toggle="yes">C</italic>
<sub>max</sub>
</term><def><p>maximum plasma concentration</p></def></def-item><def-item><term>DMPK</term><def><p>drug metabolism
and pharmacokinetics</p></def></def-item><def-item><term>ER</term><def><p>efflux ratio</p></def></def-item><def-item><term>
<italic toggle="yes">F</italic>%</term><def><p>% oral bioavailability</p></def></def-item><def-item><term>FMRP</term><def><p>fragile X mental retardation protein</p></def></def-item><def-item><term>FXS</term><def><p>fragile X syndrome</p></def></def-item><def-item><term>i.p.</term><def><p>intraperitoneal</p></def></def-item><def-item><term>i.v.</term><def><p>intravenous</p></def></def-item><def-item><term>LIMK</term><def><p>LIM domain kinase</p></def></def-item><def-item><term>MRCK&#945;</term><def><p>myotonic
dystrophy kinase-related Cdc42-binding kinase &#945;</p></def></def-item><def-item><term>PAK</term><def><p>p21-activated kinase</p></def></def-item><def-item><term>
<italic toggle="yes">P</italic>
<sub>app</sub>
</term><def><p>apparent permeability</p></def></def-item><def-item><term>p.o.</term><def><p>oral administration</p></def></def-item><def-item><term>RIPK1</term><def><p>receptor-interacting protein 1 kinase</p></def></def-item><def-item><term>ROCK</term><def><p>Rho-associated
protein kinase</p></def></def-item><def-item><term>
<italic toggle="yes">T</italic>
<sub>1/2</sub>
</term><def><p>half-life</p></def></def-item><def-item><term>TESK</term><def><p>testis specific protein kinase</p></def></def-item><def-item><term>TKL</term><def><p>tyrosine kinase-like
kinase</p></def></def-item><def-item><term>
<italic toggle="yes">T</italic>
<sub>max</sub>
</term><def><p>time taken to reach maximum plasma concentration</p></def></def-item><def-item><term>
<italic toggle="yes">V</italic>
<sub>D</sub>
</term><def><p>volume of distribution</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Scott</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>M. F.</given-names></name><article-title>LIM kinases: function, regulation and association with
human disease</article-title><source>J. Mol. Med.</source><year>2007</year><volume>85</volume><issue>6</issue><fpage>555</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1007/s00109-007-0165-6</pub-id><pub-id pub-id-type="pmid">17294230</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Casanova-Sep&#250;lveda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sexton</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Turk</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Boggon</surname><given-names>T. J.</given-names></name><article-title>Autoregulation of
the LIM kinases by their PDZ domain</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><issue>1</issue><elocation-id>8441</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-44148-4</pub-id><pub-id pub-id-type="pmid">38114480</pub-id><pub-id pub-id-type="pmcid">PMC10730565</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Casanova-Sep&#250;lveda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boggon</surname><given-names>T. J.</given-names></name><article-title>Regulation
and signaling of the LIM domain kinases</article-title><source>BioEssays</source><year>2025</year><volume>47</volume><issue>1</issue><elocation-id>2400184</elocation-id><pub-id pub-id-type="doi">10.1002/bies.202400184</pub-id><pub-id pub-id-type="pmcid">PMC11663136</pub-id><pub-id pub-id-type="pmid">39361252</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Edwards</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Bokoch</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>G. N.</given-names></name><article-title>Activation of LIM-kinase
by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal
dynamics</article-title><source>Nat. Cell Biol.</source><year>1999</year><volume>1</volume><issue>5</issue><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1038/12963</pub-id><pub-id pub-id-type="pmid">10559936</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maekawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Narumiya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>K.</given-names></name><article-title>Rho-associated kinase
ROCK activates LIM-kinase 1 by
phosphorylation at threonine 508 within the activation loop</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><issue>5</issue><fpage>3577</fpage><lpage>3582</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.5.3577</pub-id><pub-id pub-id-type="pmid">10652353</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Sumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shibuya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><article-title>Activation of LIM kinases
by myotonic dystrophy kinase-related Cdc42-binding kinase alpha</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><issue>25</issue><fpage>23092</fpage><lpage>23096</lpage><pub-id pub-id-type="doi">10.1074/jbc.C100196200</pub-id><pub-id pub-id-type="pmid">11340065</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Dan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Minden</surname><given-names>A.</given-names></name><article-title>Cytoskeletal changes
regulated by the PAK4 serine/threonine kinase are mediated by LIM
kinase 1 and cofilin</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><issue>34</issue><fpage>32115</fpage><lpage>32121</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100871200</pub-id><pub-id pub-id-type="pmid">11413130</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Takemura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mishima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kasahara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fukunaga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>K.</given-names></name><article-title>Ca2+/calmodulin-dependent protein
kinase IV-mediated LIM kinase activation is critical for calcium signal-induced
neurite outgrowth</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><issue>42</issue><fpage>28554</fpage><lpage>28562</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.006296</pub-id><pub-id pub-id-type="pmid">19696021</pub-id><pub-id pub-id-type="pmcid">PMC2781398</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Prunier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prudent</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sadoul</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lafanechere</surname><given-names>L.</given-names></name><article-title>LIM kinases:
cofilin and beyond</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>25</issue><fpage>41749</fpage><lpage>41763</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16978</pub-id><pub-id pub-id-type="pmid">28445157</pub-id><pub-id pub-id-type="pmcid">PMC5522193</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Gorovoy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Profirovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Minshall</surname><given-names>R.</given-names></name><name name-style="western"><surname>Neamu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Voyno-Yasenetskaya</surname><given-names>T.</given-names></name><article-title>LIM kinase 1 coordinates microtubule stability and
actin polymerization in human endothelial cells</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><issue>28</issue><fpage>26533</fpage><lpage>26542</lpage><pub-id pub-id-type="doi">10.1074/jbc.M502921200</pub-id><pub-id pub-id-type="pmid">15897190</pub-id><pub-id pub-id-type="pmcid">PMC1403832</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Yoshioka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Foletta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><article-title>A role for LIM kinase
in cancer invasion</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2003</year><volume>100</volume><issue>12</issue><fpage>7247</fpage><lpage>7252</lpage><pub-id pub-id-type="doi">10.1073/pnas.1232344100</pub-id><pub-id pub-id-type="pmid">12777619</pub-id><pub-id pub-id-type="pmcid">PMC165861</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>McConnell</surname><given-names>B. V.</given-names></name><name name-style="western"><surname>Koto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gutierrez-Hartmann</surname><given-names>A.</given-names></name><article-title>Nuclear and cytoplasmic LIMK1 enhances
human breast cancer progression</article-title><source>Mol. Cancer</source><year>2011</year><volume>10</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.1186/1476-4598-10-75</pub-id><pub-id pub-id-type="pmid">21682918</pub-id><pub-id pub-id-type="pmcid">PMC3131252</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Malvi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janostiak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manrai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harigopal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wajapeyee</surname><given-names>N.</given-names></name><article-title>LIMK2 promotes
the metastatic progression of triple-negative breast cancer by activating
SRPK1</article-title><source>Oncogenesis</source><year>2020</year><volume>9</volume><issue>8</issue><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.1038/s41389-020-00263-1</pub-id><pub-id pub-id-type="pmid">32859889</pub-id><pub-id pub-id-type="pmcid">PMC7455732</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>You</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><article-title>Overexpression of LIMK1 promotes
tumor growth and metastasis in gastric
cancer</article-title><source>Biomed. Pharmacother.</source><year>2015</year><volume>69</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2014.11.011</pub-id><pub-id pub-id-type="pmid">25661344</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Mardilovich</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gabrielsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>McGarry</surname><given-names>L.</given-names></name><name name-style="western"><surname>Orange</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shanks</surname><given-names>E.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>M. F.</given-names></name><article-title>Elevated LIM kinase
1 in nonmetastatic prostate cancer reflects its role in facilitating
androgen receptor nuclear translocation</article-title><source>Mol.
Cancer Ther.</source><year>2015</year><volume>14</volume><issue>1</issue><fpage>246</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0447</pub-id><pub-id pub-id-type="pmid">25344584</pub-id><pub-id pub-id-type="pmcid">PMC4297197</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Nikhil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Viccaro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>C.</given-names></name><name name-style="western"><surname>Satapathy</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Tandiary</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broman</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>G.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y. J.</given-names></name><etal/><article-title>Identification of LIMK2
as a therapeutic target in
castration resistant prostate cancer</article-title><source>Cancer
Lett.</source><year>2019</year><volume>448</volume><fpage>182</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.01.035</pub-id><pub-id pub-id-type="pmid">30716360</pub-id><pub-id pub-id-type="pmcid">PMC7079209</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Aggelou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chadla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nikou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karteri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maroulis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kalofonos</surname><given-names>H. P.</given-names></name><name name-style="western"><surname>Papadaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bravou</surname><given-names>V.</given-names></name><article-title>LIMK/cofilin pathway
and Slingshot are implicated in human colorectal cancer progression
and chemoresistance</article-title><source>Virchows Arch.</source><year>2018</year><volume>472</volume><issue>5</issue><fpage>727</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1007/s00428-018-2298-0</pub-id><pub-id pub-id-type="pmid">29352327</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Hagerman</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Berry-Kravis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hazlett</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>D. B.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Moine</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kooy</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Tassone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gantois</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sonenberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mandel</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Hagerman</surname><given-names>P. J.</given-names></name><article-title>Fragile X syndrome</article-title><source>Nat. Rev. Dis. Primers</source><year>2017</year><volume>3</volume><elocation-id>17065</elocation-id><pub-id pub-id-type="doi">10.1038/nrdp.2017.65</pub-id><pub-id pub-id-type="pmid">28960184</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Kashima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ascano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Cerdeno</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ariza-Torres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Louie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leyton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>K. D.</given-names></name><etal/><article-title>Augmented noncanonical
BMP type II receptor signaling mediates the
synaptic abnormality of fragile X syndrome</article-title><source>Sci. Signaling</source><year>2016</year><volume>9</volume><issue>431</issue><elocation-id>ra58</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaf6060</pub-id><pub-id pub-id-type="pmcid">PMC5274719</pub-id><pub-id pub-id-type="pmid">27273096</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Pyronneau</surname><given-names>A.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Porch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Contractor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zukin</surname><given-names>R. S.</given-names></name><article-title>Aberrant Rac1-cofilin signaling mediates
defects in
dendritic spines, synaptic function, and sensory perception in fragile
X syndrome</article-title><source>Sci. Signaling</source><year>2017</year><volume>10</volume><issue>504</issue><elocation-id>eaan0852</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aan0852</pub-id><pub-id pub-id-type="pmcid">PMC5988355</pub-id><pub-id pub-id-type="pmid">29114038</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Santini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Koo</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Mojica</surname><given-names>E.</given-names></name><name name-style="western"><surname>D&#8217;Andrea</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bagni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Klann</surname><given-names>E.</given-names></name><article-title>Reducing eIF4E-eIF4G
interactions restores the balance between protein synthesis and actin
dynamics in fragile X syndrome model mice</article-title><source>Sci.
Signaling</source><year>2017</year><volume>10</volume><issue>504</issue><elocation-id>eaan0665</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aan0665</pub-id><pub-id pub-id-type="pmcid">PMC5858943</pub-id><pub-id pub-id-type="pmid">29114037</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Kashima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Redmond</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Ghatpande</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kornberg</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lagna</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hata</surname><given-names>A.</given-names></name><article-title>Hyperactive
locomotion in a Drosophila model is a functional readout for the synaptic
abnormalities underlying fragile X syndrome</article-title><source>Sci. Signaling</source><year>2017</year><volume>10</volume><issue>477</issue><elocation-id>eaai8133</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aai8133</pub-id><pub-id pub-id-type="pmcid">PMC5557344</pub-id><pub-id pub-id-type="pmid">28465421</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Irwin</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Idupulapati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Crisostomo</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Kooy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Willems</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Cras</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>P. B.</given-names></name><etal/><article-title>Abnormal dendritic spine characteristics in
the temporal and visual cortices of patients with fragile-X syndrome:
a quantitative examination</article-title><source>Am. J. Med. Genet.</source><year>2001</year><volume>98</volume><issue>2</issue><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1096-8628(20010115)98:2&amp;#x0003c;161::AID-AJMG1025&amp;#x0003e;3.0.CO;2-B</pub-id><pub-id pub-id-type="pmid">11223852</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>He</surname><given-names>C. X.</given-names></name><name name-style="western"><surname>Portera-Cailliau</surname><given-names>C.</given-names></name><article-title>The trouble
with spines in fragile X syndrome: density,
maturity and plasticity</article-title><source>Neuroscience</source><year>2013</year><volume>251</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.03.049</pub-id><pub-id pub-id-type="pmid">22522472</pub-id><pub-id pub-id-type="pmcid">PMC3422423</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Henderson</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Greathouse</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Ramdas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Day</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Mattheyses</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Herskowitz</surname><given-names>J. H.</given-names></name><article-title>Pharmacologic inhibition of LIMK1 provides dendritic
spine resilience against beta-amyloid</article-title><source>Sci.
Signaling</source><year>2019</year><volume>12</volume><issue>587</issue><elocation-id>eaaw9318</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaw9318</pub-id><pub-id pub-id-type="pmcid">PMC7088434</pub-id><pub-id pub-id-type="pmid">31239325</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Sivadasan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hornburg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Drepper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jablonka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hansel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lojewski</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sterneckert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>P. J.</given-names></name><etal/><article-title>C9ORF72
interaction
with cofilin modulates actin dynamics in motor neurons</article-title><source>Nat. Neurosci.</source><year>2016</year><volume>19</volume><issue>12</issue><fpage>1610</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1038/nn.4407</pub-id><pub-id pub-id-type="pmid">27723745</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Datta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arion</surname><given-names>D.</given-names></name><name name-style="western"><surname>Corradi</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D. A.</given-names></name><article-title>Altered expression
of CDC42 signaling pathway components in cortical layer 3 pyramidal
cells in schizophrenia</article-title><source>Biol. Psychiatry</source><year>2015</year><volume>78</volume><issue>11</issue><fpage>775</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2015.03.030</pub-id><pub-id pub-id-type="pmid">25981171</pub-id><pub-id pub-id-type="pmcid">PMC4600637</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Gory-Faur&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jonckheere</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lante</surname><given-names>F.</given-names></name><name name-style="western"><surname>Denarier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Peris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Buisson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lafanechere</surname><given-names>L.</given-names></name><name name-style="western"><surname>Andrieux</surname><given-names>A.</given-names></name><article-title>Pyr1-Mediated Pharmacological Inhibition of LIM Kinase
Restores Synaptic Plasticity and Normal Behavior in a Mouse Model
of Schizophrenia</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>627995</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.627995</pub-id><pub-id pub-id-type="pmid">33790791</pub-id><pub-id pub-id-type="pmcid">PMC8006432</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paine</surname><given-names>M.</given-names></name><etal/><article-title>Comparative
Analysis of Small-Molecule LIMK1/2 Inhibitors:
Chemical Synthesis, Biochemistry, and Cellular Activity</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><issue>20</issue><fpage>13705</fpage><lpage>13713</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00751</pub-id><pub-id pub-id-type="pmid">36205722</pub-id><pub-id pub-id-type="pmcid">PMC9619402</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Ross-Macdonald</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Penhallow</surname><given-names>B.</given-names></name><name name-style="western"><surname>Markwalder</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Attar</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T. A.</given-names></name><etal/><article-title>Identification of a nonkinase target mediating cytotoxicity
of novel kinase inhibitors</article-title><source>Mol. Cancer Ther.</source><year>2008</year><volume>7</volume><issue>11</issue><fpage>3490</fpage><lpage>3498</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0826</pub-id><pub-id pub-id-type="pmid">19001433</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Antonipillai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Devlin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Street</surname><given-names>I.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>O.</given-names></name><article-title>LIM kinase
inhibition reduces breast cancer growth
and invasiveness but systemic inhibition does not reduce metastasis
in mice</article-title><source>Clin. Exp. Metastasis</source><year>2013</year><volume>30</volume><issue>4</issue><fpage>483</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1007/s10585-012-9553-6</pub-id><pub-id pub-id-type="pmid">23239465</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Park</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Agnihotri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Golbourn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Luck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sabha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Byron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zadeh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Croul</surname><given-names>S.</given-names></name><etal/><article-title>Transcriptional profiling of GBM invasion genes identifies
effective inhibitors of the LIM kinase-Cofilin pathway</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><issue>19</issue><fpage>9382</fpage><lpage>9395</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2412</pub-id><pub-id pub-id-type="pmid">25237832</pub-id><pub-id pub-id-type="pmcid">PMC4253441</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Hanke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mathea</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woortman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Tumber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kashima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hata</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuster</surname><given-names>B.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>S.</given-names></name><article-title>Development
and Characterization
of Type I, Type II, and Type III LIM-Kinase Chemical Probes</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><issue>19</issue><fpage>13264</fpage><lpage>13287</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01106</pub-id><pub-id pub-id-type="pmid">36136092</pub-id><pub-id pub-id-type="pmcid">PMC9675044</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Dolan</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Duron</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Vollrath</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shankaranarayana
Rao</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Govindarajan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Tonegawa</surname><given-names>S.</given-names></name><article-title>Rescue of fragile X syndrome phenotypes
in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2013</year><volume>110</volume><issue>14</issue><fpage>5671</fpage><lpage>5676</lpage><pub-id pub-id-type="doi">10.1073/pnas.1219383110</pub-id><pub-id pub-id-type="pmid">23509247</pub-id><pub-id pub-id-type="pmcid">PMC3619302</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Harrison</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Whitlock</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Voronkov</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Almstead</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Mabon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gardyan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hamman</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gopinathan</surname><given-names>S.</given-names></name><etal/><article-title>Novel class of LIM-kinase
2 inhibitors for
the treatment of ocular hypertension and associated glaucoma</article-title><source>J. Med. Chem.</source><year>2009</year><volume>52</volume><issue>21</issue><fpage>6515</fpage><lpage>6518</lpage><pub-id pub-id-type="doi">10.1021/jm901226j</pub-id><pub-id pub-id-type="pmid">19831390</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Harrison</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Almstead</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Burgoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gardyan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Healy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mabon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marinelli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Samala</surname><given-names>L.</given-names></name><etal/><article-title>Discovery
and Development of LX7101, a Dual LIM-Kinase
and ROCK Inhibitor for the Treatment of Glaucoma</article-title><source>ACS Med. Chem. Lett.</source><year>2015</year><volume>6</volume><issue>1</issue><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1021/ml500367g</pub-id><pub-id pub-id-type="pmid">25589936</pub-id><pub-id pub-id-type="pmcid">PMC4291717</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eid</surname><given-names>N.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Bibian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><etal/><article-title>Bis-aryl urea derivatives as potent and selective LIM kinase (Limk)
inhibitors</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><issue>4</issue><fpage>1846</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1021/jm501680m</pub-id><pub-id pub-id-type="pmid">25621531</pub-id><pub-id pub-id-type="pmcid">PMC4349585</pub-id></element-citation></ref><ref id="ref38"><mixed-citation publication-type="weblink" id="cit38"><uri xlink:href="https://clinicaltrials.gov/study/NCT01528111">https://clinicaltrials.gov/study/NCT01528111</uri>.</mixed-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Baldwin</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Wahab</surname><given-names>B.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pedder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G. J.</given-names></name><etal/><article-title>Discovery of MDI-114215: A potent and selective LIMK
inhibitor to treat Fragile X syndrome</article-title><source>J. Med.
Chem.</source><year>2025</year><volume>68</volume><issue>1</issue><fpage>719</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.4c02694</pub-id><pub-id pub-id-type="pmid">39711116</pub-id><pub-id pub-id-type="pmcid">PMC11726654</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Boland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bourin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geraets</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schroeders</surname><given-names>P.</given-names></name><name name-style="western"><surname>Castermans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kindt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boumans</surname><given-names>N.</given-names></name><name name-style="western"><surname>Panitti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vanormelingen</surname><given-names>J.</given-names></name><etal/><article-title>Design, synthesis and
biological characterization
of selective LIMK inhibitors</article-title><source>Bioorg. Med. Chem.
Lett.</source><year>2015</year><volume>25</volume><issue>18</issue><fpage>4005</fpage><lpage>4010</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.07.009</pub-id><pub-id pub-id-type="pmid">26233434</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Goodwin</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Cianchetta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Burgoon</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Healy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mabon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Strobel</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamman</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Rawlins</surname><given-names>D. B.</given-names></name><article-title>Discovery of a Type III Inhibitor
of LIM Kinase 2 That
Binds in a DFG-Out Conformation</article-title><source>ACS Med. Chem.
Lett.</source><year>2015</year><volume>6</volume><issue>1</issue><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1021/ml500242y</pub-id><pub-id pub-id-type="pmid">25589930</pub-id><pub-id pub-id-type="pmcid">PMC4291701</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Mandel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mathea</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saraswati</surname><given-names>H.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Schwalm</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tawada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>T.</given-names></name><etal/><article-title>Repurposing of the RIPK1-Selective
Benzo&#173;[1,4]&#173;oxazepin-4-one Scaffold for the Development of a Type III
LIMK1/2 Inhibitor</article-title><source>ACS Chem. Biol.</source><year>2025</year><volume>20</volume><fpage>1087</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5c00097</pub-id><pub-id pub-id-type="pmid">40227881</pub-id><pub-id pub-id-type="pmcid">PMC12090182</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Yoshikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bigi</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>H.</given-names></name><etal/><article-title>Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo&#173;[3,4-
c]&#173;pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating
Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis
of Structure-Kinetic Relationships</article-title><source>J. Med.
Chem.</source><year>2018</year><volume>61</volume><issue>6</issue><fpage>2384</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01647</pub-id><pub-id pub-id-type="pmid">29485864</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Harris</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J. U.</given-names></name><name name-style="western"><surname>Nagilla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Campobasso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Capriotti</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Dare</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><etal/><article-title>Discovery
of a First-in-Class Receptor Interacting
Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for
the Treatment of Inflammatory Diseases</article-title><source>J. Med.
Chem.</source><year>2017</year><volume>60</volume><issue>4</issue><fpage>1247</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01751</pub-id><pub-id pub-id-type="pmid">28151659</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Weisel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Papp</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tompson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simeoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bertin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tak</surname><given-names>P. P.</given-names></name><article-title>Response to Inhibition
of Receptor-Interacting
Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized
Placebo-Controlled Study</article-title><source>Clin. Pharmacol. Ther.</source><year>2020</year><volume>108</volume><issue>4</issue><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1002/cpt.1852</pub-id><pub-id pub-id-type="pmid">32301501</pub-id><pub-id pub-id-type="pmcid">PMC7540322</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Weisel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>N.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tompson</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Burriss</surname><given-names>S. W.</given-names></name><etal/><article-title>A randomised,
placebo-controlled study of RIPK1
inhibitor GSK2982772 in patients with active ulcerative colitis</article-title><source>BMJ Open Gastroenterol.</source><year>2021</year><volume>8</volume><issue>1</issue><elocation-id>e000680</elocation-id><pub-id pub-id-type="doi">10.1136/bmjgast-2021-000680</pub-id><pub-id pub-id-type="pmcid">PMC8365785</pub-id><pub-id pub-id-type="pmid">34389633</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Weisel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Peterfy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Siddall</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tompson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quattrocchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Burriss</surname><given-names>S. W.</given-names></name><etal/><article-title>A randomized,
placebo-controlled experimental
medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate
to severe rheumatoid arthritis</article-title><source>Arthritis Res.
Ther.</source><year>2021</year><volume>23</volume><issue>1</issue><elocation-id>85</elocation-id><pub-id pub-id-type="doi">10.1186/s13075-021-02468-0</pub-id><pub-id pub-id-type="pmid">33726834</pub-id><pub-id pub-id-type="pmcid">PMC7962407</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Harris</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>King</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Campobasso</surname><given-names>N.</given-names></name><name name-style="western"><surname>Capriotti</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Dare</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Finger</surname><given-names>J. N.</given-names></name><etal/><article-title>DNA-Encoded Library Screening Identifies Benzo&#173;[b]&#173;[1,4]&#173;oxazepin-4-ones
as Highly Potent and Monoselective Receptor Interacting Protein 1
Kinase Inhibitors</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><issue>5</issue><fpage>2163</fpage><lpage>2178</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01898</pub-id><pub-id pub-id-type="pmid">26854747</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Harris</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Marinis</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Lich</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Chirala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Eidam</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Finger</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Gough</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J. U.</given-names></name><etal/><article-title>Identification of a RIP1 Kinase Inhibitor Clinical
Candidate (GSK3145095) for the Treatment of Pancreatic Cancer</article-title><source>ACS Med. Chem. Lett.</source><year>2019</year><volume>10</volume><issue>6</issue><fpage>857</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.9b00108</pub-id><pub-id pub-id-type="pmid">31223438</pub-id><pub-id pub-id-type="pmcid">PMC6580371</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Cohen</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Buchwald</surname><given-names>S. L.</given-names></name><article-title>Mild palladium-catalyzed
cyanation of (hetero)&#173;aryl
halides and triflates in aqueous media</article-title><source>Org.
Lett.</source><year>2015</year><volume>17</volume><issue>2</issue><fpage>202</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1021/ol5032359</pub-id><pub-id pub-id-type="pmid">25555140</pub-id><pub-id pub-id-type="pmcid">PMC4301087</pub-id></element-citation></ref><ref id="ref51"><mixed-citation publication-type="patent" id="cit51"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Schunk</surname>, <given-names>S.</given-names></string-name>; <string-name name-style="western"><surname>Reich</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Koenigs</surname>, <given-names>R. M.</given-names></string-name></person-group><article-title>Pyrazolyl Substituted Tetrahydropyranylsulfones</article-title>. U.S. Patent, <patent country="US">US10,100,041</patent>, <year>2018</year>.</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="patent" id="cit52"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Atkinson</surname>, <given-names>S. J.</given-names></string-name>; <string-name name-style="western"><surname>Demont</surname>, <given-names>E. H.</given-names></string-name>; <string-name name-style="western"><surname>Harrison</surname>, <given-names>L. A.</given-names></string-name>; <string-name name-style="western"><surname>Liwicki</surname>, <given-names>G. M.</given-names></string-name>; <string-name name-style="western"><surname>Lucas</surname>, <given-names>S. C. C.</given-names></string-name>; <string-name name-style="western"><surname>Preston</surname>, <given-names>A. G.</given-names></string-name>; <string-name name-style="western"><surname>Seal</surname>, <given-names>J. T.</given-names></string-name>; <string-name name-style="western"><surname>Wall</surname>, <given-names>I. D.</given-names></string-name>; <string-name name-style="western"><surname>Watson</surname>, <given-names>R. J.</given-names></string-name></person-group><article-title>Pyrazole Derivatives
As Bromodomain Inhibitors</article-title>. U.S. Patent, <patent country="US">US10,966,961</patent>, <year>2021</year>.</mixed-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Salah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beltrami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tumber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Preuss</surname><given-names>F.</given-names></name><name name-style="western"><surname>Canning</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaikuad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Knaus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Mathea</surname><given-names>S.</given-names></name><article-title>Lessons from LIMK1 enzymology and
their impact on inhibitor design</article-title><source>Biochem. J.</source><year>2019</year><volume>476</volume><issue>21</issue><fpage>3197</fpage><lpage>3209</lpage><pub-id pub-id-type="doi">10.1042/BCJ20190517</pub-id><pub-id pub-id-type="pmid">31652302</pub-id><pub-id pub-id-type="pmcid">PMC6835155</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Lyu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><article-title>PAK inhibitor FRAX486
decreases the metastatic potential of triple-negative breast cancer
cells by blocking autophagy</article-title><source>Br. J. Cancer</source><year>2024</year><volume>130</volume><issue>3</issue><fpage>394</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/s41416-023-02523-4</pub-id><pub-id pub-id-type="pmid">38110664</pub-id><pub-id pub-id-type="pmcid">PMC10844298</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>